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The skeleton is a mineralised tissue, which facilitates classical functions of locomotion, organ 
protection and mineral homeostasis. However, the bone has more recently been identified as 
an endocrine organ with the ability to regulate systemic glucose and thus energy metabolism. 
The acknowledgement of this previously unanticipated role of the skeleton emerged following 
the identification of a novel role of osteocalcin. This osteoblast-secreted hormone promotes 
peripheral insulin sensitivity and secretion by the pancreas. Within the bone and endocrine field, 
attention is now being paid to delineating further roles of proteins known to regulate 
mineralisation. These proteins either promote or inhibit mineralisation through various 
enzymatic pathways.  
 
Ectonucleotide pyrophosphatase phosphodiesterase-1 (NPP1 in mice, ENPP1 in humans) is 
recognised as a mineralisation regulator. By the hydrolysis of ATP, this enzyme generates 
extracellular pyrophosphate (PPi) which is a potent inhibitor of mineralisation (e.g. for bone and 
soft tissue such as the vasculature). However, NPP1 is also recognised as a pathogenic factor for 
insulin resistance, whereby it binds to the insulin receptor (IR) and abrogates downstream 
glucose mediation. This may lead to the development of insulin resistance which is a prerequisite 
for type 2 diabetes mellitus.  Previous work has demonstrated that the global knockout of NPP1 
in mice (Enpp1-/-) leads to pathological mineralisation, systemically reduced serum PPi and 
protection against insulin resistance and obesity following chronic high-fat diet feeding.  
However, the cell-specific contributions of NPP1 to the bone and metabolic phenotype remains 
unknown. 
 
The data presented in this thesis has expanded on this previous work by investigating the bone 
and metabolic phenotype of an osteoblast-specific NPP1 knockout mouse model 
(Enpp1flox/flox;Ocn-cre) compared to controls (Enpp1flox/flox). Previous work has shown that global 
Enpp1 knockout mice present with severe joint hypermineralisation, spinal ankylosis and soft 
tissue mineralisation (e.g. the tunica media of the aorta). These mice also present with a 
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paradoxical hypomineralisation of the long bone diaphysis. In contrast, the work presented in 
this thesis includes a detailed analysis of the bone phenotype which revealed a significantly 
increased bone mass and bone mineral density in the Enpp1flox/flox;Ocn-cre. This finding was 
supported by in vitro analysis of primary osteoblasts isolated from the Enpp1flox/flox;Ocn-cre mice 
and grown under mineralising conditions. This in vitro work demonstrated that Enpp1flox/flox;Ocn-
cre isolated osteoblasts mineralise more quickly, and to a greater extent, compared to their 
controls. This work also revealed that systemic levels of PPi remain unchanged in the 
Enpp1flox/flox;Ocn-cre mice; indeed these mice have an absence of pathological soft tissue 
mineralisation likely as a product of this.  
 
The metabolic phenotype of Enpp1flox/flox;Ocn-cre mice was assessed following both control and 
high-fat diet feeding. In vivo characterisation revealed unaltered blood glucose levels, insulin 
sensitivity and glucose tolerance in 16-week old control fed Enpp1flox/flox;Ocn-cre mice. These 
mice did present with significantly increased uncarboxylated osteocalcin, reflecting results 
observed in the global Enpp1-/- mice. Following high-fat diet feeding, Enpp1flox/flox;Ocn-cre mice 
did not confer protection against obesity or insulin resistance and did not demonstrate 
differences in osteocalcin (total or uncarboxylated). This is in contrast to the metabolic 
protection observed in the global Enpp1-/- mice and indicates that ablation of NPP1 within bone, 
one of its principal sites of action, is metabolically detrimental.  
 
This work adds to the increasing body of evidence supporting a role for NPP1 in metabolic 
dysfunction. I have demonstrated that the osteoblast-specific ablation of NPP1 in mice results in 
an alteration of osteocalcin carboxylation status, whilst offering reduced protection against 
insulin resistance and obesity. The mechanisms of this action remain incompletely understood 
and warrants further investigation. A greater comprehension of the tissue-specific roles of NPP1 
may aid in identifying potential therapeutic strategies for the management and treatment of 




Insulin is a major controller of energy utilisation. The maintenance of the skeleton has a high 
energetic cost, and the skeleton coordinates whole body energy utilisation through its hormonal 
interactions with other tissues. This PhD project investigated the actions of a molecule involved 
in regulating bone function called ectonucleotide pyrophosphatase/phosphodiesterase-1 
(NPP1) in controlling the body’s response body to the normal actions of insulin and bone 
development. 
 
First, the project investigated mice with the gene for NPP1 removed specifically in bone forming 
cells known as osteoblasts. This revealed how vital NPP1 in osteoblasts is for bone function, the 
regulation of insulin and the accumulation of fat tissue. Subsequent studies then examined 
whether NPP1 in osteoblasts promotes the development of obesity and insulin resistance. This 
was done by giving the transgenic mice a high-fat diet and studying their weight gain, responses 
to insulin and bone biology. Together, these studies helped to establish NPP1 as a key modulator 
of the skeleton’s ability to regulate energy usage. 
 
This project also investigated bones of mice with the gene for NPP1 removed in bone cells. This 
demonstrated how important NPP1 in osteoblasts is for bone formation. Through its enzyme 
function the NPP1 protein generates pyrophosphate which inhibits the deposition of mineral in 
bone. This work used multiple tools to assess bone structure, strength and content to assess 
bone formation.   
 
This work expands the current understanding of the role of NPP1 in energy metabolism and bone 
formation. Such work may aid in contributing to the development of therapeutic tools to target 
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Bone has been long regarded as an inert and structural organ, which facilitates an array of 
functions from locomotion to mineral homeostasis (Copp and Shim, 1963, Charles and Aliprantis, 
2014, Suchacki et al., 2017). Advances in genetic manipulation of animal models have revealed 
that bone is not only integral as a structural biomaterial but also as a regulator of metabolic 
processes (Fedde et al., 1999a, Karsenty et al., 2012, Huesa et al., 2014, Bonnet et al., 2019, 
Roberts et al., 2019b). These discoveries indicate an endocrine function of the skeleton. This 
thesis will investigate the role of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) 
as a regulator of mineralisation and energy metabolism, pertaining particularly to its role in 
osteoblasts. It is imperative to widen the understanding of mechanisms involved in these 
processes, such that therapeutics for both mineralisation disorders (e.g. generalised arterial 
calcification of infancy) and metabolic diseases, such as diabetes, may be developed.  
 
1.2. Bone structure and function 
The skeleton is recognised as a structural scaffold for an organism, made out of a rigid tissue. 
This bone tissue is a composite tissue, consisting, not exclusively, of collagen and hydroxyapatite 
(Fig. 1.1). In keeping with this classical perception, the skeleton does indeed provide many 
structurally associated functions. For example, the skeleton provides the attachment site for 
most skeletal muscles, vital organ protection, facilitates weight-bearing motion, and provides the 
hematopoietic niche (Schofield, 1978, Florencio-Silva et al., 2015b). The skeleton is also 
recognised as highly dynamic, with the coordination of numerous cell types to facilitate skeletal 
functions (Gonciulea and de Beur, 2015). Furthermore, significant developments in cellular, 
molecular, whole-systems and animal modelling have enhanced the modern-day understanding 
of bone function. The recent emergence of bone as an endocrine regulatory organ has prompted 
a reconsideration of the role of the skeleton to encompass this new, and more complex era of 
bone research (Guntur and Rosen, 2012, Karsenty and Olson, 2016, Suchacki et al., 2017). 
 
The function of bone is complemented and facilitated by its complex and highly regulated 




divided firstly by location. The skeleton comprises the axial and the appendicular skeleton. The 
axial skeleton consists of the skull, vertebral column and ribcage, whereas the fore/hind-limbs 
and pelvis form the appendicular skeleton . Further classification of the skeleton can be based 
upon the structure of bones, which include; flat bones (e.g. skull, ribs, pelvis), long bones (e.g. 
femur), short bones (e.g. bones of the wrist) and irregular bones (e.g. scapula). 
 
Within the bone, there is an inner ‘spongy’ layer of trabecular bone and an outer layer of cortical 
bone (Eriksen et al., 1994). Overall, the bone consists of a periosteal envelope, the trabecular 
(spongy) bone, endosteal envelope and the bone marrow. The periosteal envelope represents 
the outermost layer of the bone (Squier et al., 1990). The compact bone that lies beneath this 
periosteal envelope is tough and dense (Squier et al., 1990, Dwek, 2010). The medullary cavity is 
situated inside the endosteal envelope, within the trabecular bone (Moore and Dawson, 1990). 
This cavity contains red bone marrow, which is responsible for haematopoiesis, comprising of 
immature and mature erythrocytes and leukocytes, as well as haematopoietic stem cells and 
which reduces in volume with age (Moore and Dawson, 1990).  
 
The yellow bone marrow, also present in the endosteal envelope, is made up predominantly of 
adipocytes (fat cells), which during times of caloric deficit, can be used as an energy reserve 
(Zakaria and Shafrir, 1967). Interestingly, the body may also convert this yellow marrow into red 
marrow in times of food deprivation or severe illness to maximise blood cell production (Maniatis 
et al., 1971, Bigelow and Tavassoli, 1984, Gurevitch et al., 2007, Fazeli et al., 2013).  
 
1.2.1 Cortical bone 
Cortical bone accounts for 80% of the total bone mass in an adult human (Morgan et al., 2008). 
This portion of bone allows survival of mechanical pressures and tensile forces experienced by 
bone through various physiological processes, for example, to resist bending during loading 
activities (Augat and Schorlemmer, 2006). The principal building blocks of cortical bone are 




Haversian systems, referred to as ‘cortical osteons’ (Sommerfeldt and Rubin, 2001, Clarke, 2008). 
With a cylindrical shape, these osteons form a branched network within the cortical cone, giving 
rise to a large surface area. These Haversian systems contain within them a Haversian canal. 
Present within the canal are blood vessels, connective tissue, nerve fibres and lymphatic vessels. 
Within the osteons osteocytes are visible – these are embedded cells that are supplied with 
lymph and nerves within the Haversian system (Fig. 1.2) (Sommerfeldt and Rubin, 2001). There 
is evidence to show that osteocytes behave as mechanosensors and are involved in regulating 
the bone remodelling process (Pead et al., 1988, Barragan-Adjemian et al., 2006, Clarke, 2008, 










Figure 1.1. Bone is a composite material 
On the left, a bone explant is treated with hypochlorite (bleach) which 
digests the collagen to leave the bone mineral hydroxyapatite (HA) 
intact. On the right, the bone explant is next treated with hydrochloric 
acid to dissolve the bone mineral HA and leave the collagen intact. 
Images provided from the Bone Research Society, by kind permission 















Figure 1.2. Cortical bone 
Figure shows (A) Haversian (osteonal) systems in cortical bone with (B) Image demonstrating 
osteocytes in human cortical bone (arrows). Here osteocytes are visible within the concentric 





1.2.2. Trabecular bone 
The trabecular (cancellous) bone represents the innermost portion of bone, surrounding the 
bone marrow. This bone type has a ‘honeycomb’ structure, owing to its porous nature, such that 
its total surface area is 10 times that of cortical bone despite contributing only 20% of the total 
bone mass (Singh, 1978, Sommerfeldt and Rubin, 2001). The overall effect of trabecular bone is 
to give a lighter total mass of the skeletal structure and to resist mechanical stresses experienced 
by the skeleton (Bayraktar et al., 2004, Oftadeh et al., 2015). This less dense bone material is 
primarily located at the ends of long bones (metaphysis) (Dyson and Whitehouse, 1968). The 
trabecular bone exhibits a highly porous meshwork-like appearance; this structure is comprised 
of trabeculae arranged in a highly organised three-dimensional structure (Fig. 1.3). This 
arrangement provides a lower stiffness, density, calcium content and greater elasticity to 
trabecular bone compared to cortical bone (Gong et al., 1964, Dyson and Whitehouse, 1968, 
Fritsch and Hellmich, 2007, Hart et al., 2017). These properties of trabecular bone facilitate 
resistance of compressive forces experienced throughout weight-bearing activities. For both the 
cortical and trabecular bone, there is deposition of collagen fibres in alternating orientations by 
the bone-forming (osteoblast) cells (Hulmes et al., 1995, Traub et al., 1989, Clarke, 2008, Orgel 







Figure 1.3. Trabecular bone. 
(A) Mineralisation of osteoblast (bone-forming) cells in vitro, (B) very low powered scanning 
electron microscopy showing normal bone architecture of both cortical and trabecular bone in the 
fourth lumbar vertebrae of a 41-year-old male (x8), (C) low powered scanning electron microscopy 
showing normal trabecular bone architecture in the third lumbar vertebrae of a 30-year-old 
women (x20). Scanning electron microscopy images demonstrate a regular pattern of 
interconnected plates and rods. Images provided from the Bone Research Society, by kind 




1.2.3. Embryonic bone formation 
Bone is composed of organic collagen proteins (principally type I collagen), non-collagenous 
proteins (Osteocalcin (OCN), osteonectin (ONN), osteopontin (OPN), and bone sialoprotein II 
(BSP II)), poorly crystalline substituted HA mineral, proteoglycans and water (Sommer et al., 
1996, Morgan, 2001, Young, 2003, Shen, 2005, Roberts et al., 2007b). Within this, a large 
population of living cells (the osteocytes) are entombed (Parfitt, 1976, Bonewald, 2011). Bone’s 
material properties are a function of both the relative proportions of these elementary 
constituents and its structure across length scales, conveying remarkable mechanical properties 
in a range of contexts from the ear ossicles to the load-bearing bones of the lower limb (Nalla et 
al., 2004, Fantner et al., 2005, Zimmermann et al., 2011). The collagen matrix is comprised of two 
main building blocks: the osteoid (the organic portion) and hydroxyapatite (HA) crystals (the 
inorganic portion, comprising 60% of bone tissue) (Morgan, 2001, Oftadeh et al., 2015, Zhu and 
Prince, 2015). The structural support and capabilities of the skeleton to resist load-bearing are 
facilitated by the calcification of the organic portion, which is made up of a crystalline HA 
complex of calcium and phosphate [Ca10(PO4)6(OH2)] which is embedded in the collagen matrix 
(Bayraktar et al., 2004). The formation of the skeleton, during foetal development, occurs via 
two distinct models of bone formation known as intramembranous ossification and 
endochondral ossification (Karsenty and Wagner, 2002, Kronenberg, 2003a, Yang et al., 2014). 
Both of these modes of formation give rise to the synthesis of bone from pre-existing 
mesenchymal tissue (Kronenberg, 2003b). For intramembranous ossification, this process occurs 
directly, whereas for endochondral ossification occurs via an intermediate hyaline cartilage 
scaffold which becomes replaced by bone (Kronenberg, 2003b, Colnot et al., 2004). 
 
1.2.4. Intramembranous ossification 
The process of intramembranous ossification involves the formation of compact and spongy 
bone, which develops directly from sheets of mesenchymal connective tissue. Intramembranous 
ossification is important for the formation of flat bones including skill, mandible and clavicle 
(Anon, 1940). During embryonic development, this process begins: mesenchymal stem cells 
undergo condensation and begin to differentiate into specialised cells (Hall and Miyake, 1992). 




forms osteoblasts (Hall and Miyake, 1992, Ducy et al., 1997, Gerber et al., 1999). These early 
osteoblasts initially form in a cluster known as the ‘ossification centre’. These osteoblasts secrete 
osteoid which later becomes calcified and eventually, the collagen secreting osteoblast becomes 
embedded into the surrounding mineralised matrix (Anderson, 1984, Roach, 1990). Once this 
occurs, the osteoblast further differentiates and then forms the terminally differentiated 
osteocyte (Parfitt et al., 1987, Manolagas, 2000, Li et al., 2004). The continued formation of 
osteoid and its subsequent mineralisation gives rise to an arrangement of calcified bone tissue 
known as ‘woven bone’ (Moreira et al., 2000). The remodelling of woven bone gives rise to 
secondary bone known as lamellar bone (Clarke, 2008). This has a regular and parallel alignment 
of collagen into sheets and is mechanically strong and highly organised (Rho et al., 1997, Rho et 
al., 1998). 
 
1.2.5. Endochondral ossification 
The coordinated action of the skeletal cells is exemplified in the formation of the appendicular 
skeleton (long bones) through the process of endochondral ossification (Mackie et al., 2008, Cui 
et al., 2016) (Fig. 1.4). This process proceeds with a cartilaginous scaffold. Here, mesenchymal 
stem cells differentiate into chondrocytes, under the regulation of the transcription factor ‘(Sex 
determining region Y)-Box 9’ (Sox-9) (Provot and Schipani, 2005). The lineage origins of these 
mesenchymal stem cells give rise to different locations of the resultant bone. Mesenchymal cells 
from somites give rise to the axial skeleton, whereas somatopleure gives rise to the appendicular 
skeleton (Provot and Schipani, 2005, Saito et al., 2006, Nakajima et al., 2018). The chondrocyte 
cell aggregates are responsible for the secretion of an extracellular matrix (ECM) consisting 
mostly of type II collagen and proteoglycans (Akkiraju and Nohe, 2015). Regulated by several 
growth factors and transcription factors, chondrocytes will progress through morphologically 
distinct maturation zones (Hunziker et al., 1987, Ballock and O'Keefe, 2003). In the most 
peripheral region of the growth plate, chondrocytes will exit the cell cycle and thereafter become 
hypertrophic (Ballock and O'Keefe, 2003, Mackie et al., 2008). These hypertrophic chondrocytes 
mineralise their ECM through the release of matrix vesicles (MVs) containing HA (Cui et al., 2016). 
There is a further invasion of the cartilaginous scaffold, whereby specialised bone cells 




(Colnot et al., 2004, Odgren et al., 2016).  Later osteoblasts are responsible for depositing bone-
specific type I collagen-rich matrix onto the remnants of chondrocyte ECM, which subsequently 
undergoes mineralisation (Arkill and Winlove, 2008, Mackie et al., 2008). This process results in 
the formation of primary spongiosa, which is eventually reabsorbed by osteoclasts and true 







Early embryonic development until approximately 6 weeks of age 
Figure 1.4. Endochondral ossification. 
The process of endochondral ossification to approximately 6-weeks of age. Mesenchymal cells condense and (B) 
differentiate into chondrocytes forming an avascular cartilage model of the future bone. (C) At the centre of the 
condensation, the chondrocytes cease proliferating and become hypertrophic. (D) perichondral cells adjacent 
to the hypertrophic chondrocytes differentiate into osteoblasts forming a bone collar. The hypertrophic 
chondrocytes regulate the formation of mineralised matrix; the release of angiogenic factors to attract blood 
vessels and undergoes apoptosis. (E) The coordination of osteoblasts and vascular invasion form the primary 
spongiosa. The chondrocytes continue to proliferate with concomitant vascularisation resulting in a coordinated 
process that lengthens the bone. Osteoblasts of the bone collar will eventually form cortical bone; while 
osteoblasts precursors located in the primary spongiosa will eventually form trabecular bone. (F) At the ends of 
the bone, secondary ossification centres develop through cycles of chondrocyte hypertrophy, vascular invasion 
and osteoblast activity. Columns of proliferating chondrocytes form in the growth plate beneath the secondary 
ossification centre. finally, the expansion of stromal cells and hematopoietic marrow starts to take place in the 





Mineralised tissue is present within the resultant boney structure. These centres are vascularised 
(Mackie et al., 2011). Endochondral ossification is integral not only for the development of the 
majority of bones but also is an essential proponent in postnatal longitudinal bone growth and 
fracture healing (Ford et al., 2004, Miclau et al., 2007, Miller et al., 2015, Ghiasi et al., 2017).  
 
The longitudinal growth of bone is highly regulated and occurs at the growth plate through the 
process of endochondral ossification (Nilsson et al., 2005). Proliferation and hypertrophy of the 
growth plate chondrocytes tightly controlled and influenced by endocrine factors (Hunziker et 
al., 1987, Nilsson et al., 2005, Staines et al., 2012a). For example, thyroid hormones, 
oestrogens/androgens, glucocorticoids and vitamin D can all regulate this process through their 
actions on chondrocyte maturation alone (Bohme et al., 1992, Boersma et al., 1996, Talwar et 
al., 2006, Bouillon et al., 2008, Idelevich et al., 2011, Wit and Camacho-Hubner, 2011, Weise et 
al., 2001). It is worth noting that the longitudinal growth can also be governed by the surrounding 
mechanical environment (Frost, 1987, Frost, 1994, Villemure and Stokes, 2009). 
 
1.2.6. Bone modelling and remodelling 
The skeleton represents a highly dynamic and adaptive organ, such that it can respond to 
demands placed upon it (Suchacki et al., 2017). These demands may be mechanical or centred 
on erythrocyte/cytokine production and calcium homeostasis (Brown, 1982, Brown and Hebert, 
1997, Skerry, 2008, Wilson et al., 2008, Takizawa et al., 2012). The modification processes of the 
skeleton are routinely characterised into two processes known as modelling and re-modelling 
which have specific characteristics (Table 1.1). Together, these processes facilitate development 
by allowing bones to both change shape and grow whilst concomitantly maintaining proportions 
to allow ambulation. Under Wolff’s Law, the shape, size and section modulus (i.e. bending 
strength) of bones is determined by the loads placed upon them (Frost, 1987). It is modelling and 
remodelling that are the core processes enabling bones to adapt to physical stress (Cowin, 1984, 





 Modelling Remodelling 
Goal Shape bone, increase bone mass Renew bone 
Cells 
Osteoclasts or osteoblasts and 
precursors 












Primarily childhood but continues 
throughout life 
Throughout life 
Net effect on bone 
mass 
Increase Maintain or slight decrease 
Table 1.1. Characteristics of modelling and remodelling 






Modelling can be either the formation of bone by osteoblasts or resorption of bone on an existing 
surface by osteoclasts which may occur at periosteal, endosteal or trabecular surfaces (Allen and 
Burr, 2014). Despite occurring predominantly in the growth and development stages of life, this 
process may be initiated if there is damage to bone (e.g. a bone break) (Schindeler et al., 2008, 
Odgren et al., 2016). There are two forms of remodelling, including formation whereby there is 
deposition of new bone, or resorption whereby there is the breaking down of existing bone (Burr, 
2002, Clarke, 2008). Formation and resorption can work independently from each other, at 
differing anatomical locations and under different timeframes (Burr, 2002, Parfitt, 2002). The 
primary functions of bone modelling are to increase bone mass and to ensure that bone shape 
is maintained (Allen and Burr, 2014). 
 
If an individual experiences a high degree of strain, formation modelling and resorption, 
modelling may act in concert. This ensures that there is the addition of bone mass and/or the re-
shaping of bone such that future skeletal stresses may be better tolerated (Henriksen et al., 
2009). If there are low levels of strain, only resorption modelling is activated to give a reduction 
of bone mass and a resultant freeing of stored minerals into the bloodstream (Henriksen et al., 
2009).  
 
Remodelling is the process of osteoclast-mediated resorption, followed by osteoblast-mediated 
bone formation occurring at the same location (Frost, 1990, Crockett et al., 2011). This is the 
major differentiator from resorption modelling and formation modelling (Table 1.1). The process 
of bone remodelling occurs at the periosteal, endosteal, trabecular and intracortical surfaces 
(Crockett et al., 2011). The process of remodelling can be subdivided into two categories: 
targeted and stochastic. The process of targeted remodelling ensures that the mechanical 
integrity of bones is maintained. It is therefore largely recognised that this process is activated 
when bones experience micro-damage (Seeman, 2009). Conversely, stochastic remodelling 
occurs randomly and is mostly hormonally driven (Poole and Reeve, 2005, Khosla et al., 2012). 
The current working hypothesis supports the notion that stochastic remodelling is integral to 




to maintain skeletal architecture and composition, there is continuous homeostatic adjustment 
of the skeleton. Central to this adjustment is the highly regulated interplay and actions of the 
distinct bone cell types.  
 
1.2.7. Cells of the skeleton     
Skeletal biology plays key roles in maintaining homeostasis and in conditioning the body to better 
respond to future physical tasks. The process of modelling and remodelling is under constant 
control of both local factors (e.g. growth factors) and systemic factors (e.g. oestrogens) (Raisz, 
1988, Mohan and Baylink, 1996, Vaananen and Harkonen, 1996). These factors ensure that bone 
is maintained at an optimal level of conditioning to respond best to future physical tasks. It is 
important to note that an imbalance between resorption and formation of bone may result in 
development of certain bone diseases (Feng and McDonald, 2011). One such example is 
osteoporosis, whereby the resorption rate of the osteoclast outstrips the bone-formation rate 
of the osteoblasts, causing decreased bone density and increased propensity for bone fracture 
(2001, Feng and McDonald, 2011) (Fig. 1.5). Conversely, osteopetrosis is a rare bone disease 
whereby there is a genetic mutation that gives decreased bone resorption, resulting in an 
abnormal accumulation of bone mass (Saftig et al., 1998). These permutations in normal 












Figure 1.5. Comparison of normal and osteoporotic bone 
architecture. 
Low powered scanning electron microscopy of trabecular bone 
from 3rd lumbar vertebrae (marrow and other cells have been 
removed). Top panel shows normal trabecular bone architecture. 
Bottom panel shows extensive pitting caused by osteoclasts. 
Images provided from the Bone Research Society, by kind 





This bone homeostasis is regulated by the complex interplay of specialised bone cells. There are 
three universally recognised bone cell types: osteoblasts, osteocytes and osteoclasts (Fig. 1.6). 
Osteoblasts, representing 4-6% of total bone cells, exhibit a cuboidal morphology and are located 
along the bone surface  (Florencio-Silva et al., 2015a). With a mesenchymal stem cell origin, the 
lineage commitment to osteoblasts requires the expression of genes and programmed steps 
(Rutkovskiy et al., 2016). One example of this is the Wnt/β-catenin pathway (Saidak et al., 2015). 
For the differentiation of osteoblast specifically, the expression of transcription factors (runt-
related transcription factor 2 (Runx2) distal-less homebox 5 (Dlx5), and osteoblast-specific 
transcription factor osterix (Osx)) is critical (Stein et al., 2004, Jensen et al., 2010, Rutkovskiy et 
al., 2016). Specifically, Runx2 referred to as the ‘master gene of osteoblast differentiation’ is 
required to promote the up-regulation of osteoblast-specific genes (collagen type 1 alpha 
(ColIa1), alkaline phosphatase (ALP), bone sialoprotein (Bsp) and Ocn) (Jensen et al., 2010, 
Komori, 2010, Li et al., 2012, Rutkovskiy et al., 2016).  
 
  
Figure 1.6. Osteoclast and osteocyte cells. 
(A) Scanning electron micrograph of an osteoclast reabsorbing bone surface and (B) scanning 
electron microscope image of an osteocyte organised within the osteocytic lucanar-canalicular 
system. Images provided from the Bone Research Society with kind permission of (A) Tim Arnett 





Osteocytes represent the most abundant and long-lived cells within bone, comprising over 90-
95% of all bone cells in the adult skeleton (Lanyon, 1993, Florencio-Silva et al., 2015a). Owing to 
complexities in isolating the osteocytes from bone matrix, initial studies required significant time 
and effort to determine their function (Stern et al., 2012). Due to this, it was hypothesised that 
these cells are quiescent or passive, leading to a misrepresentation, until recently, of both 
structure and function (Dallas et al., 2013).  
 
The osteocytes are located within their lacunae and surrounded by mineralised matrix. This gives 
rise to the description of osteocytes as ‘buried cells’, whereby they remain embedded and 
persistent in the bone matrix (Franz-Odendaal et al., 2006). Originating from the site where the 
cell body is isolated (lacunae space), these cells exhibit cytoplasmic processes, which provide the 
osteocyte-lacunocannalicular system: the cytoplasmic processes of the neighbouring cells are 
interconnected with gap junctions, and provide a large surface area of the osteocyte population 
(Shapiro, 1997). Cell-cell communication and the presence of the lacunocannalicular system 
allow these cells to act as mechanosensors within an interconnected network which includes 
connection to neighbouring osteocytes and bone surface osteoblasts (Seliger, 1970, Cowin et al., 
1991, Burger and Klein-Nulend, 1999, Yellowley et al., 2000). This facilitates the detection of 
mechanical pressure load changes and allows adaptation of bone such that structural integrity is 
retained and any micro-damages can be repaired (Paluch et al., 2015).  
 
Osteoclasts are terminally differentiated multinucleated cells that originate from a 
hematopoietic stem cell origin (Loutit and Nisbet, 1982, Bar-Shavit, 2007). These cells, in contrast 
to osteoblasts, have the unique function of destroying the tissue in which they reside (Blair et 
al., 1989, Abu-Amer et al., 1997, Clarke, 2008). As such, these cells are responsible for the 
resorption of bone material. Osteoclasts polarise during the remodelling of bone (resorption) 
such that a ruffled border comes into contact with the bone matrix (Charles and Aliprantis, 2014). 
This ruffled structure has a vacuolar-type H+-ATPase, which facilitates the acidification of the 
resorption lacunae and allows for the dissolution of the HA crystals (Teitelbaum, 2000, 




this action is via the PTH1 receptor which is situated on the osteoblast (Juppner et al., 1991, 
Datta and Abou-Samra, 2009). Furthermore, the osteoblast (and osteocytes) secrete 
osteoprotegerin (OPG) and receptor activator of nuclear factors κB (NF-κB) ligand, which in turn 
controls osteoclast formation and activity (Udagawa et al., 2000). This cross-talk is critical in 
facilitating the coordinated function of the remodelling process.  
  
1.2.8. Matrix mineralisation 
Although controversial, HA formation in bone is largely accepted to involve membrane-limited 
specialised structures known as MVs (Bonucci, 1967, Ali, 1976, Anderson, 1967, Anderson, 1984, 
Anderson, 1995, Cui et al., 2016). These bodies are nano-spherical, with a diameter of 100 nm to 
200 nm and a trilaminar membrane (Anderson, 1995). These MVs are derived through a ‘budding 
process’ from the plasma membrane of mineral forming cells, including chondrocytes, 
osteoblasts and odontoblasts (Ali, 1976, Yamada and Ozawa, 1978, Anderson, 1969, Cui et al., 
2016). The mineralisation process is biphasic and is initiated by the accumulation of both calcium 
ions and inorganic phosphate (Pi) within the MVs (Ali, 1976, Anderson, 1984, Boyan et al., 1989, 
Genge et al., 1989, Anderson, 1995, Genge et al., 2007, Wuthier and Lipscomb, 2011). Once a 
sufficient concentration of both calcium and Pi has been reached, the calcium phosphate begins 
to precipitate (Traub et al., 1992, Traub et al., 1989, Wu et al., 2008, Landis and Silver, 2009). 
Initially, this precipitate is non-crystalline. Subsequently, a series of intermediates allow the 
formation of HA crystals (Nudelman et al., 2013). After this initial phase, there is a penetration 
of the MV membrane by HA crystals, resulting in their exposure to extracellular fluid (Nudelman 
et al., 2013). Following this, the crystals continue to grow and develop, forming in alignment with 
the collagen fibrils of the ECM (Nudelman et al., 2010, Nudelman et al., 2013, Cui et al., 2016). 
The MV-regulated mineralisation is coordinated by the ratio of mineralisation promoters and 
mineralisation inhibitors.  
 
1.2.9. Regulation of mineralisation 
For the mechanical functions of the skeleton to occur, there is a continuous homeostatic and 




down (Crockett et al., 2011). The newly laid down bone becomes mineralised, whereby HA 
crystals containing calcium and Pi are deposited into an organic ECM (Karsenty et al., 2009). The 
tightly regulated mineralisation process is maintained by the actions of mineralisation inhibitors 
including pyrophosphate (PPi) and mineralisation promoters (e.g. Pi).The ratio of Pi/PPi is 
mediated by a variety of proteins: ENPP1 and progressive ankylosis protein (ANK) which work 
synergistically to regulate PPi levels to inhibit HA accumulation (Hakim et al., 1984b, Yadav et al., 
2011b, Staines et al., 2012b, Millán, 2013). 
 
PPi is recognised as a key inhibitor of both physiological and pathophysiological mineralisation 
relating to both bone and soft tissue (Fleisch and Bisaz, 1962, Orriss et al., 2016). The 
mineralisation regulators, which suppress spontaneous mineralisation, maintain the 
physiological PPi levels. A disturbance to PPi levels, for example owing to abnormal PPi 
metabolism, is reported and associated with dysregulation or pathological mineralisation 
(Mackenzie et al., 2012). Therefore, any functional disruption to the regulatory proteins can be 
anticipated to result in phenotypic changes related to abnormal mineralisation of the skeleton.  
 
The cell-surface enzyme tissue non-specific alkaline phosphatase (TNAP) is found in a variety of 
cells including osteoblasts, chondrocytes and the surface of these cells’ MVs (Yadav et al., 2011b). 
TNAP is encoded by the Akp2 or Alpl gene in mice and the ALPL gene in humans  (Whyte et al., 
2015). TNAP hydrolyses PPi, thereby decreasing extracellular PPi concentrations and facilitating 
HA formation. In humans, mutations of ALPL can result in the inherited skeletal disease of 
hypophosphatasia (Rathbun, 1948, Mornet, 2000, Mumm et al., 2001). This disease manifests in 
a hypomineralisation phenotype, which results in infant and childhood rickets, spontaneous 
fractures, deficiency of bone alkaline phosphatase (TNAP) activity and increased extracellular PPi 
concentrations (Oikawa et al., 2014, Whyte et al., 2015). The severity of hypophosphatasia is 





Mouse studies have been key in determining the importance of TNAP in regulation of 
mineralisation. The Alpl knockout mouse, a model for infantile hypophosphatasia, reflect the 
human disease whereby this mouse model demonstrates rachitic abnormalities and growth plate 
chondrocyte differentiation arrest (Fedde et al., 1999b, Liu et al., 2014). These mice also present 
with a disturbed bone remodelling and associated disordered matrix architecture and notable 
skeletal hypomineralisation with associated elevated PPi concentration (Liu et al., 2014). 
Furthermore, transgenic overexpression of TNAP in mice has been shown to cause decreased PPi 
concentrations further indicating the key role TNAP plays in promoting mineralisation by 
decreasing PPi and thus decreasing inhibitory regulation of mineralisation (Savinov et al., 2015, 
Romanelli et al., 2017). 
 
Phosphatase orphan 1 (PHOSPHO1) is also important for the regulation of mineralisation 
(Roberts et al., 2007a, Huesa et al., 2015a, Houston et al., 2016). PHOSPHO1 exhibits its action 
within osteoblast and chondrocyte-derived MV’s and generates Pi (Stewart et al., 2006, Roberts 
et al., 2007a). The expression of Phospho1 is approximately 100-fold higher in mineralising 
chondrocytes in comparison to non-skeletal tissues and has been shown to exhibit highly specific 
activity for phosphoethanolamine (PEA) and phosphocholine (PChol) (Roberts et al., 2007a). It is 
largely regarded that PHOSPHO1 is integral in the generation of Pi to facilitate skeletal 
mineralisation through its highly specific phosphohydrolase activity for PEA and PChol and that 
this occurs within the MVs derived from both osteoblasts and chondrocytes (Stewart et al., 
2006). Analysis of mice deficient in PHOSPHO1 (Phospho1-/-) have demonstrated that PHOSPHO1 
is essential for physiological endochondral ossification and for normal bone fracture healing to 
occur (Morcos et al., 2018). These Phospho1-/- mice present with spontaneous fractures, 
hypomineralisation of the skeleton, bowed long bones and scoliosis, particularly in young age 
cohorts (Huesa et al., 2011, Yadav et al., 2011b, Javaheri et al., 2015). In 2001, Yadav et al., 
demonstrated that the double knockout of TNAP and PHOSPHO1 resulted in the complete 
absence of a mineralised matrix. As such, it is proposed that intra-vesicular PHOSPHO1 facilitates 
Pi influx to the MV, which is crucial for the mineralisation and the function of TNAP, NPP1 and 





Encoded by the progressive ankylosing gene (Ank), ANK is responsible for facilitating the 
extracellular movement of intracellular PPi (Ho et al., 2000, Kim et al., 2010). This protein acts as 
a transmembrane PPi-channelling protein and is detectable on the surface of both osteoblasts 
and chondrocytes (Ho et al., 2000, Harmey et al., 2004). Disruptions to this transporter are 
associated with significant skeletal phenotypes. Mice possessing a spontaneous loss-of-function 
mutation in the Ank gene present with a progressive form of generalised arthritis, boney 
outgrowths, pathological joint formation and increased mineral deposition (Sweet and Green, 
1981, Gurley et al., 2006b). These Ank/Ank mutant mice also show a significant decrease in 
extracellular PPi, with a concomitant increase in intracellular PPi (specific to fibroblasts), 
compared to wild-type counterpart cells (Mitton-Fitzgerald et al., 2016).  As such, ANK regulates 
PPi to mediate physiological mineralisation and the incidence of arthritis, particularly in calcium 
pyrophosphate deposition disease (CPPD).  
 
In concert, ENPP1, TNAP, PHOSPHO1 and ANK are key regulators for the controlled and 
physiological mineralisation of both the skeleton and soft tissue mineralisation (Fig. 1.7). 
Investigation into both rare tissue mineralising diseases and transgenic mouse models have been 
integral in the early research conducted to determine the role of these enzymes concerning 
mineralisation (Rashdan et al., 2016). The first definitive link of defective Enpp1 and disturbed 
mineralisation was shown in the ‘tiptoe walking’ (ttw/ttw) mouse model, whereby there is a 
premature stop codon in the Enpp1 coding sequence resultant of a homozygous GRT substitution 
(Okawa et al., 1998b). As a result, these mice have a truncated NPP1 protein, which leads to a 
loss of calcium-binding domain and putative glycosylation sites. The bone phenotype associated 
with such disruption includes abnormal bone hypermineralisation (progressive ankylosing 
intervertebral and peripheral joint hyperostosis), as well as ectopic calcification including 
spontaneous arterial and articular cartilage calcification (Okawa et al., 1998b).  
 
The second mouse model to demonstrate the link of Enpp1 mutation and abnormal bone 




(Enpp1-/-) (Johnson et al., 2003). The resultant phenotype resembled that of ttw/ttw mice. In 
both mouse models, decreased extracellular PPi was observed, with abnormal long bone and 
calvaria mineralisation, as well as pathological ectopic calcification of soft tissues, including peri-
spinal and arterial calcification. This phenotype is also reflected in mutant Enpp1asj mice. These 
mice harbour a missense mutation, p.V246D, in the Enpp1 gene and develop stiffened joints 
accompanied by decreased systemic PPi and extensive soft tissue and vasculature mineralisation 






Figure 1.7. Regulation of mineralisation by bone factors. 
HA crystals consist of phosphate (Pi) and calcium (Ca2+). In MVs released from osteoblasts, extracellular Pi (ePi) is 
intracellularly channelled by Pit1/2 phosphate transporters. Additionally, ePi is generated via phosphomonoester 
(PEA/Pchol) hydrolysis by the phosphatase PHOSPHO1. Ca2+ is transported into MV via annexin channels. HA nucleates 
from MVs into extracellular space. Extracellular PPi (ePPi) is generated by hydrolysis of ATP by ENPP1, and also 
intracellular PPi is extracellularly exported by ANK at the site of osteoblast membranes. Both ePPi and OPN inhibit HA 
formation. The majority of ePi is generated by the actions of TNAP via ePPi hydrolysis and facilitates HA formation. OPG, 




1.2.10. Energetic cost of the skeleton 
The regenerative process of bone, a structure which contributes a large proportion of body mass 
(approximately 15% in men, and 10% in women), requires a great number of proteins to be 
synthesised and secreted (Vaananen et al., 2000, Karsenty et al., 2012).  It is possible, therefore, 
to consider that this comes at a high energetic cost to the organism. Bones themselves likely 
represent a survival factor which was strongly selected for, owing to skeletal structure providing 
motility such that scavenging, survival of injury and thus survival of the organism could occur 
(Karsenty et al., 2012). Yet, it is likely that the selection of the skeleton involved other important 
evolutionary components: for example, that part of the selection process for bones involves its 
integral role in the regulation of endocrine control of whole-body energy metabolism (Karsenty 
and Olson, 2016).   
 
1.2.11. Bone is an endocrine organ 
In addition to the structural roles and homeostatic roles in the regulation of calcium and Pi, the 
skeleton is also well recognised as an endocrine target (Guntur and Rosen, 2012). Central to the 
theory of homeostasis is that there is a reciprocal cross-talk between the signalling organ and 
the target organ (Ramsay and Woods, 2014). It is therefore important to discuss the endocrine 
signalling actions of the skeleton. Despite a currently vague understanding of the skeleton’s 
recently discovered metabolic-endocrine function, there is increasing evidence to support this 
new paradigm. Investigation into this field was catalysed following the discovery of hormonally 
active OCN, which is the most abundant of the osteoblast-specific non-collagenous proteins 
(Ducy et al., 1996).  
 
Released from the osteoblast and present in the general circulation, OCN exists in carboxylated, 
partially-carboxylated and fully under-carboxylated forms (Ferron et al., 2010b, Clemens and 
Karsenty, 2011, Karsenty and Olson, 2016). Of these forms, the latter represents the hormonally 
active variant, whereby there is promotion of pancreatic b-cell proliferation, insulin secretion, 
peripheral insulin sensitivity and energy expenditure (Karsenty et al., 2012). This un-




ECM, is decarboxylated at the acidic pH (4.5) of the osteoclastic resorption lacunae (Faienza et 
al., 2015). This points towards the delicate interplay between the two opposing, yet related, cell 
types (osteoblasts and osteoclasts) and their integral role in regulating bone-specific factors 
related to both skeletal formation and whole-body metabolism. By utilising primary human and 
rat long-bone derived osteoblast-like cells, it has been revealed that a paracrine communication 
exists between osteoblast and endothelial cells, mediated by vascular endothelial growth factor 
to regulate bone vascularisation (Clarkin et al., 2008). 
 
Further evidence supports the key role of osteoblast-associated bone factors and energy 
metabolism. One example of which is PHOSPHO1, a member of the large haloacid 
dehydrogenase superfamily of Mg2+ dependent hydrolases (Houston et al., 2004). This bone-
factor is active whilst inside the osteoblast-derived MV: at this site, Pi is scavenged from MV 
membrane proteins to promote the intra-vesicular HA deposition. Yet, novel roles of PHOSPHO1 
in energy homeostasis exist. Mice with Phospho1 ablation exhibit a decreased body size and 
protection against both obesity and diabetes, regardless of the carboxylation status of OCN 
(Oldknow et al., 2014, Dillon et al., 2019).  Evidence also exists to suggest that sclerostin (SOST) 
plays a role in a bone-metabolic phenotype regulation. Since SOST, predominantly released from 
osteocytes, inhibits the Wnt-signalling pathway, it also serves to inhibit osteoblast differentiation 
and bone formation, whilst promoting adipogenesis (Klangjareonchai et al., 2014). Putative 
investigations in human cohorts have revealed positively correlated circulating sclerostin and fat 
mass (abdominal and gynoid), as well as in type 2 diabetes mellitus (T2DM) patients 
(Klangjareonchai et al., 2014). This indicates a bone-fat interrelationship. The identification of 
links amongst these bone-secreted proteins will improve our understanding of the potential 
bone-adipose-muscle interactions, which may aid in developing a therapeutic intervention for 
the disease of these tissues, whilst avoiding adverse side effects on non-targeted tissues.  
 
Indeed, the last decade has seen an increasing understanding of the skeleton’s ability to act as 
an endocrine regulator (Fig. 1.9).  Significant development of both mouse models and cellular 




endocrine function. This adds further credence to the importance of the skeleton for survival 
beyond its mechanical roles. It is logical to propose that the skeleton produces hormones to 
regulate skeletal mineralisation, and, at the same time, cooperates with other endocrine organs 
to regulate calcium, phosphate and wider metabolic parameters. Continued identification of 
bone-secreted factors and their function will aid in answering the questions of how and why 






Figure 1.8. Schematic of newly discovered endocrine functions of bone, muscle and 
adipose tissue. 
Insulin secretion from the pancreas acts upon the IR on the osteoblast, which subsequently inhibits 
Forkhead box protein O 1 (FoxO1) expression and suppresses twist basic helix-loop-helix transcription 
factor 2 (Twist2), favouring bone resorption via osteoclast activation. The adipocyte-derived hormone 
leptin has been shown to have two opposing roles, acting centrally to inhibit bone mass accrual and 
peripherally, increasing osteoblast number and activity. The acidic pH generated in the resorption lacunae 
decarboxylates OCN on its three glutamic acid residues (GLU13, GLU17 and GLU20), which enable it to be 
released from the bone matrix into the general circulation. Once circulating, OCN can regulate global 
energy metabolism via the stimulation of insulin secretion and β-cell proliferation in the pancreas; energy 
expenditure by muscle and insulin sensitivity in adipose tissue, muscle and liver. Furthermore, OCN favours 
hippocampal development in offspring; brain function in adults and male fertility by stimulating 
testosterone synthesis in Leydig cells of the testis. A bone–muscle feed-forward axis exists where systemic 
undercarboxylated OCN signals to myofibres favouring uptake and subsequent catabolism of glucose and 
fatty acids, facilitating physical adaptation to exercise and release of exercise-induced IL-6. The latter 
drives the production of bioactive OCN. Adiponectin release from bone marrow adipose tissue may act to 
indirectly increase bioactive OCN by suppressing osteoblast proliferation, potentially favouring osteoclast 
activity. Another possibility is that excess local OCN production is responsible, at least in part, for elevated 
adiponectin production from MAT; however, this remains unclear (Arrow key: black solid – accepted; black 




1.2.12. Members of the ENPP family 
The ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) family is comprised of 7 
structurally related members (Terkeltaub, 2006). These family members have been recognised 
for over 20 years and are known to have roles in nucleotide recycling, purinergic signalling, 
homeostasis of PPi, cell motility and regulation of IR activity (Terkeltaub, 2001, Robson et al., 
2005, Vorhoff et al., 2005, Terkeltaub, 2006).  Although the principal focus of this project is on 
ENPP1, this section will address the six other members of the ENPP enzymatic family. As 
previously discussed, all members of the ENPP family share a structurally related catalytic 
domain: despite this, there is diversity in the enzymatic (and non-enzymatic) functions of each 
family member (Goding et al., 2003). Consequently, there is variation amongst the pathology 
suffered from deleterious mutations or aberrant expression of each ENPP family member.  
 
ENPP1-3 are expressed in a wide range of tissues, although specific individual isoforms are 
reportedly restricted in a tissue-specific nature (Harahap and Goding, 1988, Narita et al., 1994, 
Bollen et al., 2000). The catalytic function of ENPP1-3 has been determined, which has allowed 
classification of these three isozymes as the alkaline ENPP’s (Narita et al., 1994, Deissler et al., 
1995). There is a wide range of substrates which can be acted upon by ENPP1-3, whereby both 
pyrophosphatase and phosphodiesterase bonds are catalysed in a two-step fashion (Bollen et 
al., 2000, Gijsbers et al., 2001). It is important to note that the substrate specificity of the ENPP 
family is not solely restricted to nucleotides and indeed encompasses a wide variety of other 
substrates (Goding et al., 2003). This signifies that the ENPP family may be involved in the 
regulation of many different physiological processes. Indeed, abnormal expression of ENPPs has 
been recognised in pathologies ranging from mineralisation disorders, cell motility, angiogenesis, 
cancer and metabolic diseases (Goding et al., 2003, Terkeltaub, 2006). Much remains unknown 
about the mechanism, which govern these diverse biological processes.  
 
Of the seven isoenzymes, ENPP1-3 have received the majority of focus regarding investigation 
into their modular structure and functions in normal and disease states. The remaining members 




catalytic site, although less detail is known of their physiological catalytic functions (Bollen et al., 
2000). ENPP4-7 are predicted to be type I transmembrane orientation exhibiting shorter C-
terminal domains, which are intracellular, along with a smaller extracellular domain when 
compared to their ENPP1-3 counterparts (Goding et al., 2003). In contrast, ENPP1-3 are type II 
transmembrane glycoproteins, which have a short intracellular domain, a single transmembrane 
domain and one large, extracellular domain (Andoh et al., 1999, Bollen et al., 2000, Kamikubo et 
al., 2002, Goding et al., 2003). 
  
When considering the different isoenzymes, the most obvious structural difference is the lack of 
conservation of the intracellular domain, which is the N-terminal region of ENPP1-3, and the C-
terminal region of ENPP4-5 (Gijsbers et al., 2001). These domain lengths range, both between 
isoforms and species. For example, ENPP1 has the longest of the intracellular domains; the 
human form is 76 amino acids long whereas the mouse 58 amino acids long (Belli et al., 1993, 
Frittitta et al., 1998, Banakh et al., 2002). Additionally, ENPP1-3 have been identified as having 
active forms of the enzyme in a soluble form, both in serum and conditioned media (Hosoda et 
al., 1999). This is achieved by the cleavage of the protein, which sits out-with the transmembrane 
region, resulting in a 125kD enzymatically active fragment, yet to date, the physiological roles of 
these soluble ENPPs remain undetermined (Meerson et al., 1998). 
 
ENPP2, also referred to as autotaxin, was first identified as an autocrine motility factor and was 
identified during a cell culture study (Stracke et al., 1992). Here, investigators discovered the 
autocrine factor in the conditioned media from human melanoma cell line A2058 (Stracke et al., 
1992). The main expression of ENPP2 is within the brain, placenta, ovary and small intestine in 
humans, with further identification in the ciliary, iris pigment epithelial cells, cartilage and cranial 
bone of rats (Narita et al., 1994, Fuss et al., 1997, Bachner et al., 1999). It has been determined 
that ENPP2 hydrolyses lypophophatidylcholine (LPC) to generate the active form of phospholipid 
lysophosphatidic acid (LPA), concurrently generating choline (Tokumura et al., 2002, Umezu-
Goto et al., 2002). The resultant LPA is capable of influencing a range of physiological processes 




coupled receptors (Moolenaar, 1995, Fukushima et al., 2001, Mills and Moolenaar, 2003). 
Observations of chronic hepatitis C patients have revealed that an increase in serum LPA and 
ENPP2 activity are associated with greater severity of liver disease (Pleli et al., 2014). Studies in 
rats have revealed that increased LPA leads to an activation of pro-fibrotic signals within the liver 
(Kaffe et al., 2017). Although these are early observations, it signifies the role of ENPP2 in liver 
health and potentially points towards a therapeutic approach for the treatment of fibrotic liver.  
 
ENPP3 is also capable of hydrolysing ATP (together with ENPP1 and ENPP2) and is well recognised 
as an activation marker of human basophils (Buhring et al., 1999, Bühring et al., 2001). As such, 
ENPP3 can be used as a diagnostic marker for allergic diseases (Buhring et al., 2004). Studies of 
murine basophil mast cell have revealed an increase in the expression of ENPP3 when stimulated 
with IgE and antigen compared to unstimulated controls (Tsai et al., 2015). Little is known about 
ENPP3 and its activity. ENPP4 and ENPP5 are even more poorly understood, and have to date 
been mapped to their respective locations which include 17B2 and 17C in mice, 6p12.3 and 
6p21.1-p11.2 in human and both at 9q12 on the rat genome, respectively (Goding et al., 2003). 
 
It has been determined that ENPP6 is a choline-specific phosphodiesterase which is capable of 
hydrolysing a range of substrates, with a preference for lysopohlysophosphatidylcholine (LPC), 
sphingosylphosphorylcholine (SPC) and glycerophosphorylcholine (GPC) (Sakagami et al., 2005, 
Stewart et al., 2017). The exact localisation of ENPP6 within tissues/cells remains to be 
confirmed, although initial studies have located it within the brain and kidney proximal tubules 
(Stewart et al., 2017). It has also been shown that ENPP6 is present in bone, and is expressed in 
osteoblasts lining the bone surface (Stewart et al., 2017). The function of ENPP6 within both 
normal and disease physiological states remains to be determined.  
 
ENPP7 was initially thought to be an alkaline sphingomyelinease and was discovered in 1969 
(Nilsson, 1969). However, cloning studies in the early 2000’s revealed that this gene actually 




species, as well as in the bile and liver exclusive to humans (Duan et al., 2003, Wu et al., 2005).  
This member of the family is distinct from the others, excluding ENPP6, in that it has no 
nucleotide activity, but instead exhibits phospholipase C activity (Duan et al., 2003). Most 
attention has been paid to its action in the intestinal tract, where ENPP7 digests ingested 
sphingomyelin, promotes cholesterol absorption and inhibits colon cancer formation (Cheng et 
al., 2007). Less attention has been paid to roles in the liver, an expression site of ENPP7 that is 
unique to humans.  
 
Due to the wide range of actions, and many associated biological processes, a member, or 
members, of the ENPP family, could be targeted therapeutically. Continued efforts to 
comprehend this family of isoenzymes, their functions, interactions and co-dependency, effects 
of redundancy and the mechanisms which govern them will undoubtedly reveal prognostic and 
diagnostic value and warrants further investigation.  
 
1.2.13. Roles of ENPP1 in soft tissue mineralisation 
The investigation of mouse models of disease has undeniably increased our understanding of the 
genetic basis of skeletal-associated mineralisation defects relating to ENPP1. Additionally, 
observations of rare genetic diseases of mineralisation have also allowed insight to be gained. 
Generalised arterial calcification of infancy (GACI) is a rare autosomal recessive disease, which 
can be characterised by the formation of calcification in mineralisation competent tissues (Li et 
al., 2014b). This includes the deposition of calcium in the medium-sized arteries, which may 
ultimately lead to arterial stenosis due to intimal proliferation (Rashdan et al., 2016). Those 
individuals most severely affected by GACI will usually die within 6-months as a product of the 
sequelae associated with damage to the organs from myocardial infarction due to ectopic 
calcification (Glatz et al., 2006). A further investigation of patients presenting with GACI revealed 
that a subset of individuals develop aberrant calcification of the greater joints, characterised by 
lower than average levels of PPi, due to defective ENPP1 enzymatic function (Nitschke et al., 




patients with GACI suffered mutations in the ENPP1 encoding gene (predominantly with bi-allelic 
mutations of ENPP1) (Nitschke and Rutsch, 2012) (Fig. 1.9). 
 
1.2.14. ENPP1 pathways 
This research project focuses on ENPP1, also referred to as plasma-cell membrane glycoprotein 
1 (PC-1) (Jansen et al., 2012). Specific to ENPP1 is the hydrolysis of ATP, yet other ENPP’s 
hydrolyse substrates including, but not limited to, nucleoside triphosphates, lysophospholipids 
and choline phosphate esters (Bollen et al., 2000, Stefan et al., 2005, Zimmermann et al., 2012).  
ENPP1 is a glycoprotein that forms disulphide-bonded homodimers, present both in the plasma 
membrane and in the mineral depositing MVs of osteoblasts and chondrocytes  (Jansen et al., 
2012). Through the generation of PPi as a by-product of ATP hydrolysis, ENPP1 serves to potently 
inhibit HA crystal formation that occurs in mineralisation-competent tissues (bone and soft 
tissue) (Addison et al., 2007).  
 
Furthermore, ENPP1 regulates glucose homeostasis via suppression of the IR signalling in various 
tissues, including adipose, bone, and muscle (Maddux et al., 1995, Mackenzie et al., 2012). ENPP1 
binds to the α-subunit of the IR, resulting in inhibition of insulin-induced IR conformational 
changes. The binding of ENPP1 prevents the recruitment, and binding, of tyrosine kinase to the 
intracellular region of the β-subunit of the IR, as such abrogating the IR β-subunit 
autophosphorylation (Maddux et al., 1995). Here, the Akt/P13K pathway is not activated and 
thus no translocation of insulin-regulated glucose transporter 4 (GLUT4) receptor from the 
GLUT4 receptor vesicles to the cell membrane (Zhou et al., 2009, Pan et al., 2012). As a product 
of this altered signalling pathway, there is a disruption to glucose homeostasis and as such, 
ENPP1 is considered a pathogenic factor in the development of insulin resistance (Huesa et al., 









Figure 1.9. Schematic of insulin receptor binding in the absence and presence of ENPP1. 
 In the absence of ENPP1 (left), insulin binds to the α-subunits of the insulin receptor (IR) and 
stimulates a cascade of events. Notably, this binding facilitates tyrosine kinase-mediated auto-
phosphorylation of the IR β-subunits, leading to the downstream mediation of glucose regulation 
by the subsequent activation of pathways (e.g. P13K and AKT activation) and resulting in altered 
gene expression and/or growth. Insulin binding also stimulates the translocation of the GLUT4 
receptor to the plasma membrane where it regulates intracellular glucose transport to muscle and 
adipose tissues and, in turn, leads to pleiotropic effects such as the use of glucose, the formation of 
glycogen, the promotion of lipid synthesis, and protein synthesis. In the presence of ENPP1 (right), 
insulin binds to the α-subunit of the IR. This results in a conformational change of the β-subunit, 
preventing tyrosine kinase binding and thus inhibiting IR β-subunit auto-phosphorylation. As such, 
the downstream mediation of glucose is disturbed. There is an absence of GLUT4 translocation to 
the plasma membrane and dysregulation of glucose homeostasis, resulting in insulin resistance 
(Roberts et al., 2019b). 
 
36 
Insulin resistance is a widely acknowledged pathogenic risk factor for the development of both 
T2DM and cardiovascular disease. Amongst humans suffering from insulin resistance, levels of 
ENPP1 expression in metabolic tissues (e.g. muscle) have been reported as elevated (Frittitta et 
al., 2001, Pan et al., 2012). Furthermore, studies have shown that increased ENPP1 expression in 
muscle correlates with increased body mass index and decreased stimulation of muscle glucose 
transport by insulin (Frittitta et al., 1998, Goldfine et al., 2008). These described findings indicate 
that there is an important role in glucose homeostasis and insulin signalling centred on the 
functions of ENPP1 and that ENPP1 may link muscle and insulin resistance through its mode of 
action.  
 
ENPP1 may also contribute to T2DM through its actions in the liver. A recent study by Di Paola 
et al., revealed that suppressed ENPP1 expression in the liver, skeletal muscle and pancreatic β-
cells of mice results in improved insulin sensitivity (Di Paola et al., 2011). Furthermore, improved 
insulin sensitivity is observed following the liver-specific adenoviral knockdown of Enpp1 
expression in the db/db mouse model of diabetes (Zhou et al., 2009). These liver-specific Enpp1 
knockdown mice exhibited an 80% lower Enpp1 mRNA level, with a 25% lower fasting plasma 
glucose (Zhou et al., 2009). Interestingly, transgenic mice which over-express ENPP1 (regulated 
by a cytomegalovirus promoter) demonstrated hyperglycaemia, hyperinsulinemia and impaired 
glucose tolerance (Zhou et al., 2009). Furthermore overexpression of human ENPP1 using 
recombinant adenovirus caused an increase in the expression of gluconeogenic associated 
genes. Further studies are required to fully elucidate the complex regulatory hepatic mechanisms 
of ENPP1’s action, PPi production and regulation of T2DM.   
 
37 
It has also been demonstrated that ENPP1 polymorphisms in humans are associated with T2DM. 
There are several documented genetic studies which have mapped insulin resistance 
associations to the ENPP1 chromosome locus. For example, the ENPP1 K121Q polymorphism is 
well documented to be associated with T2DM (Leitão et al., 2008). The K121Q polymorphism (a 
missense mutation) demonstrates a stronger insulin receptor inhibition (Frittitta et al., 2001). 
Reportedly, there is a 38% increased risk for the development of T2DM in European individuals 
who are homozygous for the K121Q mutation, and the K121Q allele is associated with 
hyperglycaemia and insulin resistance (McAteer et al., 2008, Stolerman et al., 2008). 
 
 The majority of studies have focused upon the over-expression of Enpp1 in rodent models to 
elucidate its mechanisms of action. Interesting work by Zhou et al., investigated the impact of 
Enpp1 knockdown using siRNA. It reported that Enpp1 knockdown significantly increased insulin-
stimulated Akt-phosphorylation in HuH7 human hepatoma cells (Zhou et al., 2009). As such, the 
suppression of Enpp1 expression may be used as a potential therapeutic approach to the 
treatment of T2DM. The pathways that underpin the effects of insulin resistance are currently 
unknown, this action may be mediated through the hormonally active form of OCN. This would 
result in insulin secretion through pancreatic β-cell proliferation, which augments peripheral 
insulin sensitivity, and thus energy expenditure (Ferron et al., 2010a, Fulzele et al., 2010). 
 
NPP1 is capable of hydrolysing nucleotides. Nucleotides are present in the extracellular and are 
critical signalling molecules which are able to regulate a variety of biological affects via the 
purinergic cell-surface receptors (Ralevic and Burnstock, 1998). There are two main purinergic 
receptor families including the P1 receptors (which are activated adenosine) and P2 receptors. 
The P2 receptors can be divided into two families including the P2X and P2Y receptors and these 
are activated by nucleotides including ADP, ATP, UDP and UTP (Müller and Jacobson, 2011, Lee 
and Müller, 2017). Nucleotides activate these receptors and can alter processes including, but 
not limited to,  smooth muscle contraction, hormonal secretion, immune response modulation, 
cell proliferation, cellular differentiation and apoptosis (Lee and Müller, 2017). Relatedly, there 
is a tight control of nucleotides via their hydrolysis and this includes the action of NPP1 which 
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accepts a range of substrates including nicotinamide adenine dinucleotide, 3’-
phosphoadenosine-5’-triphosphate or diadenosine tetraphosphate and UDP-glucose, cyclic 
guanosine-(2’-5’)-monophosphate-adenosine’(3”,5”)-monophosphate (2’,3”-cGAMP) 
(Namasivayam et al., 2017, Bollen et al., 2000, Kelly et al., 1975, Zimmermann, 2001, Li et al., 
2014a, Barber, 2014). There are also several synthetic substrates of NPP1 including p-Nitrophenyl 
5ʹ-thymidine monophosphate (p-Nph-5ʹ-TMP), p-Nitrophenyl phenyl phosphate (p-NPPP) and 
bis(p-nitrophenyl) phosphate (bis(p-NP)P) (Henz et al., 2007, Lee et al., 2012). These actions of 
NPP1 on substrates other than ATP (and the subsequent generation of PPi) and the effects on 
purinergic signalling remain beyond the scope of this thesis, although would be enlightening.  
 
ENPP1 plays multifaceted roles in normal physiology, including the regulation of calcium and Pi 
homeostasis, the inhibition of soft tissue mineralisation by generation of PPi, the maintenance 
of skeletal function, regulation of insulin signalling and energy homeostasis. Yet the exact 
function and mechanisms of ENPP1 within this relationship remains unclear, with many 
unanswered questions. For example, which cells types are responsible for the current poorly 
understood metabolic-related roles of ENPP1? 
 
The rationale for further investigating cell-specific roles in metabolism lies in the knowledge that 
the osteoblast-derived hormones may be responsible for many of the skeleton’s energy 
homeostatic actions. This has been demonstrated by the partial ablation of osteoblasts in mice, 
which resulted in profound effects in glucose metabolism, gonadal fat mass and an increased 
energy expenditure (Yoshikawa et al., 2011). OCN administration partly corrected the metabolic 
phenotype, however, it did not improve the increased energy expenditure or decrease gonadal 
fat (Yoshikawa et al., 2011). This suggests that osteoblasts can affect glucose metabolism through 
both OCN-dependent and OCN-independent mechanisms. Since the osteoblast is integral to 
OCN-related bone-endocrine functions, could this cell also play a key role in the actions of 
ENPP1? Much remains to be explored regarding specific mechanisms of actions and pathways of 
new candidates relating to skeletal-metabolic homeostasis. Once determined, this knowledge 
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may aid in identifying novel pharmacological approaches for the management and treatment of 
skeletal and metabolic diseases.  
 
1.3. Aims and strategy 
ENPP1 is well known as a generator of PPi which potently inhibits mineralisation. Less well known 
is ENPP1’s identified role as a pathogenic factor, predisposing to insulin resistance and 
subsequent T2DM (Bacci et al., 2007). Indeed, T2DM is an independent risk factor for further 
downstream metabolic diseases. Previous studies have revealed that Enpp1-/-  mice have  notable 
skeletal and metabolic phenotypes (Mackenzie et al., 2012, Huesa et al., 2014). These mice 
exhibit hypomineralisation of the long bones and abnormal pathological calcification of soft 
tissues including the vasculature. The insulin-sensitive metabolic phenotype, which is 
pronounced following high-fat diet challenge, results in protection against both obesity and 
insulin resistance (Huesa et al., 2014). ENPP1 is highly expressed in certain tissue and cell types 
including kidney, pancreas and muscle, as well as chondrocytes and osteoblasts. However, the 
organ and cell-specific contributions remain unknown.   
 
In the present project, I hypothesised that the ablation of NPP1 in the osteoblasts of mice would 
recapitulate the metabolic protection observed in the Enpp1-/- mice, and would result in 
increased bone mineralisation as a product of reduced PPi. To investigate this hypothesis the 
following aims were addressed in this thesis:  
 
1. To determine the impact of osteoblast-specific NPP1 ablation on bone geometry and 
micro-architecture, matrix mineralisation and biomechanical properties in mice. 
 
2. To investigate the profile of NPP1 during osteoblast matrix mineralisation in vitro. This 
involves the use of established cell lines and cells isolated from the novel osteoblast-




3. To investigate the impact of osteoblast-specific NPP1 ablation on the metabolic 
phenotype of mice following control-diet feeding and chronic high-fat diet feeding.  
 
To address the aims of this PhD both in vitro and in vivo models have been utilised. The work 
presented in chapter 4 demonstrates that osteoblast-specific NPP1 ablation engenders increased 
bone mass and bone mineral density in juvenile mice. Primary osteoblasts were isolated from 
the novel NPP1 conditional mouse model to investigate and confirm whether a 
hypermineralisation phenotype was reflected in vitro. These findings support the hypothesis that 
ablated Enpp1 mouse models would have increased bone formation likely due to decreased PPi 
levels.  
 
Due to the concomitant role of ENPP1 in bone and insulin resistance, this project then 
investigated the impact of Enpp1 ablation in osteoblasts on metabolic phenotype, including both 
under normal dietary conditions, and under obesogenic dietary conditions of a high-fat diet. 
Multiple parameters were investigated in detail including in vitro glucose regulation, detailed 
histological analysis of organs, and biochemical analysis (chapter 5 and 6). These data are 
essential to further understand the link between energy metabolism, bone formation and cell-








2.1. Chemicals, media and buffers 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (Dorset, UK) and 
tissue culture medium and buffers from Thermo Fisher (Loughborough, UK). Polymerase chain 
reaction (PCR) primers were purchased from Qiagen (West Sussex, UK) and Sigma (Dorset, UK). 
A table of primers used can be found in Appendix I.  A list of buffers and solutions can be found 
in Appendix II. 
 
2.2. Cell culture 
2.2.1 Cell culture reagents 
Cell and tissue culture reagents were prepared in a sterile category 2 hood. Cell media was 
supplemented with broad-spectrum antibiotic gentamicin (0.05 mg/ml), and 10% heat-
inactivated foetal bovine serum (FBS) (Life Technologies), which was filter-sterilised using a 0.22 
µm filter (Sigma-Aldrich, UK) before use. For minerlisation experiments, mineralisation media 
was used, further supplemented with 50 µg/ml ascorbic acid and 5 mM b-glycerophosphate (b-
GP) disodium salt hydrate. 
 
2.2.2 Cell types 
For time-course mineralisation studies up to 21 days, the murine pre-osteoblastic cell line 
MC3T3-E1 sub-clone C14 (a fast mineralising variant) was selected (Wang et al., 1999a). Primary 
osteoblasts from Enpp1flox/flox and Enpp1flox/flox;Ocn-cre mouse pups (2-5 days old) were isolated 
(Section 2.7.1) and used for time-course mineralisation studies up to 28 days. 
 
2.2.3 Maintaining and passaging cells 
Once cells reached sub-confluence (70-80%), the cells were passaged by trypsinisation. The 
culture medium was initially removed and the cell monolayer subsequently rinsed with wash 
buffer consisting of Hank’s Buffered Salt Solution (HBSS; Life Technologies, Paisley, UK) 
containing 1% gentamicin. Cells were subsequently detached from plastic by incubation with 
TrypLE Express Enzyme (Life Technologies) for 5 minutes at 37°C, in a humidified incubator, in 
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the presence of 5% CO2. The trypsinisation reaction was then neutralised with the addition of at 
least double the volume of appropriate cell culture medium containing 10% FBS. Cellular 
suspensions were then collected and centrifuged at 2000 g for 5 minutes such that a cellular 
pellet was obtained the supernatant was discarded and the cells were subsequently re-
suspended in 1 ml of appropriate fresh culture medium (warmed to 37°C). The cells were 
subsequently counted using a Neubauer haemocytometer and resuspended in a known volume 
of required culture medium.   
 
2.2.4 Freezing/thawing of MC3T3-E1 sub-clone c14 cells  
To maintain stocks of the MC3T3-E1 sub-clone c14, cells were initially grown to 100% confluence 
in T175 flasks and subsequently counted (Section 2.2.3). Cells were then centrifuged at 2000 g 
for 5 minutes, and resuspended in a 1:1 culture media and freezing media containing dimethyl 
sulfoxide (DMSO) (Appendix 2), at a density of 4 x 106/ml. Cells were transferred to cryovials 
(Corning, U.K), and placed in a polystyrene box, and kept for 48-72 hours at -80°C. Subsequently, 
cryovials were moved to -150°C for long term storage. When cells were required, the cryovial 
was warmed in a 37°C water bath and immediately added drop by drop to 20mL of pre-warmed 
culture media. The cell suspension was then centrifuged at 2000 g for 5 minutes to remove the 
DMSO and any cellular debris. The cell pellet was resuspended in culture media and transferred 
to a T175 flask and left to propagate in a humidified atmosphere of 95% air/5% CO2 at 37°C.  
 
2.2.5 Dissection and extraction of primary osteoblasts from calvariae 
All steps were conducted under sterile conditions. One calvariae per new-born mouse (2- to 5-
days old) was dissected and collected into a universal containing 6mls of HBSS containing 1% 
gentamicin and washed. The HBSS was removed and calvariae digested as follows: 
 
1. 2-3 mls collagenase type 2 (Worthington, Lakewood, NJ) was added to the universal 
containing calvariae at 1 mg/ml and shaken for 10 minutes in a heated and shaking 




2. The supernatant was discarded, 2-3 mls of fresh collagenase type 2 (Worthington) at 1 
mg/ml was added, shaking at 37°C for 45 minutes. The supernatant (referred to as 
‘fraction 1’) was removed and retained.  
 
3.  Calvariae were washed with 6 mls of phosphate-buffered saline (PBS), which was 
subsequently removed and added to fraction 1.  
 
4.  The calvariae were then treated with 2-3 mls of 4 mM ethylenediaminetetraacetic acid 
(EDTA) (Thermo-Fisher), shaking at 37°C for 10 minutes. The supernatant was removed 
and retained (referred to as ‘fraction 2’). The calvariae were washed with 6 mls HBSS, 
which was subsequently removed and added to fraction 2.  
 
 
5.  Fresh 2-3 mls of collagenase was added to the calvariae, shaking at 37°C for 45 minutes. 
The supernatant from this final digest was collected (referred to as ‘fraction 3’).  
 
From fractions 1-3, osteoblasts were isolated by centrifuging (2000 g for 5 minutes) and were 
resuspended in primary osteoblast medium before being pooled to obtain a single-cell 
suspension. The extracted osteoblast cells were seeded into a T75 flask in a humidified 
atmosphere of 95% air/5% CO2 at 37°C. After 3 hours, media in the flask was replaced with fresh 
media and returned to the incubator. The flasks were left to reach 85-90% confluence and were 
then plated at 100,000 cells/well in 6-well plates for individual experiments. For a schematic 
representation of this process see Appendix III.   
 
2.2.6 Plating of cells for experiments 
The cells (either MC3T3-E1 sub-clone c14 or primary osteoblasts) were trypsinised and counted 
(Section 2.2.3), and then resuspended media. Of this cell suspension, 2 mls of media were added 
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to each well of a 6-well plate to ensure 10,000 cells/well. For 12-well experiments, cells were 
plated at 50,000 cells/well. Appropriate culture media was changed every 2-3 days until cells 
reached confluence (day 0). After this point, for mineralisation time point experiments, 
mineralisation media (containing 50 µg/ml ascorbic acid, and 5 mM b-GP) replaced the culture 
media and was changed every 2-3 days.  
 
2.3. RNA methods 
2.3.1 Isolation of RNA from cells 
Before RNA extraction, cultured cells were washed with PBS and scraped from individual wells in 
RLT buffer containing 1% β-mercaptoethanol (Qiagen, Crawley, UK) and stored at 4°C. The 
RNeasy Kit (Qiagen, Crawley, UK) was used to isolate mRNA from cell lines as follows. An equal 
volume of 70% alcohol was added and mixed by pipetting up and down. The cell lysate solution 
was transferred into a Qiagen RNeasy spin column provided by the kit. The column was 
centrifuged at 8000 g and the flow-through was discarded. Next, the column was washed with 
RW1 buffer and then twice with RPE buffer. The RNA was eluted with 40 µl nuclease-free distilled 
water (dH2O). The extracted mRNA sample concentrations were determined using a NanoDrop 
Spectrophotometer (Labtech, Tampa, USA), and all samples were diluted using nuclease-free 
water (NFW) to achieve a concentration equal to that of the least concentrated samples or 
5µg/ml. 
 
2.3.2 Reverse transcription 
Complementary DNA (cDNA) was prepared from 20 µl of the diluted RNA using reverse 
transcription. Briefly, 4 µl of random primers (diluted 1:60, Life Technologies) was added to the 
20 µl of diluted mRNA. Samples were then heated for 10 minutes at 70°C in a Hybaid polymerase 
chain reaction (PCR) Express Thermal Cycler (Thermo Scientific, Northumberland, UK). Samples 
were then incubated at 4°C to block non-specific sites. The Superscript II kit was used to obtain 
cDNA following manufacturer’s guidelines: 15 µl of Mastermix (5 µL 5x First-Strand buffer (Life 
Technologies), 2 µl Dithiothreitol (DTT; 0.1M, Life Technologies, 2 µl dNTP (10mM; Life 
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Technologies) and 1 µl Superscript II Reverse Transcriptase (Invitrogen; Renfrewshire, UK) was 
added to each mRNA. Samples were then run on the following programme in the Hybaid PCR 
machine: 25°C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes. The cDNA was then 
diluted with NFW to 5 ng/µl and stored at -20°C until use. 
 
2.3.3 Real-time quantitative PCR (qPCR) and quantification of gene expression 
For each qPCR sample, a master-mix was made consisting of: 10 µl SYBR Green PrecisionPLUS 
qPCR Master Mix (PrimerDesign, UK), 1 µl of the forward/reverse primer (10 µM) for the target 
gene and 4 µl dH2O. Total reaction volume was 20 µl, comprising 15 µl of master-mix and 5 µl of 
cDNA sample. Technical duplicates of samples were used for all reactions. For the negative 
control, a reaction consisting of 5 µl of dH20 and 15 µl of mastermix was used. Real-time qPCR 
reactions were conducted in a 96-well plate (Thermo Scientific) and cycled using a Stratagene 
mx300P PCR cycler (Agilent Technologies, Santa Clara, USA) with the following programme; 1 
cycle of 95°C for 10 minutes, 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. Results were 
compared to the β-Actin (ACT-B) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
housekeeping-gene(s). To test the efficiency of primers, serial dilutions of cDNA (which express 
the target gene) were used to create a standard curve. Primers used had an amplification 
efficiency between 85-110%, and an R2 value between 0.90 and 1.00. The primer specificity was 
demonstrated by the generation of a clean, single peak in the dissociation curve. The reactions 
were analysed using standard curves and amplification plots, which shows the fluorescence 
signals versus cycle numbers. The baseline for the plot is defined by Rox (reference dye). For 
analysis, the fold change in the expression of the gene of interest’s relative to the housekeeping 
gene(s) was calculated using the ∆∆Ct method, where an arbitrary amplification threshold (CT) 
is set and the relative expression levels of samples are calculated by comparison to the number 
of amplification samples required to cross this CT (Livak and Schmittgen, 2001). 
 
2.3.4. Genotyping 
As needed, agarose gel was made by diluting 1.5 g of agarose in 100 ml of Tris-
acetateethylenediaminetetraacetic acid (TAE) buffer (Ambion, Cambridge, UK) containing 0.1 
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µl/ml SYBR-Safe (Thermo Fisher). The samples were loaded at a volume of 20 µL per well. As a 
negative control, an equal volume of dH2O was used to replace cDNA. The gel was run in TAE 
buffer, in an electrophoresis tank at 100 V for 50 minutes. HyperLadder 1 kb Bioline) was used 
as molecular weight markers. The resulting gel was visualised under UV light using the Gel Logic 
200 Imaging System and software (Kodak, Herts, UK). 
 
2.4. Protein methods 
2.4.1 Protein extraction from cells for western blot analysis 
From each well, the culture media was discarded and the cellular monolayers were washed with 
PBS to remove excess media. An appropriate volume of RIPA buffer (Sigma-Aldrich) was added 
to scrape the cellular monolayer. All samples were centrifuged and the supernatant removed 
and stored at -20°C before quantification.  
 
2.4.2 Quantification of protein concentration: Bio-Rad DC assay 
The media from the cellular monolayer was discarded and cell monolayers were washed with 
PBS to remove excess media. An appropriate volume of 0.1 M NaOH 0.1% sodium dodecyl 
sulphate (SDS) lysis buffer was added to the cellular monolayer to denature cellular proteins and 
incubated at room temperature on a shaker for 1 hour. The cells were scraped and collected into 
Eppendorf tubes. Tubes were subsequently vortexed and centrifuged at 10,000 rpm for 10 
seconds. To quantify protein concentrations, Bio-Rad DC Protein Assay (Bio-Rad Hertfordshire, 
UK) was used according to manufacturer’s instructions, with a protein standard used to obtain a 
standard curve. The protein standard of bovine γ-globulin protein (0.125 – 2 mg/mL; Bio-Rad) 
was prepared in a solution of 0.1 M NaOH 0.1% SDS. For both protein standard and protein, 5 µl 
of sample was assessed in duplicate on a 96-well plate, with 25 µl alkaline copper tartrate 
(Reagent A) and 200 µl Folin’s reagent (Reagent B) subsequently added. The 96-well plate was 
incubated at room temperature for 15-60 minutes before the absorbance measurement (at a 
wavelength of 690 nm) using the Synergy HT Multi-Mode Microplate reader (BioTek, 




2.4.3. Western blot analysis  
Bone marrow was removed from cut humeri by centrifugation. The bones were next 
homogenised in cold RIPA buffer (Invitrogen) containing ‘phosphatase inhibitor cocktail 2’ 
(Sigma) and ‘complete’ protease inhibitor cocktail (Roche) according to the manufacturer’s 
instruction. Western blotting was conducted with specific antibodies against ENPP1 (LI-COR 
Biosciences, 1:15000 dilution in Blocking buffer (Odyssey)) and b-actin (LI-COR Biosciences, 
1:15000 dilution in Blocking buffer (Odyssey)). Following the determination of protein 
concentration (Section 2.4.2.), samples were diluted to the same concentration (between 10-30 
µg) and the appropriate volume of 4x lithium dodecyl sulphate (LDS) sample buffer and reducing 
agent DTT was added to each sample. Diluted protein samples were denatured at 70°C for 10 
minutes. The denatured protein samples and a pre-stained molecular weight marker to 
accurately determine protein size (All blue, Bio-RAD) were chilled on ice before being loaded 
onto a pre-cast 10% Bis-Tris gel (Invitrogen, Paisley, UK). Gels were run in a Novex Gel Tank 
(Invitrogen) containing 1x Tris Acetate or 1x MOPS running buffer, respectively. Anti-oxidant was 
added to the centre compartment of the tank to preserve reduced proteins (2.5 μl/ml; 
Invitrogen). Proteins were separated by electrophoresis for 5 minutes at 170 V followed by 55 
minutes at 150 V. The gel was subsequently transferred to a methanol activated polyvinylidene 
difluoride (PVDF) membrane via a semi-dry transfer (Bio-Rad) for 90 minutes at 18 V. Following 
transfer, the membrane was washed several times in Tris-Buffered Saline and Tween 20 (TBST). 
The membrane was blocked in Odyssey blocking buffer (Licor). Primary antibody was applied 
overnight at 4°C with agitation.  Membranes were next washed in TBST and incubated in a 
secondary antibody diluted in Oddysey blocking buffer with agitation at room temperature for 1 
hour. Membranes were protected from light due to the light-sensitivity of Licor antibodies. 




2.5. Cell-based assays and staining 
2.5.1 O-cresolphthalein complexone calcium assay 
Media from the cellular monolayer was discarded and the cell monolayers were washed with 
PBS. Next, 500 µl of 0.6 M HCl was added to the monolayer and incubated at 4°C to disrupt the 
cellular membrane. A Calcium Assay Kit (Randox, County Antrim, UK) was used to quantify the 
calcium deposition in the cells, with samples and standard run in duplicate. The working principle 
of this assay is based upon the binding between o-cresolphthalein complexone and calcium ions 
in an alkaline media. A negative control using the leaching solution, 0.6 M of HCl, was included, 
as well as a calcium standard (10.2 ng/ml) needed for calcium concentration calculation, 
provided by the kit. Next, 6.25 µl of  standard/negative control/sample was added to a 96-well 
plate, in duplicate. Subsequently, 250 µl of 1:1 ratio of 2-amino-2-methyl-propan-l-ol (R1) and o-
Cresolphthalein complexone, 8-Hydoxyquinoline, HCl (R2) were added to each well. The optical 
density (OD) was then read on a Synergy HT Multi-Mode Microplate reader at 570 nm. The 
calcium concentration of each sample was determined using the following equation:  
 
Concentration = +mmolL / = +	
Sample	OD
Standard	OD/ ∗ standard	concentration	 +
	mmol
L / 
Calcium concentration was then normalised to total protein concentration. 
 
2.5.2 Alizarin red S staining and quantification 
The media from each culture well was discarded and the cellular monolayer was washed with 
PBS. Cells were then fixed with 4% PFA for 15 minutes at room temperature. The PFA was 
discarded, and cellular monolayers were washed three times with PBS. Subsequently, 2% (w/v) 
Alizarin Red S Stain (pH 4.2) was added and incubated at room temperature for 10 minutes. 
Cellular monolayers were washed with water until any unbound Alizarin red S stain had been 
removed. The cellular monolayer was allowed to dry and was photographed. After 
photographing, cells were stored dry at -20°C. When required, bound Alizarin red S stain was 
solubilised using 10% cetylpyridinium chloride. Samples were collected and run in duplicate, 
using cetylpyridinium chloride as a blank, in a 96-well plate to measure the optical density at 570 
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nm. Optical density was determined using the Synergy HT Multi-Mode Microplate reader 
(BioTek, Bedfordshire, UK).  
2.6. In vivo studies  
2.6.1 Animal welfare and generation 
Animal experiments were approved by the Roslin Institute’s Animal Users Committee. All animals 
were maintained in accordance with the Home Office Guidelines for the care and use of 
laboratory animals. To further study NPP1 function, the osteoblast-specific Enpp1 ablated mouse 
model (Enpp1flox/flox;Ocn-cre) was generated. Here, a commercially available Enpp1flox/flox mouse 
(Cyagen Biosciences, California, USA) with floxing site on exon 9 was crossed with an Osteocalcin-
Cre mouse (Ocn-cre) (Yoshikawa et al., 2011, Staines et al., 2017). The resultant mice express Cre 
recombinase specifically in osteoblast cells: therefore, floxed Enpp1 in this cell type will not be 
expressed (Fig 2.1). Male and female mice were culled at 6-weeks (juvenile), 16-weeks, and 22-
weeks (adult) of age; gender and number of mice studied are specified in each experiment. 
Genotyping as required was performed on genomic DNA isolated from ear clips and analysed 
using PCR protocols (Section 2.3.4). Confirmation of knockout status as required was performed 
by western blot analysis for NPP1 from protein isolates of tissues (Fig. 2.2) (Section 2.4.3). For a 
schematic of animals used for metabolic or bone phenotyping, associated ages and sex of mice 
see Appendix III.  
 
2.6.2 Maintenance of Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice  
The generation and characterisation of Enpp1flox/flox;Ocn-cre is described above. Genotyping of 
pups (aged 2-5 days) was performed using genomic DNA isolated from tail snips, whereas 
genomic DNA isolated from ear clips was used for all other mice. Offspring carrying the Ocn-cre 
gene were identified using Genomic DNA, which was analysed using PCR protocols (developed 
by Professor Thomas Clemens, USA) (Section 2.3.4). For primary osteoblast cell culture 
experiments, mice were culled between 2-days and 5-days of age. Mice involved in metabolic 
phenotyping experiments were fed either a control diet (6.2% fat; Harlan Laboratories, 
Indianapolis, IN, USA) or a high-fat diet (HFD) (58% from fat; Research Diets, Inc, New Brunswick, 
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NJ, USA) from 4-weeks of age until culling. Ad libitum food consumption and weight gain was 






Figure 2.1.  Breeding Scheme for osteoblast-specific ablated Mice. 
The first breeding scheme generates mice which are heterozygous for the LoxP-flanked allele of 
Enpp1. These mice were selected and mated with a homozygous LoxP ‘floxed’ mouse in a second 
breeding. This generates approximately 25% of progeny which are homozygous for the LoxP-flanked 
allele and heterozygous for the cre transgene. These are the experimental mice. Homozygous 







    
Figure 2.2. Representative western blot analysis 
Assessment of NPP1 protein in bone and selected soft tissues of mice. The order on the blot is 
as follows: bone (humerus) of Enpp1flox/flox;Ocn-cre moose, bone (humerus) of Enpp1flox/flox 
mouse, kidney of Enpp1flox/flox;Ocn-cre and liver of Enpp1flox/flox;Ocn-cre mouse.  
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2.6.3. Metabolic analysis of animals 
A total of 300 g of food was provided per cage and food remaining after 7 days was recorded and 
average weekly food consumption per mouse calculated from 4 to 16-weeks of age. Blood was 
extracted from these mice via cardiac puncture and collected via a 4% EDTA laced syringe and 
into 4% EDTA coated tubes (Sarstedt, Numbrecht, Germany). Tubes were then centrifuged at 
1000 g resulting in separation of plasma. This plasma was carefully collected and stored at -80°C 
until use.   
 
2.6.4 Glucose and insulin tolerance testing 
For glucose tolerance testing (GTT), adult  Enpp1flox/flox and Enpp1flox/flox;Ocn-cre male mice (14-
weeks of age) were fasted for 4 hours and administered 2 mg of D-Glucose per g of body weight 
by oral gavage.  For insulin tolerance testing (ITT), 16-week old mice were fasted for 4 hours and 
administered 0.75 mU of insulin (Actrapid, NovoNordisk, Bagsvaerd, Denmark) per g of body 
weight intraperitoneally (i.p). At time points of 0, 15, 30, 60 and 120 minutes post-
administration, blood glucose was measured with an Accu-Check® Aviva glucose meter (Roche 
Diagnostics LTD, Lewes, UK) and glucose-stimulated insulin secretion (GSIS) was measured by 
ELISA (ChrystalChem, Chicago, IL, USA). Mice were allowed to recover before subsequent 
sacrifice occurring at 16-weeks of age. Tissues including pancreas, liver, quadriceps femoris 
muscle, and brown, subcutaneous, mesenteric and gonadal fat pads were collected for 
histological assessment, gene and protein expression analysis.  
 
2.6.5. Catwalk analysis 
Gait analysis was recorded using a CatWalk XT gait analysis system (Noldus Information 
Technology, the Netherlands) and previously described (Hamers, Lankhorst, Van Laar, Veldhuis, 
Gispen 2001; Maschocha & Parvathy, 2009). Briefly, each mouse was placed on the catwalk and 
moved at their own free will down a glass walkway corridor that detects their gait and 
locomotion (Fig. 2.3). Mice were habituated to the equipment for 2-weeks before analysis. Data 












Figure 2.3. Schematic of catwalk gait analysis. 
Representative walking pattern of mouse on Catwalk gait analyser. Examples of measured 
parameters include the base of support (BOS) and stride length (the distance between one 
right front (RF) and another RF footprint). Other footprints include Right hind (RH), left front 
(LF) and left hind (LH). Other parameters include coupling of different paws, paw print width, 




2.7. Ex vivo bone analysis and gross analysis 
2.7.1 Bone length and 3-point bending 
The length of tibiae and femora from male and female Enpp1flox/flox and Enpp1flox/flox;Ocn-cre mice 
at ages 6-weeks, 16-weeks and 22-weeks of age were measured using DigiMax digital Vernier 
callipers (R. S. Components Ltd, Corby, Northants, UK). Three-point bending was also conducted 
on tibiae and femora using an LXR materials testing machine (Lloyds Instruments, West Sussex, 
U.K.) fitted with a 500 N load cell. The lowering of the crosshead was set at a speed of 1 mm/min. 
To ensure the same sight of the anvil head, tibiae and femurs were placed on the anvil in a pre-
determined, consistent orientation. Data began recording after every 0.2 N change in load and 
after 0.1 mm change in deflection (Fig. 2.4). Both tibiae and femora were tested until the point 
of fracture. From the generated load extension curve, failure (being the point of maximum load), 
fracture (whereby the load rapidly decreases to 0), maximum stiffness (defined as the maximum 





















Figure 2.4. Three-point bending and load extension curve. 
(A) Figure demonstrates the typical placement of a bone on the apparatus platform with load 
head aimed at central diaphysis. (B) A typical load extension curve that is obtained during 3-point 






2.7.2. Micro-computed tomography imaging 
Tibiae and femora were dissected from 6-week and 22-week old male and female Enpp1flox/flox  
and Enpp1flox/flox;Ocn-cre, fixed in 10% NBF for 24 hours and subsequently stored in 70% ethanol. 
The long bones were scanned using a micro-computed tomography (µ-CT) system (Skycan 1172, 
Bruker, Aartselaar, Belgium) to assess trabecular architecture and cortical geometry. High-
resolution scans with an isotropic voxel size of 4-5 µM were acquired (50 kV, 200 µA AI filter, 0.4° 
rotation step). Scan time was approximately 1 hour per bone. The scans were reconstructed 
using NRecon software (Skyscan, Bruker, Belgium). For each bone, the growth plate was used as 
a standard reference point, and a region of 1 mm in height was analysed. A 0.4 mm and 2.50 mm 
offset from the growth plate was used for trabecular and cortical bone respectively. All bones 
were corrected in DataViewer to ensure the same orientation.  
 
Bone tissue was identified by thresh-holding, whereby the optimum threshold was determined 
using the image histogram, and set to exclude soft tissue whilst still including poorly mineralised 
bone. The thresh-hold used remained consistent throughout the analysis of all samples at values 
of 80 and 225. For calculation of bone mineral density, an appropriate calibration of the Skyscan 
CT analyser was conducted using phantoms known calcium hydroxyapatite densities of 0.25 and 
0.75 g/cm-3.  
 
The following parameters were analysed using CTan software (Skyscan, Belgium); in trabecular 
bone.bone volume (BV/TV), trabecular number (TB.N;/mm) bone mineral density (BMD; g/cm3), 
trabecular thickness (Tb.Th; mm), trabecular separation (Tb.Sp) and structural  model index (SMI) 
were evaluated. For cortical bone, % BV/TV, BMD (g/cm3), cortical thickness, cross-sectional area 
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2.7.3 Gross analysis 
Following the euthanasia of male Ocn-cre;Enpp1flox/flox and Enpp1flox/flox mice for metabolic 
phenotyping at 16-weeks of age, the following were weighed using an analytical balance (Fisher 
Scientific); total body weight, brown fat, hind-body subcutaneous fat, gonadal fat, mesenteric 
fat, spleen, pancreas, kidney, liver, right and left quadriceps. 
 
2.7.4 Histopathological assessment 
Following euthanasia at 16-weeks of age, the following soft tissues were fixed in 10% neutral 
buffered formalin (NBF), embedded in paraffin wax using standard procedures. Kindly performed 
by Prof Elspeth Milne, the 5 µM thick sections were stained with Hematoxylin and Eosin (H&E) 
and Von Kossa to assess calcification status of heart, brain, kidney, liver, pancreas, quadriceps 
femoris muscle and whisker follicle.  
 
2.7.5. Osmium staining of marrow adipose tissue 
Following euthanasia of male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice from both control-diet 
fed and high-fat diet fed (Section 2.7.2) cohorts at 16-weeks of age, femora and tibiae were 
dissected and soft tissue was cleaned from the bone. Bones were fixed in an appropriate volume 
of 10% NBF for 24 hours at room temperature. Tibiae and femora were separated from each 
other, ensuring the tibia remained 100% intact. Bones were subsequently decalcified in 14% 
EDTA (pH 7.4) for a minimum of 14 days at 4°C (EDTA was changed every 3-4 days). Upon 
complete decalcification, bones were washed in Sorensen’s buffer (3 changes, each wash for 1 
hour). Bones were then stained with 1% osmium tetroxide solution (2% w/v, Agar Scientific, 
UK diluted 1:1 in Sorensen’s Phosphate buffer) for 48 hours at room temperature, washed 
in Sorensen’s buffer (3 changes, each wash for 1 hour) and stored in Sorensen’s phosphate buffer 
(pH 7.4) at 4°C until use (maximum of 7 days). For µ-CT analysis of the osmium stained marrow 
adipose tissue, layers of 4 to 5 stained tibia were arranged in parallel in 1 % agarose in a 30 mL 
universal tube and mounted in a Skyscan 1172 desktop µ-CT (Bruker, Kontich, Belgium). The 
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samples were scanned through 360° using a step of 0.4° between exposures. A voxel resolution 
of 12 µm was obtained in the scans and the following control settings were used: 54 kV source 
voltage, 185 µA source current and an exposure time of 885 ms. A 0.5-mm aluminium filter and 
a two-frame averaging were used to optimise the scan. Following scanning, data were 
reconstructed using Skyscan software NRecon v1.6.9.4 (Bruker, Kontich, Belgium). The 
reconstruction thresh-holding window was optimised to encapsulate the target image. 
Volumetric analysis of marrow adipose tissue stained with osmium was conducted using CT 
Analyser v1.13.5.1 (Bruker Kontich, Belgium). This work was kindly performed by Dr Karla 
Suchacki and Dr Will Cawthorn of the University of Edinburgh. 
 
2.8. Histological analysis 
2.8.1. Preparation of tissue for microscopical analysis  
All soft tissues were fixed in 10% NBF, embedded in wax and sections were cut to appropriate 
thickness for microscopical analysis using a Thermo microtome. For fat pads (brown, mesenteric, 
gonadal and subcutaneous) 4 µM thick sections were stained with H&E to assess adipocyte 
number and size distribution. For pancreas, 5 µM thick sections were stained with H&E to assess 
insulin-secreting β-cell number and size. For liver, 5 µM sections were H&E stained to assess 
tissue architecture, and 8 µM sections were stained with picrosirius red (with fast-green 
counterstain) to identify collagen deposition and assess fibrosis. Similarly, long bones were fixed 
in 10% NBF and decalcified in 10% EDTA for 14 days at 4°C and embedded in wax and 4 µM thick 
sections were cut using conventional means.  
 
 2.8.2. Paraffin-embedded tissues 
For wax sections, tissues were fixed in either 4% PFA or 10% NBF for a minimum of 48 hours and 
subsequently transferred to 70% ethanol. For calcified tissues, a decalcification was performed 
before fixing. Here, tissues were decalcified in 10% EDTA (pH 7.4) for approximately 21 days, with 
gentle agitation at 4°C. Throughout the 21 days, EDTA was regularly changed. The NBF and PFA 
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fixed tissues were placed in cassettes and underwent the following automated protocol involving 
two changes of the following:  
• 70% ethanol (1 hour)  
• 80% ethanol (1 hour)  
• 95% ethanol (1 hour)  
• 100% ethanol (1 hour)  
• Xylene (VWR, Leicester, UK) for 1 hour 
• Overnight in paraffin wax (VWR) and 60 °C 
Subsequently, cassettes were placed in fresh paraffin wax for 1 hour. The processed tissues were 
then embedded in paraffin wax using plastic moulds. After setting at 4°C, paraffin blocks were 
trimmed to size and stored at room temperature until required. For thirty minutes before 
sectioning, paraffin blocks were cooled on an ice block. A microtome with blades (MX35 Premier+ 
Microtome Blades, Thermo Scientific, Cheshire, UK) was used to section at 5 µM thickness. 
Sections were placed to float on water at 40°C for 1 minute before transferring to Superfrost 
microscope slides. Slides were placed to dry at 37°C overnight to ensure that sections adhered 
to the slide. Slides subsequently stored at room temperature until required.  
 
2.8.3. Haemotoxylin and eosin staining 
Paraffin-embedded tissue sections were stained with haemotoxylin and eosin (H&E). Slides were 
initially de-waxed in xylene and rehydrated through a series of alcohols to dH2O and stained with 
H&E using a Leica Autostainer and mounted in DePeX (VWR, Lutterworth, UK). This involved 
submerging sections in alum haemotoxylin for 5 minutes and rinsing with running tap water for 
5 minutes. Slides were then differentiated by dipping in 0.5% acid alcohol and rinsed again with 
running tap water for 5 minutes. Next, slides were blued with 0.2% ammonia for 30 seconds, 
before washing with running tap water for 5 minutes and rinsed by dipping in 95% ethanol. Lastly, 
the slides were counterstained with eosin for 2 minutes, dehydrated with 2x 5-minute 
incubations in 95% ethanol and cleared with 2x 5-minute incubations in xylene. Slides were then 




2.8.4 Von kossa staining 
Von kossa staining was performed to allow an assessment of calcification in soft tissue. For tissue 
staining, the sections were rinsed with dH20 and slides were placed in a Coplin jar and 5% silver 
nitrate. The slides were subsequently exposed to strong light for 30 minutes and rinsed with 
dH20. Un-reacted silver was removed by incubation with 5% sodium thiosulfate for 4 minutes. 
Slides were then dehydrated with 3x changes of absolute ethanol and cleared with 3x changes 
of xylene. The slides were then mounted with DePex. Scott Dillon provided the protocols of this 
work. Staining was performed by Dr Elspeth Milne.  
 
2.8.5. Toluidine blue/fast green staining 
For toluidine blue/fast green staining of sectioned bone, sections were deparaffinised, blotted 
dry and rinsed with dH2O. A sodium acetate buffer was made (13.6 g of sodium acetate diluted 
in 1 L of dH2O) and titrated to pH 4 using glacial acetic acid This solution was stored at 4°C. A 
0.4% toluidine blue solution was made (0.4 g of toluidine blue O in 100 mls of sodium acetate 
buffer), wrapped in foil and stored at 4°C and equilibrated to room temperature before staining. 
A 0.002% fast green solution was made (0.05 g of Fast Green dissolved in 250 mls dH2O). The 
deparaffinised sections were incubated in the toluidine blue solution for 10 minutes, rinsed in 
three changes of dH2O. Slides were then counterstained in 0.002% fast green for three minutes 
and rinsed in three changes of dH2O. Slides were blotted dry, quick mounted using DePex and 
visualised using a Nikon CoolScan V (Nikon, Surrey, UK). Scott Dillon provided the protocols of 
this work. 
 
2.8.6. Goldner’s trichrome staining 
All solutions were made according to Table 2.1. For staining of sectioned bone to assess osteoid 
and cartilage, sections were deparaffinised and stained in Wiegert’s haematoxylin solution for 
10 minutes. Sections were next differentiated in 1% acid alcohol for 15 seconds and washed well 
under agitation for 10 minutes in dH2O. Slides were stained next in Red solution for 5 minutes 
rinsed in 1% acetic acid, stained in Orange solution for 10 minutes, rinsed in 1% acetic acid, 
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stained in Green solution for 5 minutes and rinsed in dH2O.  Slides were blotted dry, quick 
mounted and visualised using a Nikon CoolScan V (Nikon, Surrey, UK). Scott Dillon provided the 







Wiegert’s hematoxylin (Sigma-Aldrich) Mix equal parts of solutions A and B immediately before 
staining. Mix well  
Ponceau de Xylidine-acid fuschin stock Add 2 ml glacial acetic acid to 98 mls dH2O 
Dissolve 1.5 g of Ponceau de Xylidine and 0.5 g of acid 
fuschin  
Azophloxine stock  Add 0.6 mls of glacial acetic acid to 99.4 ml of dH2O. 
 Dissolve 0.5 g of axophlozine.  
Red solution Make up 80 mls of 0.2% acetic acid in dH2O 
Add 12 mls of Ponceau de Xylidine acid-fuschin stock 
solution and 8 mls of azophloxine stock solution. 
Orange solution Dissolve 3 g phosphomolybdic acid and 2 g Orange G in 
500 mls dH2O 
 
Green solution Add 1 ml of glacial acetic acid to 499 mls of dH2O 
Dissolve 1g of light green 
Table 2.1. Goldner's trichrome staining solutions 
 
 
2.8.7. Measurement of pancreatic islet number and size 
Sections at 4 µM were cut through each pancreas, stained with H&E and scanned using a Nikon 
CoolScan V (Nikon, Surrey, UK). The total area of stained pancreas section was measured, along 
with the number and size of the islets in that section using ImageJ Software (Wayne Rasband, 




2.8.8. Measurement of adipocytes in fat pads 
Sections at 4 µM were cut through each fat pad (including mesenteric, subcutaneous, brown and 
gonadal), stained with H&E and scanned using a Nikon CoolScan V (Nikon, Surrey, UK). The total 
area of fat was measured, along with the number and size of adipocytes in that section using 
ImageJ Software (Wayne Rasband, National Institutes of Health, USA).  
 
2.8.9. Liver staining 
Liver sections were taken at 5 µM and stained with H&E (Section 2.9.3). Liver sections were also 
taken at 8 µM and used for picosirius staining with Weigert’s haemotoxylin and fast-green 
counterstaining. For tissue staining, sections were deparaffinised and the nuclei were stained 
with Weigert’s haematoxylin for 8 minutes, followed by a 10-minute wash in running tap water. 
Slides were stained in picosirius red for 1 hour and washed in two changes of acidified water (5 
mls of glacial acetic acid in 1 L of dH2O). Slides were blotted dry, dehydrates in three changes of 
100% ethanol, cleared in xylene and quick-mounted in DePex before being visualised using a 




Pancreas sections were taken at 5 µM (Section 2.9.3). For immunohistochemistry, sections were 
deparaffinised and immersed in a 1% H2O2 solution (1% H2O2 in methanol) for 10 minutes. Slides 
were subsequently rinsed in running tap water and a sodium citrate epitope retrieval protocol 
was performed. Slides were placed in a sodium citrate buffer (10 mM Sodium citrate (Tri-sodium 
dehydrate) and 0.05% Tween 20 in 1 L of distilled water; pH to 6.0 using 1 M HCl) and autoclaved 
at 121°C for 15 minutes. The slides were slowly cooled using running water for 15 minutes and 
subsequently rinsed in cool running tap water. A Pap pen was used to draw a small section 
around the tissue, and slides were washed in a Wash buffer (PBS/0.1% BSA). Slides were next 
incubated for 20 minutes with diluted normal blocking serum (5% Normal Goat Serum in PBS). 
The serum was removed, excess serum tapped was gently removed from sections and the slides 
were incubated in a humidified chamber with an insulin primary antibody (Rabbit polyclonal 
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insulin antibody, Cell Signalling Technology) diluted in 5% normal goat serum at a 1:100 antibody 
dilution. Slides were left to incubate with primary antibody overnight in a humidified chamber at 
room temperature. Following incubation, slides were washed for five minutes in wash buffer 
(PBS/0.1% BSA) three times. Slides were incubated for 30 minutes in a humidified chamber with 
diluted biotinylated secondary antibody solution: A goat anti-rabbit:biotinylated antibody 
diluted 1:400 in 5% Normal Goat Serum. Slides were next washed in wash buffer for 5 minutes 
three times. Slides were incubated for 30 minutes using the ABC Elite PK6100 kit (VECTOR 
laboratories, Maraval LifeSciences), and next washed in wash buffer for 5 minutes three times. 
The slides were next stained using a DAB staining kit as according to manufacturer’s protocols 
(Abcam) for a maximum of 8 minutes and subsequently rinsed in tap water. Slides were finally 
counterstained with H&E (Section 2.9.3) and coverslips applied.  
 
2.9. Blood and further tissue analysis 
2.9.1. Serum analysis by ELISA 
Following euthanasia of animals, blood samples from 6-week and 22-week old male and female 
Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice and 16-week old male Enpp1flox/flox;Ocn-cre  
Enpp1flox/flox mice were obtained by cardiac puncture using heparin-coated needles and collected 
Eppendorf tubes. Samples were centrifuged at 1000 g for 20 minutes and serum samples were 
gently aspirated and placed in a clean Eppendorf tube. To analyse the difference in bone 
remodelling rates, bone formation and bone resorption markers were measured in serum 
samples were analysed. This was conducted using a Procollagen 1 N-Terminal Peptide ELISA Kit 
(Mouse) (AMSBIO, Abingdon, UK) and a C-terminal telopeptide of Type I Collagen ELISA Kit 
(Mouse) (AMSBIO, Abingdon, UK).  
 
2.9.2. Serum osteocalcin and biochemistry analysis 
Total carboxylated OCN and undercarboxylated-OCN in serum was measured as previously 
described (Ferron et al., 2010). Julian Berger of Columbia University (USA) kindly completed this 
work. Colin Wood of the University of Edinburgh completed general biochemistry analysis of the 
serum including cholesterol, globulin, protein, and albumin quantification. 
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2.9.3. Serum pyrophosphate analysis   
Blood was collected from Enpp1flox/flox and Enpp1flox/flox;Ocn-cre using a 1 ml syringe with 27 G 
needle, pre-lubricated with heparin solution and kept cool on ice before collection. Plasma 
pyrophosphate analysis was performed in accordance with the previously described protocol 
(Pomozi et al., 2019). Samples were centrifuged for 10 minutes at 4°C and 1000 g. Serum was 
carefully separated and transferred to 300,000 molecular weight separation tubes (Sartorius, 
Germany) and filter-centrifuged for 25 minutes at 4°C and 2000 g. The supernatant was 
transferred to pre-cooled Eppendorf tubes and samples were frozen at -80°C until required. For 
the bioluminescence assay, samples and reagents were slowly thawed on ice. A mastermix for 
the reaction was made according to Table 2.2 and stored in a precooled Eppendorf tube on ice 
until use. Subsequently, 35 μl mastermix was added to each well of a 96-well PCR plate which 
was centrifuged at 1400 g for 4 minutes to ensure the absence of air bubbles. All samples and 
PPi calibration curve (5, 2.5, 1.25, 0.625, 0.3126, 0.0156. 0.078 and 0 μm) were added (5 μl) and 
run in duplicate. The 96-well plate was briefly centrifuged and spun at 1400 g for 4 minutes. The 
96-well plate was subsequently incubated for 30 minutes at 37°C, and heat-inactivated for 10 
minutes at 90°C. Plate was spun at 1400 g for 4 minutes. Following this, 30 μl of 
sample/mastermix solution was transferred to an opaque 96 well plate, and 15 μl of BacTiter-
Glo (Promega, USA), which was pre-warmed to room temperature for a minimum of 15 minutes, 
was added. Sample and BacTiter-Glo were mixed several times by gentle pipetting to avoid air 
bubbles. The opaque 96-well plate was then centrifuged at 1400 g for 4 minutes. The plate was 
subsequently covered with tinfoil, to prevent damage to the light-sensitive BacTiter-Glo reagent, 
and incubated at room temperature for a maximum duration of 10 minutes. Luminescence was 
measured using a Synergy HT Multi-Mode Microplate reader (BioTek), pre-warmed to 24°C. This 
protocol was developed together with Janna Zoll and Professor Olivia Le Saux of John A. Burns 






Table 2.2. Components of master mix for PPi analysis. 
 
2.9.4. Analysis of liver triglycerides 
Following euthanasia of male mice at 16-weeks of age, livers were collected, frozen, and stored 
at -80° C. Tissue was prepared and total triglyceride was measured using a Triglyceride (TG) Assay 
(Sentinel Diagnostics, Milan, Italy).  
 
2.10. Statistical analysis 
Data were checked to be normally distributed using a Kolmogorov-Smirnov normality test using 
GraphPad Prism Veresion 8.11 (La Jolla California USA). For data from two experimental groups, 
a Student’s t-test analysis was used. For data from more than two experimental groups, two-way 
analysis of variance (ANOVA) incorporating Tukey post-hoc pairwise comparisons was 
performed. If data were not normally distributed, a suitable non-parametric test was performed 
Data are presented as the mean ± standard error of the mean (S.E.M) where appropriate, with 
all statistical analysis performed using Minitab (Minitab Inc., Coventry, UK). Regression and 
correlation coefficients are given with the intervals of confidence as (P = 0.05) and P<0.05 was 
considered significant. For graphing and table representations, P values are represented as * 
P<0.05, ** P<0.01, *** P<0.001.
 Stock solution Final conc. Per 1 sample (μl) 
MgCl2 800 μM 80 μM 4 
ATPS (ProSpec, Israel) 4 U/ml 32 mU/ml 0.32 
APS (Santa Cruz 
Biotechnology, USA) 
640 μM 16 μM 1 
Hepes pH 7.4 (Life 
Technologies) 
0.25 M 50 mM 8 
Sample - - 5 




Chapter 3. Investigating the effect of osteoblast-specific 
NPP1 ablation on bone phenotype.  
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3.1. Introduction  
As discussed in chapter 1, mineralisation of the ECM is a tightly regulated process (Anderson, 
1995). Controlled mineralisation is critical for maintaining the integrity of the skeletal structure 
and function, occurring during development and throughout the life-long remodelling of bone 
(Kenkre and Bassett, 2018). However, mineralisation may also be pathological, occurring 
abnormally at the site of the bone, cartilage or soft tissues such as the vasculature (Yiu et al., 
2015). There are many factors involved in the phenomenon of mineralisation regulation (Harmey 
et al., 2004). The emergence of sophisticated technologies in cell biology, imaging of genetically 
altered mouse models and mineral phase chemical characterisation has progressed 
understanding of the fine control of matrix mineralisation during skeletal development and the 
pathological ramifications if mineralisation is poorly or abnormally regulated. This has led to a 
conceptualisation of the network and mechanisms of action of the various mineralisation 
regulators at play (including promotors and inhibitors) (Fig. 1.7). These regulators maintain an 
appropriate ratio of Pi (which facilitates the mineralisation of the skeleton and soft tissue) and 
PPi (which inhibits the mineralisation of the skeleton soft tissue), a process which is regulated by 




The enzyme ENPP1 is important in the generation of PPi by the cleavage of ATP, which is critical 
for the inhibition of mineralisation (Meyer, 1984, Bollen et al., 2000, Harmey et al., 2004). The 
scientific community has utilised mouse models to elucidate the specific actions of ENPP1 
regarding bone and soft tissue calcification. To date, there are several different mouse models 
of Enpp1-deficiency (described in chapter 1) all of which demonstrate an increase in ectopic 
tissue mineralisation, an expected result due to the absence of NPP1 enzymatic activity.  
 
In addition to mouse models that target only Enpp1, there are double-knockout mice, which 
have facilitated further understanding of bone mineralisation regulation. As previously 
highlighted, the controlled mineralisation is mediated by the presence of mineralisation 
inhibitors and promoters. The protein TNAP is encoded by the gene Akp2 which is also known as 
Alpl, generates Pi by the hydrolysis of PPi. This Pi is a constituent part of HA, although the main 
role of matrix mineralisation regulation is via the hydrolysis and thus depletion of PPi. The role 
of TNAP has been well studied by analysis of a mouse model with globally deleted TNAP (Akp2-/-
). This mouse presents with hypophosphatasia, which includes rickets, poorly mineralised long 
bones, bone fractures and increased PPi levels (Waymire et al., 1995, Narisawa et al., 1997, 
Wennberg et al., 2000, Anderson et al., 2005a). Additionally, these mice die by 20-days of age as 
a result of severe skeletal hypomineralization and epileptic seizures (Waymire et al., 1995).  
 
The Akp2-/- mouse has been previously crossed with the Enpp1-/- mouse, resulting in a respective 
correction of the bone mineralisation abnormalities of both the TNAP (Akp2) and NPP1 (Enpp1) 
genes (Hessle et al., 2002). This further supports the hypothesis that TNAP and NPP1 work in 
close concert to allow physiological mineralisation of bone by the generation and hydrolysis of 
PPi, maintaining a physiologically preferential Pi/PPi ratio.  
 
ANK (encoded by ANKH gene (Ank in mice)), is responsible for channeling of PPi to the 
extracellular space, which has been conclusively linked with ECM mineralisation regulation in 




the PPi/Pi ratio, resulting in dysregulated pathological mineralisation in humans (Ferreira et al., 
1993, Mitton-Fitzgerald et al., 2016). Mice that have a mutated Ank locus and subsequent non-
functional ANK protein demonstrate a phenotype reflective of the Enpp1-/- mice, with joint 
ankylosis and concomitantly decreased PPi levels (Gurley et al., 2006a). As such, ANK and NPP1 
are functional partners in the regulation of extracellular PPi concentration.  
 
It is imperative to further delineate the specific mechanisms of action of ENPP1 such that 
therapeutic intervention options for ENPP1-related disease may be identified and developed. To 
date, the cell-specific contributions of NPP1 have not been elucidated despite the literature 
reporting relatively higher levels of expression in specific tissues such as bone and cartilage, and 
cell types including osteoblasts and chondrocytes (Caswell and Russell, 1988, Harahap and 
Goding, 1988, Huang et al., 1994, Huang et al., 2018).   
 
The availability of mouse models with loss-of-function of specific genes in vivo has dramatically 
altered the field of bone biology in the last 20 years. The use of genetically altered animals 
(mainly mice) has been utilised to demonstrate the role of a specific gene (or genes) in a variety 
of biological processes related to bone including its development, remodelling, metastasis and 
repair. However, mouse models are not without their limitations, notably when considering 
global knockouts. A global knockout mouse model is relevant to address the question of ‘what is 
the contribution of this gene to bone homeostasis?’ However, the use of a conditional knockout 
(such as cell-specific knockout) allows the scientist to dissect the putative and distinctive roles 
of one gene within one cell type. The interpretation of such conditional (and single Cre transgenic 
mouse lines to delete a gene of interest) must be completed with caution, whereby control mice 
must be compared to Cre-negative, exon-floxed controls, from mice of the same background 
strain. 
 
Given that OCN is secreted solely by osteoblast, the use of an OCN-based cre-drive is unique to 




in mice can be assessed by crossing with ROSA and mT/mG reporter mice. Indeed, the specificity 
of Ocn-cre has been demonstrated in this way (Zhong et al., 2012). 
 
The osteoblast is key to the formation of bone: determining the roles that specific genes (and 
their translated proteins) play within this cell type will undoubtedly enhance understanding of 
bone formation and the identification of potential therapeutic routes for those suffering 
mineralisation related diseases. As such this thesis determined the role of osteoblast-specific 
NPP1 in bone formation at both juvenile (6-week old) and adult (22-weeks old) ages of mice.  
This work utilised the Cre-lox system to specifically ablated ENPP1 in mouse osteoblasts. To 
achieve an osteoblast-specific ablation, the Ocn-cre mouse, and an Enpp1flox/flox mouse was 
utilised. It is important to acknowledge that this Ocn-cre mouse is well characterised and does 
not present with a notable phenotype compared to wild-type controls (Zhang et al., 2002, 
Staines et al., 2017), thus addressing limitations of genetically altered mouse models as 
previously discussed. The overarching aim of this chapter was to characterise the skeletal 
phenotype of the Enpp1flox/flox;Ocn-cre mouse model and to investigate whether potentially 
decreased PPi in the osteoblast-specific ablated mouse can result in ectopic mineralisation. 
 
3.2. Hypothesis 
The decreased Enpp1 activity and serum PPi concentration of the Enpp1flox/flox;Ocn-cre mouse will 
result in an altered bone (and soft tissue) phenotype, presenting with increased levels of 
mineralisation compared to age-matched control (Enpp1flox/flox) mice. This hypothesis will be 
addressed by assessing the following aims: 
I. To analyse the bone phenotype in juvenile (6-week old) mice. 
 
II. To analyse the bone phenotype in adult (22-week old) mice. 
 
III. To analyse serum PPi levels. 
 






3.3 Materials and methods 
3.3.1. Generation of mice 
The Enpp1flox/flox;Ocn-cre and age-matched Enpp1flox/flox control male and female mice were 
generated (Section 2.7.1). Mice were fed a control diet and were culled at 6-weeks of age and 
22-weeks of age for skeletal phenotyping analysis, and 16-weeks for histopathological analysis.   
 
3.3.2. Histopathological assessment of soft tissue and bone 
Following euthanasia of adult Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice soft tissue and bone 
tissue was fixed in 10% NBF, embedded in paraffin wax and 5 µM thick sections were stained 
with H&E. Soft tissue was also stained with Alizarin red S to assess mineralisation.  
 
3.3.3. Osmium staining of marrow adipose tissue 
Following euthanasia at 16-weeks of age, Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice femora and 
tibiae were dissected and soft tissue removed. Bones were prepared by fixing in 10% NBF for at 
least 24 hours. Bones were next washed with Sorensen’s buffer and stained with 1% osmium 
tetroxide. Bones were µ-CT, reconstructed and analysed to determine quantitative volumetric 
data of marrow adipose tissue (Section 2.6.6). Dr Karla Suchacki of The University of Edinburgh 
kindly performed this work. 
 
3.3.4. Gross analysis of bone  
Tibiae and femora from male and female Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice aged 6-
weeks and 22-weeks of age were dissected and soft tissue removed. The length of the long bones 






3.3.5. Three-point bending analysis 
Tibiae and femora from male and female Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice aged 6-
weeks and 22-weeks of age were dissected out and soft tissue removed. Three-point bending 
was performed using an LXR materials testing machine (Lloyds Instruments, West Sussex, U.K.) 
fitted with a 500 N load cell (Section 2.6.1).  
 
3.3.6. Micro-computed tomography imaging 
Tibiae and femora were dissected from 6-week and 22-week old male and female 
Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were fixed in 10% NBF and scanned using a µ-CT 
scanner (Section 2.6.2). The scans were reconstructed using NRecon software and analysed. 
Trabecular parameters assessed included trabecular bone volume/tissue volume (BV/TV; %), 
trabecular pattern factor (Tr.Pf), structural model index (SMI), trabecular thickness (Tr.Th; mm), 
trabecular number (Tr.No) and trabecular separation (Tr/Sp; mm). Cortical parameters assessed 
included endosteal diameter (mm), periosteal diameter (mm), bone volume (BV; mm3), cortical 
thickness (Ct.Th; mm) and per cent open porosity (Po(oP); %).  
 
3.3.7. Tissue preparation for microscopy and Bioquant histomorphometric analysis  
Femora were dissected from 6-week and 22-week old male and female Enpp1flox/flox;Ocn-cre and 
Enpp1flox/flox mice and soft tissue was removed. Femora were decalcified and fixed in 10% NBF 
(Section 2.9.2). Tissues were subsequently processed, embedded in paraffin wax and sectioned 
at 5 µM (Section 2.9.2). Sectioned tissues were air-dried, dewaxed using Leica Autostainer and 
stained with H&E (Section 2.8.3), toluidine blue-fast green stained (Section 2.8.5) and Goldner’s 
Trichrome stained (Section 2.8.6). Sections were imaged using a Nikon CoolScan V (Nikon, 
Surrey, UK) and analysed by Scott Dillon using Bioquant software to support observations of µ-
CT data. The following parameters were determined; trabecular separation (mm), trabecular 
diameter (mm), trabecular number, tissue volume (µm2), bone volume (µm3), bone 
volume/tissue volume, bone surface (mm), bone surface/bone volume, osteoid volume (µm3), 




width (mm), adipocyte volume (µm3), and adipocyte volume/tissue volume. The analysed area 
was referred to as the ‘region of interest’ and is a region of bone defined below the growth 
plate (Fig. 3.1). The same region was assessed for each different stain. Two sections were 
analyzed with an N=6 for each genotype and each sex.  
 
 
Figure 3.1. Region of Interest delimitation for Histomorphometry Analysis. 
Representative image of region of interest (ROI) for histomorphometry analysis in proximal 
femur. The dotted outline represents the region of interest to be assessed by BioQuant analysis. 
Tb stands for trabecular bone, Ct stands for cortical bone. GP stands for growth plate. Figure 
adapted from work by Dion et al.  (Dion et al., 2011). 
 
 
3.3.8. Analysis of serum bone formation and bone resorption markers 
Serum samples were collected (Section 2.10.1). To analyse the difference in bone modelling 
and remodelling rates, bone formation and bone resorption markers were measured in serum 




Kit (Mouse) (AMSBIO, Abingdon, UK) and a C-terminal telopeptide of CtX Kit (Mouse) (AMSBIO, 
Abingdon, UK).  
 
3.4. Results 
3.4.1. Gross anatomy - body mass and long bone length of juvenile mice 
At 6-weeks of age, sex-effects were observed whereby male Enpp1flox/flox mice were significantly 
heavier than female Enpp1flox/flox mice (22.59 g vs. 16.05 g; P<0.01) (Fig. 3.2A). This was also true 
of male Enpp1flox/flox;Ocn-cre mice compared to female Enpp1flox/flox;Ocn-cre mice (21.98 g vs. 
17.57 g; P<0.001) (Fig. 3.2A). No significant genotype effect was observed for male mice, 
however female Enpp1flox/flox;Ocn-cre mice were significantly heavier than their Enpp1flox/flox 
controls (17.57 g vs. 16.04; P<0.01) (Fig. 3.2A).  
 
The male Enpp1flox/flox mice tibiae were significantly longer than those of female Enpp1flox/flox mice 
(16.58 mm vs. 15.04 mm; P<0.001) as were those of the male Enpp1flox/flox;Ocn-cre mice 
compared to female Enpp1flox/flox;Ocn-cre mice (15.65 mm vs. 14.94 mm; P<0.01) (Fig. 3.2B). No 
differences between genotype were observed for female 6-week old mice. Male 
Enpp1flox/flox;Ocn-cre mice exhibited decreased tibiae length compared to Enpp1flox/flox controls 
(16.48 mm vs. 14.65 mm; P<0.01) (Fig. 3.2B). For femora, no significant difference in bone length 
between genotype was observed for either male or female mice (Fig. 3.2C). Again, sex 
differences were observed; the tibiae of Enpp1flox/flox male mice were significantly longer than 
tibiae of female Enpp1flox/flox (13.76 mm vs.  12.42 mm; P<0.001) as were the tibiae of male 
Enpp1flox/flox;Ocn-cre mice compared to the tibiae of female Enpp1flox/flox;Ocn-cre mice (13.04 mm 





Figure 3.2. The mass and long bone length of male and female 6-week old mice show 
genotype and sex specific differences. 
 (A) The bone mass at 6-weeks of age for Enpp1flox/flox;Ocn-cre and Enpp1flox/flox male and female mice 
and the (B) tibiae and (C) femora length. Data are presented as the mean ± S.E.M (n=6). Significance 





3.4.2. Serum pyrophosphate and markers of bone resorption and formation of juvenile 
mice 
No significant differences in serum PPi concentration were observed between genotypes for 
male or female mice (Fig. 3.3A). Additionally, no sex-effect was observed regarding PPi 
concentration (Fig. 3.3A). Given the investigation into gross anatomy of long bones revealed 
genotype-specific significant differences in length, I next investigated whether there were 
increased bone resorption and formation marker concentrations. This revealed no significant 
difference between genotype or sex for bone formation (P1NP) or resorption (Ctx) (Fig. 3.3B, Fig. 
3.3C).  
 
3.4.3. Gross histological analysis of joint and soft tissue 
A detailed histological assessment was completed by Prof Elspeth Milne to aid in understanding 
more fully the physiological role of osteoblast-specific NPP1 on skeletal development and 
pathological mineralisation. An absence of ectopic (soft tissue) pathological mineralisation as 
evidenced via analysis of soft tissue H&E staining and soft tissue Alizarin red S staining (Table 
3.1) . Similarly, no pathological or abnormal architecture was observed amongst the analysed 





















Figure 3.3. Serum concentration of PPi, Ctx and P1NP from male and female mice are 
unchanged between genotype.  
(A) The serum concentration of PPi of male and female Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice 
and the (B) marker of bone resorption (Ctx) and of (C) bone formation (P1NP). Data are presented 









Table 3.1 Histopathological assessment of soft and bone tissue demonstrating no 
abnormal pathology.  
Professor Elspeth Milne conducted assessment of 1 mouse of each genotype with Von Kossa and 
Alizarin red staining to assess mineralisation and tissue architecture. No reported pathology was 





3.4.4. µ-CT analysis of the long bones of juvenile mice  
The differences in bone architecture between genotypes are less evident at 6-weeks old in males 
compared to females. For both tibiae and femora, no significant differences between genotype 
for male 6-week old mice were observed in the measured trabecular parameters (Table 3.2). 
Regarding femora cortical parameters, a significantly decreased femora cortical thickness (mm) 
was observed in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox control mice (0.109 mm 
vs. 0.117 mm; P<0.05). However, a significantly increased tibiae periosteal diameter was 
observed in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox control mice (1.817 mm vs. 












Bone Genotype BV/TV (%) Tr. Pf. SMI Tr. Th. (mm) Tr. No. Tr. Sp. (mm) 
Femur 
















21.587 (1.93) 1.7125 (0.05) 0.040 (0.00) 4.122 (0.015) 0.150 (0.00) 
Table 3.2. µ-CT analysis of tibiae and femora trabecular bone from 6-week male mice shows no differences between 
genotype. 
The following parameters were measured; per cent bone volume (BV/TV), trabecular patterning factor (Tr. Pf.), structural model index 








Bone Genotype Peri. Di (mm) Endo. Di (mm) BV (mm3) Ct. Th (mm) Po(op) (%) 
Femur 
Enpp1flox/flox 2.144 (0.06) 1.773 (0.06) 0.800 (0.05) 0.117 (0.00) 2.059 (0.30) 
Enpp1flox/flox;Ocn-cre 2.147 (0.04) 1.783 (0.06) 0.815 (0.02) 0.109 (0.00)* 2.828 (0.19) 
Tibia 
Enpp1flox/flox 1.66 (0.05)* 1.277 (0.07) 0.857 (0.04) 0.101 (0.01) 3.467 (0.50) 
Enpp1flox/flox;Ocn-cre 1.817 (0.02) 1.357 (0.03) 0.859 (0.02) 0.09 (0.00) 4.128 (0.29) 
Table 3.3. µ-CT analysis of tibiae and femora cortical bone from 6-week male mice demonstrates largely unaltered 
parameters between genotype. 
The following parameters were analysed; periosteal diameter (Peri. Di), endosteal diameter (Endo. Di), bone volume (BV), cortical 





The female 6-week old Enpp1flox/flox;Ocn-cre mice demonstrate notable significant differences 
both in cortical and trabecular parameters investigated, indicating an increased bone mass in 
these mice compared to their Enpp1flox/flox controls. For the femora trabecular parameters, 
female Enpp1flox/flox;Ocn-cre mice exhibit increased bone volume/tissue volume (17.50% vs. 
11.67%; P<0.01), decreased trabecular pattern factor (15.23 vs. 24.46; P<0.01), decreased 
structural model index (1.39 vs. 1.71; P<0.01), increased trabecular number (4.61 vs. 3.19; 
P<0.001) and decreased trabecular spacing (0.157 vs. 0.187; P<0.01) compared to Enpp1flox/flox 
mice (Table. 3.4). For the tibiae trabecular parameters, Enpp1flox/flox;Ocn-cre female mice 
demonstrate increased bone volume/tissue volume (11.54% vs. 7.72%; P<0.01), increased 
trabecular number (3.32 vs. 2.24; P<0.001) and decreased trabecular spacing compared to their 
Enpp1flox/flox controls (0.180 mm vs. 0.230 mm; P<0.001) (Table 3.4). For the cortical parameters, 
Enpp1flox/flox;Ocn-cre female 6-week old mice increased femora endosteal diameter (1.95 mm vs. 
1.67 mm; P<0.001), and increased open porosity compared to their Enpp1flox/flox controls (2.46% 
vs. 2.04%; P<0.05) (Table 3.5). For the cortical tibia factors an increased endosteal diameter was 
also observed for the Enpp1flox/flox;Ocn-cre mice compared to their Enpp1flox/flox controls (1.48 mm 










Bone Genotype BV/TV (%) Tr. Pf. SMI Tr. Th. (mm) Tr. No. Tr. Sp. (mm) 
Femur 
Enpp1flox/flox 11.67 (0.93) 24.46 (1.61) 1.71 (0.05) 0.036 (0.08) 3.19 (0.18) 0.187 (0.006) 
Enpp1flox/flox;Ocn-cre 17.50 (0.58)** 15.23 (1.42)** 1.39 (0.04)** 0.038 (0.01) 4.61 (0.15)*** 0.157 (0.004)** 
Tibia 
Enpp1flox/flox 7.72 (0.55) 33.23 (1.96) 1.97 (0.05) 0.034 (0.06) 2.24 (0.13) 0.230 (0.009) 
Enpp1flox/flox;Ocn-cre 11.54 (0.43)** 26.73 (1.78) 1.80 (0.03) 0.034 (0.01) 3.32 (0.08)*** 0.180 (0.005)** 
Table 3.4. µ-CT analysis of tibiae and femora trabecular bone from 6-week female mice show significant differences 
between genotype. 
The following parameters were measured; per cent bone volume (BV/TV), trabecular patterning factor (Tr. Pf.), structural model index 
(SMI), trabecular thickness (Tr. Th.),  trabecular number (Tr. No.), trabecular spacing (Tr. Sp.). Data are presented as the mean ± S.E.M 









Bone Genotype Peri. Di (mm) Endo. Di (mm) BV (mm3) Ct. Th (mm) Po(op) (%) 
Femur 
Enpp1flox/flox 1.97 (0.03) 1.67 (0.03) 0.565 (0.03) 105.73 (2.07) 2.04 (0.09) 
Enpp1flox/flox;Ocn-cre 2.25 (0.03) 1.95 (0.03)*** 0.64 (0.04) 98.32 (3.40) 2.46 (0.14)* 
Tibia 
Enpp1flox/flox 1.57 (0.13) 1.29 (0.02) 0.624 (0.02) 91.15 (2.20) 3.35 (0.28) 
Enpp1flox/flox;Ocn-cre 1.89 (0.04)* 1.48 (0.03)*** 0.68 (0.03) 85.20 (2.58) 3.53 (0.16) 
Table 3.5. µ-CT analysis of tibiae and femora cortical bone from 6-week female mice show significant differences 
between genotype. 
The following parameters were measured; periosteal diameter (Peri. Di.), endosteal diameter (Endo. Di), bone volume (BV), cortical 
thickness (Tb. Th.), open porosity (%) (Po(op)). Data are presented as the mean ± S.E.M (n=6). Significance between genotype is denoted 





The results from the epiphyseal trabecular bone, the lateral subchondral bone of the 
femorotibial joint, and the medial subchondral bone of the femorotibial joint also demonstrate 
genotype differences indicative of increased bone formation.  
 
Male mice 6-week old Enpp1flox/flox;Ocn-cre mice exhibit increased epiphyseal bone 
volume/tissue volume (41.35% vs. 35.12; P<0.05) (Fig. 3.4), unaltered trabecular number and 
trabecular separation (Fig. 3.4b, Fig. 3.4C) compared to Enpp1flox/flox controls. However, the male 
6-week old Enpp1flox/flox;Ocn-cre mice do show significantly increased trabecular thickness 
compared to their Enpp1flox/flox controls (0.06 mm vs. 0.05 mm; P<0.05) (Fig. 3.4D). The trabecular 
pattern factor (an indicator of trabecular connectedness) and structural model index (an 
indicator of whether the trabeculae are in a more rod or plate-like in their geometry), remained 
unchanged between genotypes (Fig. 3.4E, Fig. 3.4F). Female 6-week old Enpp1flox/flox;Ocn-cre mice 
demonstrate, to a greater extent than the male mice, an increase in epiphyseal increased bone 
mass compared to their Enpp1flox/flox controls. The female mice have significantly increased 
epiphyseal bone volume/tissue volume (37.41% vs. 28.87%; P<0.001) (Fig. 3.4A), trabecular 
number (6.85 vs. 5.76; P<0.001) (Fig. 3.4B), with unaltered trabecular separation compared to 
their Enpp1flox/flox controls (Fig. 3.4C). The trabecular thickness of the female Enpp1flox/flox;Ocn-cre 
mice was also significantly increased (0.06 mm vs 0.05 mm; P<0.05), as was the trabecular 
pattern factor (16.87 vs 8.62; P<0.001), indicating a greater degree of connectedness compared 
to their  Enpp1flox/flox controls (Fig. 3.4D, 3.4E). The structural model index for female 
Enpp1flox/flox;Ocn-cre was also significantly decreased, indicating that the trabecular bone is more 
plate-like than the Enpp1flox/flox controls (1.33 vs. 1.65; P<0.01) (Fig. 3.4.F).  
 
Analysis of the medial and lateral subchondral bone parameters indicated only decreased lateral 
subchondral bone porosity in the Enpp1flox/flox;Ocn-cre male 6-week old mice compared to their 
Enpp1flox/flox controls (0.27 mm3 vs 0.22 mm3; P<0.05)  (Fig. 3.5C) and increased medial 
subchondral bone porosity in the Enpp1flox/flox;Ocn-cre female 6-week old mice compared to 
























Figure 3.4. µ-CT analysis of the epiphyseal bone from male and female mice show genotype specific differences. 
The parameters analysed include the trabecular (A) bone volume/tissue volume, (B) trabecular number, (C) trabecular separation, (D) 
trabecular thickness, (E) trabecular pattern factor and (F) structural model index. Data are presented as the mean ± S.E.M (n³5). 



























Figure 3.5. µ-CT analysis of the lateral and medial subchondral bone from male and female mice show largely 
unaltered differences between genotype. 
The subchondral bone parameters measured include (A) lateral bone volume, (B) lateral trabecular thickness, (C) lateral 
porosity, (D) medial bone volume, (E) medial trabecular thickness and (F) medial trabecular porosity. Data are presented as 




3.4.5. Analysing bone mineral density of long bones of juvenile mice 
µ-CT scanning was used to quantitatively determine whether osteoblast-specific NPP1 ablation 
impacts the ability of bones to form mineral at a juvenile age point. The use of bone mineral 
density measurements is a common surrogate assessment of the strength of bone tissue.  
Analysis revealed no significant difference between genotype in the cortical bone mineral density 
of the tibiae and the femora (Fig. 3.6A, C). A sex difference was observed whereby the female 
Enpp1flox/flox mice exhibit greater femora cortical bone mineral density compared to male 
Enpp1flox/flox mice (0.42 mg/cm3 vs 0.37 mg/cm3; P<0.05): this result was not reflected in the 
Enpp1flox/flox;Ocn-cre male and female mice (Fig. 3.6C). Although no significant differences were 
observed for the trabecular bone mineral density of the femora, I observed notable alterations 
in the tibiae bone mineral density (Fig. 3.6B & 3.6D). A sex-specific effect was again observed, 
whereby the female Enpp1flox/flox mice exhibit this time significantly reduced trabecular bone 
mineral density compared to the Enpp1flox/flox male mice (0.20 mg/cm3 vs. 0.26 mg/cm3; P<0.01) 
(Fig. 3.6B). A significantly increased bone mineral density of the tibia trabecular bone of the 
female Enpp1flox/flox;Ocn-cre 6-week old mice compared to the Enpp1flox/flox female 6-week old 




; P<0.05) (Fig. 3.6B).   
 
3.4.6. Analysing the mechanical properties of long bones in juvenile mice 
To determine whether the micro-architectural changes in bone translated to altered mechanical 
properties, the tibiae and femora of Enpp1flox/flox;Ocn-cre and Enpp1flox/flox control mice were 
subjected to 3-point bending analysis. At 6-weeks of age, two parameters showed significant 
differences. The female 6-week old Enpp1flox/flox;Ocn-cre mice exhibited increased work to 
rupture for the femora bone (4.19x10
-3
 J vs. 2.97  4.19x10
-3
 J; P<0.01) (Table 3.6) , and the male  
Enpp1flox/flox;Ocn-cre mice showed increased deflection at rupture (1.20 mm vs. 0.90 mm; P<0.05) 
(Table 3.7) compared to Enpp1flox/flox sex-matched controls. This indicates that there is a small 
increased amount of energy required to break the bones of the Enpp1flox/flox;Ocn-cre mice 










Figure 3.6. µ-CT analysis of tibiae and femora cortical and trabecular bone mineral 
density from 6-week female mice. 
(A) Tibiae cortical and (B) trabecular bone mineral density. (C) femora cortical and (D) trabecular 





























































































Table 3.6. 3-point bending analysis of femora from 6-week old mice reveals an absence of functional consequence from 
osteoblast-specific NPP1 ablation. 
Values are shown for femora dissected from 6-weeks and 22-weeks of age from female and male Enpp1flox/flox and Enpp1flox/flox;Ocn-cre 
mice. Bones were tested to fracture, whereby fracture points were identified from the load-extension curve whereby the maximum load 
decreased rapidly to 70% of the maximum value. The maximum stiffness was defined as the maximum gradient of the rising portion of 





































Enpp1flox/flox 4.72 (0.24) 0.52 
 (0.03) 







Enpp1flox/flox;Ocn-cre 5.19 (0.78) 0.66  
(0.09) 





























Table 3.7. 3-point bending analysis of tibiae from 6-week old mice an absence of functional consequence from osteoblast-
specific NPP1 ablation. 
Bones from Enpp1flox/flox and Enpp1flox/flox;Ocn-cre were tested to fracture, whereby fracture points were identified from the load-extension 
curve whereby the maximum load decreased rapidly to 70% of the maximum value. The maximum stiffness was defined as the maximum 
gradient of the rising portion of the load-extension curve. Data are presented as mean ± S.E.M (n≥4). Significance between genotype is 




3.4.7. Histomorphometry analysis of juvenile mice using Bioquant OSTEO software 
To further investigate the micro-architecture of the bone, and to investigate the mineralisation 
of the bone tissue, a histomorphometry assessment was conducted using Bioquant software on 
sectioned sections of the femora, as this is the bone where I observed the majority of 
architectural differences by µ-CT analysis by assessing specific regions (See section 3.3.7). This 
region is determined as the region of interest and is below the growth plate. For all stains, the 
same region was assessed. This analysis was performed to support and confirm the findings 
observed by µ-CT analysis, and in particular to assess osteoid and adiposity, which is a limitation 
of basic µ-CT analysis. Overall, one sex-specific difference was observed in the 
histomorphometry analysis: female Enpp1flox/flox mice have significantly decreased trabecular 
diameter compared to male Enpp1flox/flox mice at 6-weeks of age (0.05 mm vs. 0.07 mm; P<0.05) 
(Fig. 3.7B). Several genotype-specific differences were also observed. Male Enpp1flox/flox;Ocn-cre 
mice demonstrated significantly reduced spacing between their trabeculae compared to 
Enpp1flox/flox control mice (0.05 mm vs. 0.08 mm; P<0.05) (Fig. 3.7A). Male Enpp1flox/flox;Ocn-cre 
exhibit increased bone volume compared to Enpp1flox/flox controls (0.28 µm2 vs. 0.17 µm2; P<0.05) 
as did female mice  (0.24 µm2 vs. 0.15 µm2; P<0.05) (Fig. 3.7E). Additionally, male 
Enpp1flox/flox;Ocn-cre mice demonstrate increased bone volume/tissue volume compared to 
Enpp1flox/flox controls (0.28 vs. 0.17; P<0.05) (Fig. 37F).  Females Enpp1flox/flox;Ocn-cre mice show 
significantly decreased osteoid surface (8.42 mm vs. 15.68 mm; P<0.05) (Fig. 3.7G) and decreased 
osteoid surface/bone surface (0.073 mm vs. 0.51 mm; P<0.05)  (Fig. 3.7H) compared to 
Enpp1flox/flox female controls. This suggests less osteoid tissue, which can be explained by 
increased bone tissue volume observed in the Enpp1flox/flox;Ocn-cre mice. The osteoid width of 
the female Enpp1flox/flox;Ocn-cre mice was also significantly increased compared to Enpp1flox/flox 
controls (7.46 mm vs.  6.28 mm; P<0.05) (Fig. 3.7K), in keeping with findings from µ-CT of a 
significantly increased width of bone (periosteal and endosteal diameter analysis). The female 
Enpp1flox/flox;Ocn-cre mice also demonstrate significantly increased bone marrow adiposity 






Figure 3.7 Part 1. Histomorphometry analysis of 6-week old male and female femora 
demonstrates increased bone volume in osteoblast-specific NPP1 ablated mice.   
Parameters investigated include (A) trabecular separation, (B) trabecular diameter, (c) trabecular 
number, (D) trabecular tissue volume and (E) Bone volume. Data are presented as mean ± S.E.M 
(n³5). Significance is denoted by *P<0.05. 























Figure 3.7: Part 2. Histomorphometry analysis of 6-week old male and female femora 
reveals largely significant differences between genotype.  
Parameters investigated include (G) Bone surface, (H) Bone surface/bone volume, (I) osteoid 
volume, (J) osteoid volume/bone volume. Data are presented as mean ± S.E.M (n³5). Significance 
is denoted by *P<0.05. 























Figure 3.7: Part 3. Histomorphometry analysis of 6-week old male and female femora 
demonstrates increased mineralized bone and bone material in female osteoblast-
specific NPP1 ablated mice.  
Parameters investigated include (K) Osteoid surface, (L) Osteoid surface/bone surface, (M) 
Osteoid width, (N) Adipocyte volume and (O) adipocyte volume/tissue volume. Data are 
presented as mean ± S.E.M (n³5). Significance is denoted by *P<0.05. 






















3.4.8. µ-CT analysis of bone marrow adiposity of 16-week old male mice 
Given that the histomorphometry data indicated a genotype effect on adipocyte volume, µ-CT 
was next utilised to analyse bone marrow adiposity using osmium staining. At the time of 
analysis, 6-week old samples bone samples were no longer available. The 16-week old male 
Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mouse long bones were utilised to determine whether a 
genotype effect on marrow adiposity could be detected by µ-CT. Whilst this cannot be 
considered reflective of the 6-week old mice, it does provide information on the marrow adipose 
tissue of skeleton which has not reached full maturity. The use of this technique is of notable 
importance, given that marrow adipose tissue is not evenly distributed throughout the bone 
marrow of long bones, and histomorphometric analysis of one bone section area may not be 
representative of the total bone marrow adiposity. Indeed, the conventional quantitative 
analysis of marrow adipose tissue is dependent upon sectioning to overcome issues associated 
with uneven distribution, yet this comes with limitations including being labour and resource-
intensive, and is  inconsistent between individuals and laboratories. The utilisation of osmium 
tetroxide staining and µ-CT analysis represents a rapid, systemic and reproducible method to 
quantitate marrow adipose tissue. The analysis conducted focused on four different regions: 
1. The tibia-fibular junction to the distal end of the bone 
2. The growth plate to the tibia-fibular junction 
3. The proximal epiphyseal region 
4. The total bone 
 
Analysis of male 16-week old mice tibiae did not reveal any significant differences between 
genotypes for the regions analysed (Fig. 3.8). Unfortunately, the male femora and female age-
matched mice were not available for analysis, representing a limitation of the data obtained by 






























































Figure 3.8. µ-CT analysis of osmium stained tibiae for marrow adiposity 
reveals no difference between genotype. 
Four regions of interest were analysed including (1) the tibia-fibular junction (T/F/J) to 
distal end of bone, (2) the growth plate (GP) to T/F/J, (3) the proximal epiphysis (Prox. 





3.4.9. Gross anatomy - body mass and long bone length of adult mice 
Given that the analysis of 6-week old Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice revealed a bone 
phenotype, the adult (22-weeks of age) mice were next investigated. The aim was to determine 
whether the genotype-specific differences observed in the Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
juvenile mice were recapitulated in the developed skeleton of the 22-week old adult mice. As 
observed at 6-weeks of age, sex-specific differences were observed concerning the weight of 
mice at 22-weeks of age. Here, I observed that the male Enpp1flox/flox;Ocn-cre mice were 
significantly heavier than the female Enpp1flox/flox;Ocn-cre mice (30.99 g vs. 22.12 g; P<0.001) (Fig. 
3.9A), and the same was true for Enpp1flox/flox male mice compared to Enpp1flox/flox female mice 
(31.90 g vs. 24.77 g; P<0.001). No difference in body weight was observed between genotype, 
suggesting that the osteoblast-specific NPP1 ablation is not significant to abrogate growth as 
observed in the global Enpp1-/- mice (Huesa et al., 2014). Regarding long bone length, no 
difference in length was observed between genotype for female mice regarding the tibiae (Fig. 
3.9B) or femora (Fig. 3.9C). Male Enpp1flox/flox;Ocn-cre mice exhibit increased tibiae length (17.80 
mm vs. 17.32 mm; P<0.05), and decreased femora length (15.30 mm vs. 17.32 mm; P<0.001) 
compared to age-matched Enpp1flox/flox male mice (Fig. 3.9B, 3.9C). Furthermore, female 22-week 
old Enpp1flox/flox mice exhibited significantly shorter femora length compared to male Enpp1flox/flox 
(15.23 mm vs. 17.32 mm; P<0.001) (Fig. 3.9C) – an expected result given the significantly smaller 





























  Figure 3.9. The mass and long bone length of male and female 22-week old mice 
demonstates genotype and sex-specific differences. 
(A) The mass at 6-weeks of age for Enpp1flox/flox;Ocn-cre and Enpp1flox/flox male and female 
mice and the (B) tibiae and (C) femora length. Dare represented as the mean ± S.E.M (n=6).  




3.4.10. Serum markers of bone resorption and formation in adult mice 
Quantification of serum markers of bone resorption and formation showed no sex-specific 
differences for either Enpp1flox/flox;Ocn-cre or Enpp1flox/flox mice at 22-weeks of age (Fig. 3.10A, 
4.10B). Female mice showed no difference in bone resorption (CtX) (Fig. 3.13A) or bone 
formation (P1NP) markers between genotypes (Fig. 3.10B). Male Enpp1flox/flox;Ocn-cre mice had 
similar Ctx levels (Fig. 3.10A) but significantly reduced P1NP levels (355.81 pg/ml vs. 535.32 
pg/ml; P<0.001) compared to Enpp1flox/flox controls (Fig. 3.10B). This suggests that male 
Enpp1flox/flox;Ocn-cre mice have a reduced osteoblast activity and the female Enpp1flox/flox;Ocn-cre 



































Figure 3.10. Serum concentration of Ctx and P1NP from male and female 
adult mice are largely unaltered between genotypes. 
(A) marker of bone resorption (Ctx) and of (B) bone formation (P1NP). Data are 





3.4.11. µ-CT analysis of the long bones of adult mice  
The investigation of the micro-architecture of 6-week old mice using µ-CT revealed notable 
significant difference between genotypes, evident mostly in the female cohorts. Upon analysis 
of the male 22-week old mice, no difference was observed between genotype regarding femora 
or tibiae trabecular (Table 3.8) or cortical (Table. 3.9) bone. As with the 6-week old mice, the 
changes were evident amongst the female cohorts. Female Enpp1flox/flox;Ocn-cre mice exhibited 
significantly increased femora trabecular bone volume/tissue volume (13.34% vs. 7.79%; 
P<0.05), indicative of overall increased bone tissue compared to Enpp1flox/flox mice (Table 3.9). 
The female Enpp1flox/flox;Ocn-cre mice showed significantly decreased femora structural model 
index (SMI) (1.72 vs. 2.12; P<0.05) which suggests a more plate-like, as opposed to rod-like, 
geometric organization of bone compared to the Enpp1flox/flox controls (Table. 3.10). Furthermore, 
the Enpp1flox/flox;Ocn-cre female mice demonstrated increased trabecular number (2.43 vs. 1.57; 
P<0.05) compared to Enpp1flox/flox controls (Table 3.10).  
 
When considering the cortical parameters, female 22-week old Enpp1flox/flox;Ocn-cre mice also 
demonstrated increased bone mass. The femora endosteal diameter (Endo. Di) is significantly 
greater in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox mice (1.66 mm vs. 0.84mm; 
P<0.05) (Table 3.9) indicating a wider bone. Additionally, the femora cortical bone volume was 
significantly increased in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox mice (1.05 mm3 
vs. 0.59 mm3; P<0.001) (Table 3.11). Largely, the tibiae cortical bone showed no changes 
between genotype in the parameters investigated, although trabecular thickness was 
significantly increased in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox mice (0.17 mm 













Bone Genotype BV/TV (%) Tr. Pf. SMI Tr. Th. (mm) Tr. No. Tr. Sp. (mm) 
Femur 
Enpp1flox/flox 16.03 (2.69) 17.12 (5.15) 1.63 (0.30) 54.38 (3.50) 2.92 (0.32) 0.201 (0.001) 
Enpp1flox/flox;Ocn-cre 16.57 (2.23) 13.79 (3.20) 1.42 (0.18) 50.73 (2.14) 3.23 (0.35) 0.199 (0.007) 
Tibia 
Enpp1flox/flox 14.44 (1.45) 20.81 (4.08) 1.93 (0.24) 53.33 (1.29) 2.71 (0.21) 0.199 (0.009) 
Ocn-Cre;Enpp1flox/flox 16.32 (1.34) 16.87 (1.38) 1.65 (0.13) 50.15 (1.42) 3.21 (0.05) 0.187 (0.004) 
Table 3.8. µ-CT analysis of tibiae and femora trabecular bone from 22-week male mice reveals no difference between 
genotypes. 
The following parameters were measured; per cent bone volume (BV/TV), trabecular patterning factor (Tr. Pf.), structural model index 










Bone Genotype Peri. Di (mm) Endo. Di (mm) BV (mm3) Ct. Th (mm) Po(op) (%) 
Femur 
Enpp1flox/flox 2.56 (0.16) 2.15 (0.17) 0.92 (0.06) 173.29 (3.33) 2.43 (0.23) 
Enpp1flox/flox;Ocn-cre 2.57 (0.09) 2.24 (0.10) 0.96 (0.03) 168.79 (4.84) 2.75 (0.20) 
Tibia 
Enpp1flox/flox 1.97 (0.06) 1.37 (0.06) 0.91 (0.05) 156.61 (4.24) 4.87 (0.36) 
Ocn-Cre;Enpp1flox/flox 2.05 (0.04) 1.55 (0.04) 0.98 (0.03) 162.53 (4.42) 4.88 (0.98) 
Table 3.9. µ-CT analysis of tibiae and femora cortical bone from 22-week male mice reveals no difference between 
genotype. 
The following parameters were measured; periosteal diameter (Peri. Di.), endosteal diameter (Endo. Di), bone volume (BV), cortical 










Bone  Genotype BV/TV (%) Tr. Pf. SMI Tr. Th. (mm) Tr. No. Tr. Sp. (mm) 
Femur 
Enpp1flox/flox 7.79 (4.50) 28.70  (16.57) 2.12 (1.23) 0.05 (0.03) 1.57 (0.91) 0.266 (0.15) 
Enpp1flox/flox;Ocn-cre 13.34(1.52)* 16.60 (2.59) 1.72 (0.12)* 0.05 (0.001) 2.43 (0.23)* 0.24  (0.09) 
Tibia 
Enpp1flox/flox 7.89 (3.47) 17.64 (7.79) 1.68 (0.55) 0.21 (0.18) 1.34 (0.50) 0.34 (0.08) 
Ocn-Cre;Enpp1flox/flox 12.75 (1.29) 17.90 (3.02) 1.97 (0.12) 0.06 (0.002) 2.32 (0.38) 0.26 (0.03) 
Table 3.10. µ-CT analysis of tibiae and femora trabecular bone from 22-week female mice demonstrates significant 
differences in the femora.  
The following parameters were measured; per cent bone volume (BV/TV), trabecular patterning factor (Tr. Pf.), structural model index 
(SMI), trabecular thickness (Tr. Th.),  trabecular number (Tr. No.), trabecular spacing (Tr. Sp.). Data are presented as the mean ± S.E.M 










Bone Genotype Peri. Di (mm) Endo. Di (mm) BV (mm3) Ct. Th (mm) Po(op) (%) 
Femur 
Enpp1flox/flox 1.14 (0.02) 0.84 (0.003) 0.59 (0.28) 0.11 (0.90) 1.72 (0.5) 
Enpp1flox/flox;Ocn-cre 2.19 (0.07) 1.66 (0.05)* 1.04 (0.03)** 0.19 (0.004) 3.13 (0.18) 
Tibia 
Enpp1flox/flox 1.16 (0.38) 0.74 (0.23) 0.73 (0.20) 0.13 (0.03) 3.34 (0.91) 
Ocn-Cre;Enpp1flox/flox 1.63 (0.06) 1.05 (0.04) 1.00 (0.03) 0.17 (0.007)* 4.12 (0.03) 
Table 3.11. µ-CT analysis of tibiae and femora cortical bone from 22-week female mice reveals significant differences 
between genotypes. 
The following parameters were measured; periosteal diameter (Peri. Di.), endosteal diameter (Endo. Di), bone volume (BV), cortical 










Analysis of the epiphyseal bone of 22-week old male mice revealed no micro-architectural 
differences between genotypes (Fig. 3.11A-3.11F). The female Enpp1flox/flox;Ocn-cre exhibited 
increased epiphyseal trabecular number (5.60 vs. 5.03; P<0.01) (Fig. 3.11B) and a decreased 
trabecular pattern factor compared to Enpp1flox/flox mice (7.06 vs 13.83; P<0.05) indicating a 
greater quantity and connectedness of trabeculae (Fig. 3.11E). All other parameters were 
unchanged between genotypes for female mice.  
 
Whilst 6-week old mice revealed largely no micro-architectural differences to the 
subchondral bone, changes regarding the subchondral bone were more evident at 22-weeks 
of age. For male mice, only the medial trabecular thickness showed genotype changes, 
whereby the male Enpp1flox/flox;Ocn-cre mice exhibited increased thickness (0.10 mm vs. 0.08 
mm; P<0.05) compared to Enpp1flox/flox control mice (Fig. 3.12E). As with the majority of µ-CT 
findings, significant differences between genotypes were most prolific amongst the female 
cohorts of mice. Indeed, female Enpp1flox/flox;Ocn-cre mice demonstrated increased lateral 
subchondral bone volume (0.28 mm
3
 vs. 0.21 mm
3
; P<0.05) (Fig. 3.12A), increased lateral 
subchondral bone trabecular thickness (0.10 mm vs. 0.08 mm; P<0.001) (Fig. 3.12B), 
increased medial subchondral bone volume (0.26 mm
3
 vs 0.20 mm
3
; P<0.05) (Fig. 3.12D) and 
increased medial subchondral bone trabecular thickness (0.10 mm vs. 0.08mm; P<0.01) (Fig. 
3.12E) compared to female Enpp1flox/flox mice. Neither male nor female mice showed a 




























































Figure 3.11. µ-CT analysis of the epiphyseal bone from male and female mice reveals significant differences between genotype for 
female mice. 
The parameters analysed include the trabecular (A) bone volume/tissue volume, (B) trabecular number, (C) trabecular separation, (D) trabecular 

























Figure 3.12. µ-CT analysis of the lateral and medial subchondral bone from 22-week old male and female 
mice reveals genotype specific differences.  
The subchondral bone parameters measured include (A) lateral bone volume, (B) lateral trabecular thickness, (C) 
lateral porosity, (D) medial bone volume, (E) medial trabecular thickness and (F) medial bone porosity. Data are 









































3.4.12. Analysing the mechanical properties of long bones in adult mice 
To determine whether the alterations in the 22-week old long bones translates to altered 
mechanical properties, three-point bending analysis was performed. For both female and 
male mice, no differences in mechanical properties of the tibia and femora were observed 
between genotypes (Table. 3.12, 3.13). There was one exception however, female 
Enpp1flox/flox;Ocn-cre tibiae exhibit increased deflection at rupture compared to female 
Enpp1flox/flox mice (0.95643 mm vs. 0.58949 mm; P<0.05).  
 
3.4.13. Analysing bone mineral density of long bones of adult mice 
To determine whether osteoblast-specific NPP1 ablation resulted in long-term  alterations to 
bone mineral density, bone mineral density of 22-week old mice long bones were 
determined using µ-CT analysis.  Analysis revealed largely similar bone mineral density in 
male and female mice of both genotypes which included the tibiae cortical (Fig. 3.13A) 
trabecular (Fig. 3.13B) and the femora trabecular (Fig. 3.13D) bone. Whilst, the femora 
cortical bone mineral density was similar in male mice of different genotypes it was 
significantly decreased in female Enpp1flox/flox;Ocn-cre mice compared to female Enpp1flox/flox 

































































































Table 3.12. 3-point bending of 22-week old femora demonstrates unaltered function as a result of osteoblast-specific 
NPP1 ablation.  
Values are shown for femora dissected from 6-weeks and 22-weeks of age from female and male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
mice. Bones were tested to fracture, whereby fracture points were identified from the load-extension curve whereby the maximum load 
decreased rapidly to 70% of the maximum value. The maximum stiffness was defined as the maximum gradient of the rising portion of 
































































































Table 3.13. 3-point bending showing largely unaltered mechanical strength of 22-week old tibiae. 
Values are shown for femora dissected from 6-weeks and 22-weeks of age from female and male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
mice. Bones were tested to fracture, whereby fracture points were identified from the load-extension curve whereby the maximum load 
decreased rapidly to 70% of the maximum value. The maximum stiffness was defined as the maximum gradient of the rising portion of 








































Figure 3.13. Tibiae and femora cortical and trabecular bone mineral density of 6-week 
female mice demonstrates largely no differences between genotype. 
(A) Tibiae cortical and (B) trabecular bone mineral density. (C) femora cortical and (D) trabecular 







As detailed in section 4.1, previous studies have demonstrated that NPP1 is critical in the 
regulation of skeletal mineralisation (Okawa et al., 1998b, Hessle et al., 2002, Johnson et al., 
2003, Johnson et al., 2005, Li et al., 2013, Li et al., 2014b, Albright et al., 2015). These studies 
involved the use of global knockouts or naturally occurring mutants of Enpp1. As such, the 
cell-specific contributions of NPP1 to the observed skeletal phenotype remain unknown.  
 
The current study demonstrates that juvenile osteoblast-specific NPP1 knockout mice have 
largely unaltered body-weight, contradicting the findings of global Enpp1-/- mice which 
present with significantly reduced body weight at 6-weeks of age (Huesa et al., 2014). The 
long bone length of osteoblast-specific NPPP1 were unaffected, reflecting findings observed 
for global Enpp1-/- mice (Huesa et al., 2014). Furthermore, the markers of resorption and 
formation of bone were unchanged, again reflecting findings observed for 6-week old global 
Enpp1-/- mice, suggesting unaltered osteoblast and osteoclast activity (Huesa et al., 2014).  
 
This study revealed that the systemic (serum) concentration of PPi was similar in both 
osteoblast-specific NPP1 knockout mice and their controls. This contradicts findings in Enpp1 
global knockout and mutated mice, whereby serum PPi is routinely reported as decreased 
(Sakamoto et al., 1994, Okawa et al., 1998b, Okawa et al., 1999, Rutsch et al., 2001, Hessle 
et al., 2002). These findings indicate that the ablation of NPP1 in osteoblasts cannot 
recapitulate the alterations to systemic PPi observed when NPP1 is deleted within every 
tissue. It is likely that the liver, which is reported as a major contributor of systemic PPi, 
generating up to 60% of overall PPi, generates significant quantities of PPi in the osteoblast-
specific knockout mouse such that systemic PPi is unaltered between genotypes (Terkeltaub, 
2001, Terkeltaub, 2006). This likely explains the absence of pathological (ectopic) joint and 
soft tissue mineralisation observed in the osteoblast-specific NPP1 knockout mice, whereas 
the global Enpp1-/- mice present with aberrant and pathological aortic and kidney 
mineralisation likely due to systemically decreased PPi (Mackenzie et al., 2012). An alternate 
hypothesis exists that tissues undergo mineralisation due to the local (i.e. tissue-specific) 
levels of PPi. To further investigate this, alternate cell-specific NPP1 ablated mouse models 




whereby the enzyme is no longer present. One such example would be the liver-specific 
NPP1 conditional knockout.  
 
Previous investigations of global Enpp1-/- mice have demonstrated reduced long bone 
mineral content, with reduced bone volume fraction and trabecular thickness (Mackenzie et 
al., 2012). This finding is intriguing, given that the majority of studies looking at Enpp1 
knockout mice have reported an accompanying decrease of systemic PPi concentration. One 
would expect this decreased PPi to be associated with increased bone formation. The 
paradoxical hypermineralisation of soft tissue and joints alongside decreased long bone 
mineralisation and bone volume observed in the global Enpp1 knockout mouse indicates that 
the mechanism through which NPP1 exerts its control of mineralisation are complex and 
multiple (Mackenzie et al., 2012, Huesa et al., 2014). This led to the hypothesis that there 
are cell-specific contributions towards the multiple possible mechanisms of NPP1 function. 
Indeed, it is evident that there are liver cell-specific contributions of NPP1 in regarding 
metabolic phenotype. A virus-mediated liver-specific Enpp1 deficient mouse model 
demonstrated a 25% lower plasma glucose (Zhou et al., 2009). However, until this point the 
osteoblast-specific actions of NPP1 regarding both metabolic and skeletal phenotype was 
unknown. Interestingly, the osteoblast-specific Enpp1 mouse model analysis reported in this 
chapter did not reveal significantly increased systemic PPi – contradictory to the global Enpp1 
knockout. This indicates an extra-osteoblastic role of NPP1 in regulation of systemic serum 
PPi.   
 
To determine whether micro-architectural changes occurred in the long bones as a result of 
osteoblast-specific NPP1 ablation a comprehensive high-resolution µ-CT analysis was 
conducted. This included the regions of mid-diaphyseal cortical and trabecular bone, the 
epiphyseal trabecular bone, the lateral subchondral bone of the femorotibial joint, and the 
medial subchondral bone of the femorotibial joint.  Most notably, this work for the first time 
demonstrated that the ablation of NPP1 (at the site of the osteoblast) resulted in an 
increased bone mineral density. As such, the suggested mechanism of local reduction of PPi 
due to decreased local NPP1 activity (in the osteoblast) drives an increase in mineral 




The 6-week old mice with an osteoblast-specific NPP1 ablation present with a notable 
skeletal phenotype, whereby there is an increase in bone mass and bone volume. This is in 
keeping with my hypothesis for this mouse model. This was confirmed at multiple levels, 
including comprehensive µ-CT analysis. The 6-week old Enpp1flox/flox;Ocn-cre demonstrate 
notable differences in the trabecular and cortical mid-diaphyseal femora and cortical 
parameters indicative of overall increased bone tissue. It is important to note here that the 
genotype-specific differences observed in µ-CT were more prolific amongst female mice 
compared with male mice.  Furthermore, the data presented in this chapter indicates that 
the architectural alterations observed in the 6-week old Enpp1flox/flox;Ocn-cre bones does not 
translate to altered biomechanics in the juvenile age. As the skeleton is still developing at 
this age time point, it is pertinent to look at later time points (e.g. once skeletal maturity has 
been reached) to see if the results noted here are recapitulated in a mature skeleton. 
 
The µ-CT analysis revealed notable differences in bone architecture between genotypes. 
Alterations to bone architecture are known to be associated with changes to mechanical 
function. To determine whether the osteoblast-specific NPP1 ablation resulted in ability to 
resist load as a product of altered architecture, 3-point bending assessment was conducted. 
No notable difference in mechanical function were observed, suggesting that the changes 
observed in µ-CT are not able to alter the mechanical function of the bone.  
 
The use of histological analysis of the bone (distal femora) of 6-week old mice supported the 
findings of µ-CT, indicating increased Enpp1flox/flox;Ocn-cre bone mass. This observation was 
more evident in female juvenile cohorts and less evident in male cohorts. Histological 
analysis revealed increased bone marrow adiposity in Enpp1flox/flox;Ocn-cre mice, however, 
this was not reflected in the more detailed µ-CT analysis of osmium stained bones; this is 
suggestive of non-uniform dispersal of marrow adipose tissue throughout the bone. A 
deleterious imbalance of adipocytes and osteoblasts are commonly reported in pathological 
situations including ageing and diabetes – whereby an increase in bone marrow adipose 
tissue occurs at the expense of osteoblast renewal (Justesen et al., 2001, Botolin and 




This occurs due to the common progenitor lineage of mesenchymal stem cells for adipocytes 
and osteoblasts (Caplan, 1991, Teitelbaum, 2000). Furthermore, the adipocytes are reported 
to secrete a large number of signalling molecules that can affect bone homeostasis and bone 
remodelling (e.g. adiponectin) (Pajvani et al., 2003). The absence of adipocyte changes 
observed in the Enpp1flox/flox;Ocn-cre mice at this stage indicates protection against, or at 
least absence, of the pathological osteoblast/bone marrow relationship. To further 
investigate this, it is necessary to conduct a metabolic challenge for the osteoblast-specific 
NPP1 knockout mice to induce a diabetic phenotype and investigate potential pathological 
effects of marrow adipose tissue expansion during caloric excess and glucose dysregulation 
in the mouse model (as discussed in chapter 6). Taken together, this histomorphometry 
analysis indicates an increase in the mineralised tissue alongside a reduction in osteoid tissue 
and potential increased bone marrow adiposity, most evident in female cohorts of 
Enpp1flox/flox;Ocn-cre compared to Enpp1flox/flox  controls.  
 
The investigation of skeletal phenotype continued, whereby the adult 22-week old mice 
were next assessed. Here, the expected sex-different results were observed, including longer 
length bones in male mice compared to female mice. The female Enpp1flox/flox;Ocn-cre mice 
demonstrate no differences in bone length, however, the male Enpp1flox/flox;Ocn-cre mice 
exhibited increased tibiae and decreased femora length which is suggestive of altered 
loading on the long bones. The relationship between loading and altered bone growth plate 
dynamics is published, indicating increased growth plate chondrocytes resultant of sustained 
mechanical loading (Stokes et al., 2002). Alterations to bone length in association with load 
in mouse models is also well published. For example, Killion et al., demonstrate that paralysis 
of a mouse hind limb by disruption of the sciatic nerve at post-natal day 8 results in altered 
gait and altered load. These mice present with significantly reduced bone limb length at 8-
weeks of age as a result of decreased loading, with the contralateral limb of the same mouse 
used as control (Killion et al., 2017).  
 
Largely no differences were observed in the markers of bone formation or resorption at 22-
weeks, reflecting the 6-week old mice, and as such, the altered femora length is not 




in bone length may also be attributable to the difference in sex hormones between male and 
female mice. It is well established that testosterone treatment results in an increase in bone 
accrual, and that androgens cause an upregulation of the androgen receptor on osteoblasts 
(Kasperk et al., 1997, Wiren et al., 1997, Wiren et al., 1999, Khosla et al., 2001, Seeman, 
2001). Therefore, the greater long bone length observed in the male  Enpp1flox/flox;Ocn-cre 
mice compared to female counterparts is likely endocrine-related (Ornoy et al., 1994).  
 
The data presented in this chapter demonstrates significant changes for both male and 
female Enpp1flox/flox;Ocn-cre mice cortical porosity. One limitation of this dataset is related to 
the voxel scanning resolution. A standard scanning resolution of 4-5 µm was used in this 
thesis for the assessment of long bones via µ-CT analysis (Basillais et al., 2007, Cardoso et al., 
2013). However, a resolution of less than 4 µm (ideally 1 µm) should be used to separate the 
vascular porosity from osteonal canals (Palacio-Mancheno et al., 2014). Indeed, it is reported 
that at a 4 µm resolution, vascular porosity and vascular canal diameters were 
underestimated, osteocyte lacunae was poorly detected and vascular canal separation was 
over-estimated (compared to 1 µM scans) in Sprague Dawley rat long bones. Regarding the 
data in this thesis, no difference in osteoclast activity was observed in the osteoblast-specific 
NPP1 ablated mice. As such, we can posit that the altered porosity observed was not due to 
increased osteoclast activity/altered osteoblast and osteoclast balance (and associated 
osteoporotic phenotype) (Teitelbaum, 2000). To support the µ-CT data, a detailed 
histomorphometric analysis of the cortical bone porosity may have been conducted using 
established protocols such as that described by Qiu et al. (Qiu et al., 2003), although this too 
has limitations including variability or practice between individuals.  
 
In addition, the cortical porosity of the tibiae and femora was assessed at one particular 
anatomical region, specifically a 1 mm region which is 0.4 mm from the growth plate. The 
micro-porosity of bone plays an important role in bone biology and in the mechanical quality 
of the bone. Assessing porosity has often been conducted in order to investigate mechanical 
property of bone. However, recent findings by Nunez et al demonstrate that the posterior 
region of the tibiofibular junction of 15 week old mice have higher porosity (in the form of 




anterior and posterior regions of intracortical vascular networks were assessed and 
demonstrated notable differences in porosity (Nunez et al., 2018). This translated into 
thinner cortices within the posterior cortex after 10 months of life, with no changes to the 
rest of the cortex (Nunez et al., 2018). By not assessing porosity in this more detailed way, 
potential regional changes in the Enpp1flox/flox;Ocn-cre may have been overlooked.  
 
It is recognised in several animal species that subchondral bone plays an important role in 
supporting the functional loading (exercise) of a joint following locomotion, along with 
articular cartilage (Camp et al., 2014, Smith et al., 2016, Adebayo et al., 2017, Li et al., 2017b, 
Fang et al., 2018). When derangements of the subchondral bone occur, progression to 
osteoarthritis may follow (Lajeunesse et al., 2003). The subchondral bone is a dynamic tissue, 
which can respond to various stresses, including acute and prolonged (chronic) joint stress 
(Radin and Rose, 1986, Young et al., 1991, Ding, 2010). The thickening of the trabecular bone, 
as observed in the Enpp1flox/flox;Ocn-cre mice, is associated with increased subchondral bone 
modelling, which in turn can lead to stiffer bones, with decreased elasticity and shock 
absorption (Radin et al., 1970, Goldring, 2009, Ding, 2010). These findings suggest that the 
subchondral bone is thickening, resulting in a stronger bone. This may be due to the 
increased or altered activity of osteoblasts at the subchondral site, or decreased osteoclastic 
activity in the Enpp1flox/flox;Ocn-cre mice. 
 
The global Enpp1-/- mice present with changes consistent with an osteoarthritic phenotype 
(Jin et al., 2018). Indeed, an alternate explanation could exist for the thickening of the 
Enpp1flox/flox;Ocn-cre mice subchondral bone. This may be observed when the subchondral 
bone is no longer able to compensate for physiological stresses and the subchondral bone 
thickens, which affects the ability of the articular cartilage to withstand mechanical load due 
to increased stress at the base of the articular cartilage (Sophia Fox et al., 2009). This typically 
manifests as deep, horizontal clefts within the articular cartilage, and perpetuates 
osteoarthritic changes within the joint (Stewart and Kawcak, 2018). The resultant 
maladaptive bone modelling can manifest as a mechanical failure (whereby the bone 






To conclude, a greater number of significant differences in the bone phenotype are evident 
in the female juvenile osteoblast-specific NPP1 ablated mice, notably increased bone mass. 
The Enpp1flox/flox;Ocn-cre mice potentially have decreased local PPi, which leads to this altered 
bone phenotype with concomitant unchanged systemic PPi levels. This may explain the bone-
specific mineralisation changes and the absence of ectopic calcification in the 
Enpp1flox/flox;Ocn-cre mice. The absence of altered biomechanical properties of 
Enpp1flox/flox;Ocn-cre mice suggests that the increase in bone formation does not alter the 
bone functionality. As such, the osteoblast-specific NPP1 is important in the regulation of 
skeletal formation and mineralisation. Additionally, the absence of osteoblast-specific NPP1 
is not enough to recapitulate the severe mineralisation defects observed in the global NPP1 
knockout mice (Huesa et al., 2014). 
 
Therefore, NPP1 from other organs, such as the liver, is likely to play a role in the regulation 
of mineralisation. The potential role of other organs and more complex mechanisms through 
which NPP1 may exert its action will be discussed in chapter 7. To further understand the 
osteoblast-specific NPP1 ablated mouse model mineralisation phenotype, particularly at a 
mechanistic level, it was important to establish an in vitro model of the NPP1 ablated 
osteoblasts. This further analysis aimed to assess the calcification propensity and possible 
mechanisms underlying the minerlisation phenotype, to determine whether this reflects the 
basic and functional bone phenotype at the gross level. The use of cell lines and primary cell 






























Chapter 4. Investigating the profile of Enpp1 expression 






As is discussed in chapter 1, the formation of bone is a tightly coordinated process which 
involves osteoblasts. The newly laid down osteoid becomes mineralised, whereby 
osteoblasts mineralise their ECM by promoting the formation of  HA crystals (Caetano-Lopes 
et al., 2007). This involves a highly regulated series of physiochemical and biochemical 
processes. The process of mineralisation relies upon levels of Ca2+ and Pi which, when at 
saturation levels, permit the initiation of HA crystal formation. This, in turn, is governed by 
the actions of a large network consisting of mineralisation promoters and mineralisation 
inhibitors (Fig. 4.1). 
 
Although found in virtually all cell types (e.g. liver, kidney, brain) (Harahap and Goding, 1988), 
there is a relatively higher expression of ENPP1 (and thus ENPP1-specific activity) in 
osteoblasts and chondrocytes, where it plays a major role in the regulation of HA mineral 
nucleation (Terkeltaub, 2006).  This is regulated through the catabolism of ATP through 
hydrolysis to generate PPi which potently inhibits the accumulation of HA crystals and thus 
mineralisation (Meyer, 1984). It is the balance of PPi generation relative to the PPi 
degradation (yielding Pi) which holds the extracellular PPi levels in check and thus regulates 
the pro/anti mineralisation environment. It is important to note that there are other sources 
of Pi generation as demonstrated in Fig 4.1. This ensures that pathological calcification is 
avoided and physiological mineralisation permitted. The absence of the ENPP1-catalysed 
generation of PPi in vivo results in a striking spontaneous calcification which has been 
demonstrated in a variety of different mouse models (Hosoda et al., 1981, Okawa et al., 
1998a, Banakh et al., 2002, Anderson et al., 2004, Anderson et al., 2005b, Terkeltaub, 2006, 
Babij et al., 2009).  The generation of PPi by ENPP1 also provides a substrate reservoir for the 
action of ALP-catalysed Pi generation, a pro-mineralising phenomenon. The coordinated 
actions of these two proteins regulate the ratio of PPi/Pi. Disruptions to this ratio results in 
abnormal calcification: this is evident in several naturally occurring diseases (GACI, PXE, and 








Figure 4.1.  A schematic representation of regulators involved in mineralisation. 
The HA crystals are composed of Pi and Ca2+. In the MVs, Pi is generated by the function of 
PiT1/2, as well as by the hydrolysis of the phosphomonoesters including PEA and PChol by 
PHOSPHO1. The Ca2+ transport is mediated by annexin channels that allow influx into the 
MVs. The extracellular pyrophosphate (ePPi) pool is derived both by NPP1 which generates 
PPi via ATP hydrolysis. Additionally, ePPi is transported to the extracellular by ANK 
transporter at the level of the chondrocyte and osteoblast membranes. For both tissue non-
specific alkaline phosphatase (TNSALP) and NPP1, the hydrolysis of ATP, ADP and PPi 
contributes to the extracellular Pi (ePi) pool, though TNSALP is more efficient than NPP1 at 
the level of the MVs. Moreover, a negative feedback loop exists in intracellular. PPi, which is 
produced by NPP1 and transported by ANK, inhibits the expression of Enpp1 and Ank. 







The osteoblast is key to the formation of bone, both in early development and throughout 
the lifespan, whereby osteoblasts facilitate the repair of damaged bone and the formation 
of bone in response to mechanical demand (Frost, 1994). To study bone development, 
notably concerning humans, non-invasive research techniques needed to be created and 
used. The development of in vitro cell culture models, including cells lines and use of primary 
cells has catalysed our gain-of-knowledge for bone formation and the 
mechanisms/interactions involved. 
 
To study osteoblast matrix mineralisation, a variety of clonal cell model systems have been 
previously employed. The most commonly used cell line to investigate osteoblast matrix 
mineralisation is the MC3T3-E1 – an osteoblast-like clonal and non-transformed cell line. This 
cell line was first isolated and reported in 1981 (Kodama et al., 1981, Sudo et al., 1983). There 
are over 50 sub-clones of MC3T3 cells (Wang et al., 1999b). Of these sub-clones, MC3T3-E1 
sub-clone c14 represents a fast mineralising sub-clone (Houston et al., 2016). In the presence 
of ascorbic acid (AA) and b-glycerophosphate (b-GP), these cells are reported to develop 
nodules of mineralisation (Franceschi and Iyer, 1992, Chentoufi et al., 1993, Beck et al., 
2000). It is important to note that cell lines themselves may not fully represent the primary 
cells from which they were developed. Due to this, the scientific community has increasingly 
used primary cells (in this case, primary osteoblasts) isolated commonly from the calvaria 
and less commonly from long bones (such as the femur) (Taylor et al., 2014). This line of 
investigation is of increasing importance when considering the specific contributions of a 
gene, tissue, or cell type to a phenomenon. As such, the use of primary osteoblast cell culture 
to investigate matrix mineralisation and temporal changes throughout the time course of 
mineralisation was fully utilised in this study and described within.  
 
The previous chapter has demonstrated an increase in mineralisation and bone formation at 
the site of the long bone, including the tibia and the femora, for the osteoblast-specific 
ablated mouse model. These changes are evident at the microarchitectural level. However, 
it is not evident from the bone phenotyping of chapter 3 whether there are altered cellular 




This chapter aimed to assess the osteoblasts function by using the well established isolation 
of osteoblasts form the calvaria of experimental mice. 
 
4.2. Hypothesis 
I hypothesised that primary osteoblasts isolated from the Enpp1flox/flox;Ocn-cre mouse will 
have a more rapid onset of matrix mineralisation (cultured in mineralising conditions) than 
primary osteoblasts isolated from the Enpp1flox/flox mouse which will resemble MC3T3-E1 sub-
clone c14 matrix minerlisation. I further hypothesised that this will be due to lower levels of 
PPi. This abnormal hypermineralisation phenotype will be rescued via TNAP inhibition such 
that PPi levels are returned to physiological levels.   
 
4.3 Aims 
To investigate the expressions of genes associated with mineralisation in vitro, both 
established osteoblast-like (fast mineralising) MC3T3-E1 sub-clone c14 cells and primary 
calvarial osteoblasts isolated from the osteoblast-specific NPP1 knockout mouse model 
(Enpp1flox/flox;Ocn-cre) and age-matched controls (Enpp1fl0x/flox) were utilised. For both cell 
lines and primary osteoblasts, cells were cultured in mineralising media to investigate the 
following aims; 
 
I. Changes in gene expression of both MC3T3-E1 sub-clone c14 cell line and primary 
osteoblasts isolated from Enpp1flox/flox;Ocn-cre mice in comparison to Enpp1flox/flox  
control mice throughout time course in mineralisation medium.  
 
II. Whether the inhibition of TNAP via the addition of a small molecule TNAP inhibitor 
to the mineralisation media will rescue any potential mineralisation abnormalities of 
the isolated primary osteoblasts.  
 
 
III. Any potential difference in the metabolic capacity of primary osteoblasts isolated 





4.4 Materials and methods 
4.4.1. MC3T3-E1 sub-clone c14 and primary cell culture  
MC3T3-E1 sub-clone c14 cells were seeded in 6-well plates at a density of 100,000 cells per 
well. When confluent, the media for cells was supplemented with 5 mM b-GP and 50 µg/ml 
AA (Section 2.2.6). Primary osteoblasts were isolated from 2-5 day old pups and cultured as 
(Section 2.2.5)(Appendix III for schematic representation of primary osteoblast isolation 
from calvaria). Confluent primary cultures were maintained for up to 28 days in primary 
osteoblast media supplemented with 5 mM b-GP and 50 µg/ml AA.  
 
4.4.2. qPCR analysis of MC3T3-E1 sub-clone c14 and primary osteoblast gene 
expression throughout mineralisation time course 
At defined time points, RNA was extracted from both MC3T3-E14 sub-clone c14 and primary 
osteoblasts using Qiagen RNeasy kit, as per the manufacturer’s protocol. Subsequently, 
cDNA was prepared (Section 2.3.2.) and was used at a concentration of between 5 and 15 
ng/µl for qPCR analysis (Section 2.3.3). qPCR was performed using the SYBR green detection 
method on a Stratagene Mc3000P real-time qPCR system. Primers were purchased from 
PrimerDesign Ltd, or designed in house and synthesised by Sigma and Eurofins (Appendix I). 
Reactions were run in duplicate, and results were normalised to b-actin and GAPDH 
housekeeping genes and relative gene expression was determined using the DDCt method 
(Livak and Schmittgen, 2001). 
 
4.4.3. Calcium deposition 
Media from the cellular monolayers was discarded and the cell monolayers were washed 
with PBS. Next, 500 μl of 0.6 M HCl was added to the monolayer and incubated at 4°C. A 
commercially available calcium assay Kit (Randox, County Antrim, UK) was used to quantify 
the calcium deposition in the cells, with samples and standard run in duplicate. The 
mechanism underpinning this assay is based on the binding between O-cresolphthalein 
complexone and calcium ions in an alkaline media. For each experiment, a negative control 
was included using the leaching solution (0.6 M of HCl) in place of the sample. Calcium 




calcium concentration. As such, 5.25 µl of calcium standard/negative control with  0.6 M HCl 
or sample was added to a 96-well plate in duplicate. Next, 250 µl of 1:1 ratio of 2-amino-2-
methyl-propan-1-ol (R1) and O-Cresolphthalein complexone 8-Hydroxyquinoline, HCl (R2) 
were added to each well. The Optical Density was read using Synergy HT Multi Mode 
Microplate reader (BioTek) at a wavelength of 570 nm. Calcium content was determined 
using the following equation:  
Concentration = +mmolL / = +
Sample	OD




4.4.5. Alizarin Red S staining and quantification  
The media from cellular monolayers was discarded and cellular monolayers were washed 
with PBS. Cells were then incubated with 4% paraformaldehyde (PFA; pH 7.0) for 15 minutes 
at room temperature (RT). The PFA was discarded, and cellular monolayers washed three 
times with PBS. Subsequently, 2% (w/v) Alizarin Red S Stain (pH 4.2; Sigma, Dorset, UK) was 
added and incubated at room temperature for 10 minutes. Cellular monolayers were washed 
with water until excess staining had been removed. The cellular monolayer was allowed to 
dry and was photographed, after which the cells were stored dry at -20°C. When required, 
bound Alizarin red S stain was solubilised using 10% cetylpyridinium chloride (Sigma-Aldrich). 
Samples were collected and run in duplicate, using cetylpyridinium chloride as a blank, in a 
96-well plate to measure the optical density at 570 nm. Optical density was determined using 
the synergy HT multimode Microplate reader (BioTek, Bedfordshire, UK). 
  
4.4.4. ALP activity 
MC3T3-E1 sub-clone c14 cells and primary osteoblasts were harvested in 500 µl of 1% Triton-
x-100 with 1 mM MgCl2. TNAP activity was analysed using Thermo-line TNAP reagent 
(Thermo-line, Melbourne, Australia) (Farquharson et al., 1995). Enzymatic activity of TNAP 
was measured using p-nitrophenyl phosphate (pNPP) as substrate. The optical density of the 
reaction product p-nitrophenol was read at 405 nm by the Synergy HT multimode Microplate 




DC assay (Section 3.4.5) and total TNAP activity was expressed as nmoles pNPP 
hydrolysed/min/mg protein. 
4.4.5 Bio-Rad DC assay 
The medium of the cellular monolayer was discarded and cell monolayers were washed with 
PBS to remove excess media. An appropriate volume of 0.1 M NaOH 0.1% SDS lysis buffer 
was added to the cell monolayer and incubated at RT on a shaker for 1 hour. The cells were 
scraped and collected into Eppendorf tubes. Tubes were subsequently vortexed and 
centrifuged at 10,000 g for 10 seconds to remove condensation. To quantify protein 
concentrations, Bio-Rad DC Protein Assay (Bio-Rad Hertfordshire, UK) was used according to 
manufacturer’s instruction, with a protein standard of g globulin used to obtain a standard 
curve. For both protein standard and protein, 5 μl of the samples were run in duplicate on a 
96-well plate, with 25 μl alkaline copper tartrate (Reagent A) and 200 μl Folin’s reagent 
(Reagent B) subsequently added. The 96-well plate was incubated at RT for 15-60 minutes 
before absorbance measurement (at a wavelength of 590 nm) using the synergy HT 
multimode Microplate reader (BioTek, Bedfordshire, UK). 
 
4.4.6. Seahorse metabolic analysis of primary osteoblasts 
Calvarial osteoblasts from age-matched Enpp1floxflox and Enpp1flox/flox;Ocn-cre mice were 
extracted (Section 2.2.5) and plated on a Seahorse XF24 microplate at a density of 10,000 
cells per well in 150 µL of primary osteoblast medium. The plate was transferred to a 37°C 
CO2 incubator until 100% confluency was reached (approximately 1 day). Osteoblasts were 
washed in 500 µl XF assay media supplemented with 25 mM glucose and 10 mM pyruvate 
and placed in a non-CO2 incubator at 37°C for 1 hour before the start of the assay. Calvarial 
osteoblasts were then exposed to oligomycin (1 µM - a complex V inhibitor, that inhibits 
respiration by inhibiting ATP synthase), the uncoupling agent carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP - (3 µM)), antimycin A (that inhibits respiration by 
inhibiting oxidation of ubiquinol in the electron transport chain) and rotenone (1 µM - 
complex I inhibitor involved in the inhibition of the mitochondrial respiratory chain). All 
reagents were prepared for the assay from 2.5 mM Seahorse stock solutions (Seahorse 
Bioscience, Massachusetts, US). Following equilibration, the Seahorse plate was placed in 




respiration) and extracellular acidification rate (ECAR; an indicator of glycolysis) values are 
shown as pMoles/min compared at three different time points per condition. For the 
Seahorse metabolic analysis optimisation of drug concentrations was conducted, and 
subsequently, Seahorse experiments were run twice at optimal drug concentrations. All data 
were normalised to total protein concentration by sulforhodamine B staining. The data 
shown in the assays are an average of at least three different wells per group for one 
Seahorse Run. This work was performed with the assistance of Dr Rod Carter.  
 
4.4.7. Serum PPi Assay 
Serum samples were collected (Section 2.9.3) and stored at -80°C until required. Caution was 
taken to avoid aspiration of air during sample collection. Plasma was subsequently 
transferred to separation tubes (Sartorius Centristart, 1,300,000 MW 123 79E) and filter-
centrifuged at 2000 g for 25 minutes at 4°C. Supernatant was collected and stored at -80°C 
until required. Subsequently, 35 µL PPi master mix (Section 2.9.3) and 5 µl of sample were 
added to opaque 96-well plates, with samples run in duplicate. The plate was briefly 
centrifuged, followed by incubation at 37°C for 30 minutes followed by heat inactivation at 
95°C for 10 minutes. The 96-well plate was shortly spun down, and 30 µL of sample was 
transferred to a new 96-well plate. 15 µL of BacTiter Glo (Promega G8230) pre-warmed to 
room temperature was added, and plate briefly centrifuged and incubated at room 
temperature for 10 minutes. Luminescence was subsequently measured using the synergy 
HT multimode Microplate reader (BioTek, Bedfordshire, UK) at 24°C. Master-mix without 
enzyme was used for blank, and a standard curve determined using known concentrations 
of PPi. This technique was developed in collaboration with Janna Zoll and Professor Olivier 
Le Saux of University of Hawaii. I optimised this technique for implementation in this 
experiment to measure serum PPi of the Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice.  
 
4.4.8. Treatment with TNAP inhibitor. 
Primary osteoblasts from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox control mice were plated at a 
density of 100,000 cells per well in a 6-well plate. When confluent, the culture media was 




inhibitor 2,5-Dimethoxy-N-(quinolin-3-yl)benzenesulfonamide-referred to as MLS-0038949 
(Sigma) (Huesa et al., 2015a). Confluent primary cultures were maintained for up to 28 days 
in primary osteoblast media supplemented with 5 mM b-GP and 50 µg/ml AA and TNAP 
inhibitor MLS-0038949 (Sigma). The cellular layers were analysed for calcium content by a 
Randox assay and stained for Alizarin red S (Sections 3.4.3. and 3.4.5) at days 0, 21 and 28.  
 
4.5. Results 
4.5.1. Investigating the mineralisation profile of the mouse cell Line MC3T3-E1 sub-
clone c14 
4.5.1.1. Analysing calcium content of MC3T3-E1 sub-clone c14 cells  
an in vitro pilot study regarding the mineralising profile of a well-established, mineralisation-
competent murine pre-osteoblastic cell line (MC3T3-E1 sub-clone c14) was conducted prior 
to investigating primary osteoblast cell mineralization. These results were used to draw 
comparisons of the mineralisation profile of the primary calvarial osteoblasts isolated from 
the Enpp1flox/flox;Ocn-cre and Enpp1flox/flox control mice. These MC3T3-E1 sub-clone c14 cells 
were cultured with the addition of b-GP, which is a commonly used organic phosphate source 
and AA which is required for collagen secretion into the ECM (Chung et al., 1992, Altaf et al., 
2006). At day 0, the Alizarin red S staining (representing calcium deposition in ECM) was 
minimal (0.07 AU) (Fig. 4.2A) indicating a low level of mineral deposition. Culture of cells 
under mineralisation conditions resulted in a significant increase of Alizarin red S staining at 
day 14 (0.24 AU vs. 0.07 AU; P<0.01) and day 21 (0.53 AU vs. 0.07 AU; P<0.001) (Fig, 4.2A). 
The total calcium deposition was significantly increased following 21 days of culture in 
mineralising conditions (0.64 AU vs. 0.22 AU; P<0.001) (Fig. 4.2B). These data indicate the 
formation of a mineralised matrix by MC3T3-E1 sub-clone c14 cells over a 21-day culture 







Figure 4.2. Analysis of increased temporal calcium deposition in MC3T3-E1 sub-clone c14 
cells. 
A) MC3T3-E1 sub-clone c14 cellular monolayers stained with Alizarin red S, (B) quantification of Alizarin 
red S and (C) quantification of deposited calcium content by absorbance. Data are presented as the 





4.5.1.2. Analysing the relative changes of mRNA in MC3T3-E1 sub-clone c14 cells 
The mRNA expression of genes associated with mineralisation was determined at all 
mineralisation condition time points (day 0, 7, 14 and 21). A significant decrease in Ank fold 
change, compared to day 0, was observed by day 7 (0.70 vs. 1.00; P<0.05) and day 14 (0.41 
vs. 1.00, P<0.001) (Fig. 4.3A). The Ank mRNA expression was increased at day 21 comparable 
to day 0 (Fig. 4.3A). A significant decrease in the fold change of Pit1 was observed by day 7 
(0.36 vs. 1.00, P<0.001), as was Enpp1 (0.33 vs. 1.00; P<0.001) and was maintained until day 
21 (Fig. 4.3B, Fig. 4.3C). A significant increase in Alpl mRNA expression was observed by day 
7 (119.33 vs. 1.00; P<0.001) and was maintained until day 21 (Fig. 4.3D). No significant 
differences in Runx2 (Fig. 4.3D) or Phospho1 (Fig 4.3E) mRNA expression were observed 
throughout the mineralisation time course for MC3T3-E1 sub-clone c14 cells (Fig. 4.3E-G).  
 
4.5.1.3 Investigating ALP activity in MC3T3-E1 sub-clone c14 cells 
To investigate the activity of TNAP throughout the time course mineralisation study, a 
commercially available ALP kinetic assay was used. To normalise results, the Bradford assay 
was used to quantify protein at each time point. The ALP activity, normalised to total protein, 
was significantly decreased, compared to day 0, following 21 days in mineralisation media 
(107.14 nmols pNPP hydrolysed/min/mg protein vs. 454.00 nmols pNPP hydrolysed/min/mg 










Figure 4.3. Part 1. Assessing the relative change of bone-associated mRNA expression 
in MC3T3-E1 sub-clone c14 cells demonstrates changes to Ank, PiT1, Enpp1 and Alpl. 
To assess the relative change of mRNA in MC3T3-E1 sub-clone c14 cells, qPCR was conducted. 
Cells were grown for 0, 7, 14 and 21 days post-confluence in mineralisation media and 
subsequently analysed for (A) Ank, (B) Pit1, (C) Enpp1 and (D) TNAP. The mRNA values generated 
were normalised to β-actin and Gapdh housekeeping genes. Data are presented as the mean ± 
S.E.M (number of wells assessed per time point: n=6) in comparison to day 0. Significance is 




















Figure 4.3: Part 2. Assessing the relative change of bone-related mRNA expression 
in MC3T3-E1 sub-clone c14 cells. 
To assess the relative change of mRNA in MC3T3-E1 sub-clone c14 cells, qPCR was 
conducted. Cells were grown for 0, 7, 14 and 21 days post-confluence in minerlisation media 
and subsequently analysed for mRNA expression of (E) Runx2 and (F) Phospho1. The mRNA 
values generated were normalised to β-actin and Gapdh housekeeping genes. Data are 
presented as the mean ± S.E.M (number of wells assessed per time point: n=6) in comparison 












Figure 4.4. ALP activity in MC3T3-E1 sub-clone c14 cells decreases 
after 21 days in vitro. 
ALP activity was determined and normalised to total protein. Data are 
presented as the mean ± S.E.M (n=6) in comparison to day 0. Significance is 





4.5.2. Investigating the matrix mineralisation profile of primary osteoblasts isolated 
from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
4.5.2.1. Analysing calcium deposition of primary osteoblasts 
Representative images of Alizarin red S stained cellular monolayers show progressively 
increasing stain intensity over the time course for both Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
isolated primary osteoblasts (Fig. 4.5A). Assessment of temporal changes of staining intensity 
revealed a significant increase in Alizarin red S staining by day 28 for Enpp1flox/flox isolated 
primary osteoblasts (1.57 O.D at 570 nm vs. 0.06 units O.D at 570 nm; P<0.001) (Fig. 4.5B). 
The Alizarin red S staining was significantly increased by day 21 for Enpp1flox/flox;Ocn-cre 
isolated primary osteoblasts (1.06 O.D at 570 nm vs. 0.06 O.D at 570 nm; P<0.01) and was 
maintained until day 28 (Fig. 4.5C). When observing genotype-specific difference in matrix 
mineralisation throughout the time course, a significant increase in Alizarin red S staining 
was evident at day 28, in cultures of osteoblasts from Enpp1flox/flox;Ocn-cre compared to 
cultures of Enpp1flox/flox osteoblasts  (2.50 O.D at 570 nm vs. 1.58 O.D at 570 nm; P<0.05) (Fig. 
4.5D).  
 
Total calcium deposition of primary osteoblast cells was also analysed to investigate 
temporal and genotype-specific differences. The Enpp1flox/flox isolated primary osteoblast 
demonstrate significantly increased calcium deposition by day 14 in mineralisation 
conditions compared to day 0 (18.01 µg/ml vs. 5.76 µg/ml; P<0.05) (Fig. 4.6A). A significant 
increase in calcium deposition for the Enpp1flox/flox isolated primary osteoblasts was also 
observed at day 21 and day 28 compared to day 0 (Fig. 4.6A). Reflecting the Alizarin red S 
staining, a significant increase in total calcium deposition was observed at the early time 
point of day 7 for the Enpp1flox/flox;Ocn-cre isolated primary osteoblasts compared to day 0 
(5.97 µg/ml  vs 0.94 µg/ml; P<0.001) (Fig. 4.6B). A significant increase in calcium deposition 
was also observed at day 21 and day 28 compared to day 0 (Fig. 4.5B). Genotype-specific 
differences were also investigated over the mineralisation time course. By day 14, the 
Enpp1flox/flox;Ocn-cre isolated primary osteoblasts demonstrate a significantly increased 
calcium deposition compared to Enpp1flox/flox isolated primary osteoblasts (27.72 µg/ml vs.  
18.02 µg/ml, P<0.05) (Fig. 4.6C). This was also observed for day 21 (P<0.01) and day 28 
(P<0.001) (Fig. 4.6C). These data demonstrate an enhanced ability of the Enpp1flox/flox;Ocn-




 Figure 4.5. Increased calcium content in the primary osteoblasts of osteoblast-specific NPP1 
ablated mice by Alizarin red S staining. 
(A) Primary osteoblast cellular monolayers stained with Alizarin red S, absorbance determined 
quantification of Alizarin red S stain from (B)  Enpp1flox/flox and (C) Enpp1flox/flox;Ocn-cre isolated primary 
osteoblasts showing significance over time course  and (D) showing significance between genotype over 
time (days) in mineralisation media post confluence. Data are presented as the mean ± S.E.M (n=6). 







Figure 4.6. Primary osteoblast total calcium content is increased in the primary 
osteoblasts of osteoblast-specific NPP1 ablated mice. 
Total protein concentration of (A)  Enpp1flox/flox and (B) Enpp1flox/flox;Ocn-cre isolated primary 
osteoblasts showing significance increase over the time course and (D) showing significance 
between genotype over time (days) in mineralisation media post confluence. Data are 






4.5.2.2. Analysing the mRNA expression of key osteogenic and mineralisation genes in 
primary osteoblast cells. 
Genotype-specific changes of mRNA  expression in cultured primary osteoblast cells isolated 
from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mouse calvaria were analysed by qPCR. At day 0, 
Bglap mRNA expression was significantly increased in Enpp1flox/flox;Ocn-cre primary 
osteoblasts compared to Enpp1flox/flox (fold change 1.31 vs. 1.00; P<0.05) (Fig. 4.7A). At day 
21 only, a significant decrease in Bglap and Opn (0.38 vs. 22.91; P<0.05) (Fig. 4.7A, Fig. 4.7B) 
mRNA expression was observed in Enpp1flox/flox;Ocn-cre primary osteoblasts compared to 
Enpp1flox/flox isolated primary osteoblasts. At day 21, a significant increase in Phospho1 (38.12 
vs. 1.00; P<0.05) (Fig. 4.7C) and Runx2 (18.30 vs. 3.00; P<0.01) (Fig. 4.7D) mRNA expression 
was observed for Enpp1flox/flox;Ocn-cre primary osteoblasts compared to Enpp1flox/flox isolated 
primary osteoblasts. No significant differences in mRNA expression of Mgp (Fig 4.7F) or Fgf23 
(Fig 4.7G) were noted between genotype. It is important to note that many of the changes 
at specific time points for differences in mRNA expression of genes were not significant 
between genotypes or temporal time points. The general trend observed was that a 
significant difference in mRNA expression of genes was evident at day 21 but was not 















Figure 4.7. Part 1. Bone-Related mRNA expression in primary osteoblasts shows 
significant differences between genotype for Bgalp, Opn, Runx2 and Phospho1. 
To assess the relative changes in mRNA levels of primary osteoblasts, qPCR was 
conducted. Cells were grown for 0, 7, 14, 21 and 28 days post-confluence in mineralisation 
media and subsequently analysed for (A) Bglap, (B) Opn, (C) Fgf23 and (D) Alpl. The mRNA 
values generated were normalised to β-actin and Gapdh housekeeping genes. Data are 







Figure 4.7: Part 2. Bone-Related mRNA expression in primary osteoblasts 
shows significant differences between genotype for Bgalp, Opn, Runx2 
and Phospho1.  
To assess the relative change of mRNA in primary osteoblasts, qPCR was conducted. 
Cells were grown for 0, 7, 14, 21, and 28 days post-confluence in mineralisation 
media and subsequently analysed for (E) Runx2, (F) Phospho1 and (G) Mgp. The 
mRNA values generated were normalised to β-actin and Gapdh housekeeping genes. 





4.5.2.3. Analysing the relative change of extracellular PPi in primary osteoblast cells 
Given that the Enpp1flox/flox;Ocn-cre isolated primary osteoblasts were able to mineralise their 
matrix more in comparison to Enpp1flox/flox isolated primary osteoblasts, the next aim was to 
determine if this was due to differences in extracellular PPi  levels between genotypes. Once 
cells had reached confluence, (day 0) a PPi assay was conducted and samples normalised to 
protein concentration. Initial studies aimed to optimise conditions to generate a standard 
curve (concentrations as follows; 0, 0.16, 0.31, 0.63, 1.25, 2.5 and 5 µM PPi) in α-MEM media 
which was subsequently used throughout the primary osteoblast cell culture experiments. 
Analysis of PPi concentrations revealed a significant decrease in the extracellular media 
concentration in the Enpp1flox/flox;Ocn-cre isolated primary osteoblasts compared to the 







Figure 4.8. Extracellular pyrophosphate concentration in primary osteoblast 
cells from osteoblast-specific NPP1 mice is significantly reduced. 
To assess the difference in extracellular PPi between osteoblast cells isolated from 
Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice a PPi assay was conducted. Cells were grown 
to confluence and the media was collected. Total extracellular PPi normalised to total 
protein was calculated. Data are presented as the mean ± S.E.M (n=6). Significance is 





4.5.3. Analysing the effect of TNAP inhibition on primary osteoblast matrix 
mineralisation 
Given that TNAP reduces PPi by hydrolysis to Pi, the inhibition of TNAP in Enpp1flox/flox;Ocn-
cre primary osteoblasts cultured in minerlisation media was hypothesised to restore the 
Pi/PPi ratio, and result in the restoration of normal matrix mineralisation. To investigate this, 
primary osteoblasts isolated from both genotypes of mice were cultured under 
mineralisation conditions with the addition of 30 µM TNAP-specific inhibitor MLS-0038949. 
Samples were collected at day 0 and day 21 (where Enpp1flox/flox;Ocn-cre demonstrated 
significantly increased mineralisation compared to Enpp1flox/flox controls), whereby cells from 
both genotypes demonstrated matrix mineralisation with the addition of the TNAP inhibitor 
MLS-0038949. Staining with Alizarin red S (Fig. 4.9A) and quantitative analysis (Fig 3.9B) 
demonstrated that both Enpp1flox/flox;Ocn-cre and Enpp1flox/flox primary osteoblasts have a 
minimal level of calcium deposition at day 0, which was increased by day 21 with addition of 









Figure 4.9. Analysis of calcium deposition following TNAP inhibition of primary 
osteoblasts. 
Primary osteoblasts were treated with 30 µM TNAP inhibitor MLS-0038949 during 
mineralisation time-course. (A) Primary osteoblast cellular monolayers stained with 
Alizarin red S, (B) quantification of Alizarin red S. Data are presented as the mean ± 





4.5.4. Analysing metabolic differences in primary osteoblast cells 
Given the evidence that bone may contribute to global energy homeostasis (Ducy et al., 
2000), I next aimed to investigate whether the Enpp1flox/flox;Ocn-cre primary osteoblasts 
increased propensity to mineralise their matrix was associated with altered cellular 
metabolic function. The SeahorseXF-24 extracellular flux analyser was used to measure OCR 
(indicative of aerobic respiration) and ECAR (and indicator of glycolytic function) via 
metabolic stress testing. It was observed that the Enpp1flox/flox;Ocn-cre isolated osteoblasts 
exhibit altered respiration compared to Enpp1flox/flox isolated primary osteoblasts. Basal 
respiration was significantly decreased in Enpp1flox/flox;Ocn-cre cells compared to Enpp1flox/flox 
cells (56.60 pMol/min vs 64.06 pMol/min; P < 0.01) as was ATP linked respiration (45.73 
pMol/min vs. 50.97 pMol/min; P<0.05) (Fig. 4.10A, Fig 3.10B). No significant difference in 
maximal respiration or leak respiration were observed between genotypes (Fig. 4.10C, Fig. 
4.10D). By analyzing ECAR as an indicator of glycolytic function, the Enpp1flox/flox;Ocn-cre 
osteoblasts demonstrated impaired approximate glycolytic capacity (under conditions of ATP 
mitochondrial inhibition) (4.91 pMol/min vs. 5.73 pMol/min; P<0.05), and decreased 
approximate glycolytic capacity (under conditions of ATP mitochondrial inhibition) (9.35 
pMol/min vs. 12.73 pMol/min; P<0.01)  (Fig. 4.10E, Fig. 4.10F) compared to Enpp1flox/flox 






















 Figure 4.10. Enpp1flox/flox;Ocn-cre primary osteoblasts demonstrate decreased aerobic respiration and glycolytic 
function.  
Seahorse Metabolic Analysis of primary osteoblasts isolated from the calvariae of Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice. 
(A) Basal respiration, (B) ATP-linked respiration, (C) Maximal Respiration, (D) Leak Respiration, (E) Approximate glycolytic 
function (mitochondrial inhibition conditions) and (F) Approximate glycolysis function (respiratory inhibition conditions). Data 




4.6. Discussion.  
The development of in vitro techniques have allowed for a more in-depth probing and 
analysis of the osteoblast phenotype and greater elucidation of the mechanisms involved 
regarding the mineralisation of their matrix. The requirement for available osteoblast cells 
for in vitro research was met by the development of cell lines, many of which have now been 
well characterised, both in their direct behaviour and in their comparison to human 
osteoblasts as a suitable model of mineralisation. Here, I have characterised the 
mineralisation of the MC3T3-E1 sub-clone C14 cell line - a non-transformed cell line derived 
from mouse calvariae bone (Wang et al., 1999a). This MC3T3-E1 sub-clone 14 cell type was 
originally isolated by Sudo et al and represents one of the most commonly used cell lines for 
in vitro studies relating to physiological and pathological aspect of bone biology (Sudo et al., 
1983). The use of these cell lines has led to the understanding of the temporal expression of 
key regulators and the development of ECM mineralisation. 
 
The investigation of MC3T3-E1 sub-clone c14 cells presented in this thesis demonstrates the 
capability of this cell line to mineralise their matrix over a 21-day culture period when 
cultured in mineralisation media. This was evidenced by the increasing intensity of Alizarin 
red S staining, which reached quantitative significance after 14 days of culture. These results 
are indicative of an increase of the calcium deposition within the matrix and reflect previous 
findings of MC3T3-E1 sub-clone c14 mineralisation studies utilizing AA and β-GP 
supplemented mineralisation media (Kawazoe et al., 2004).  
 
Furthermore, the relative mRNA expression of MC3T3-E1 sub-clone c14 Enpp1 was 
significantly decreased by day 7, compared to day 0, and this diminished expression was 
maintained throughout time-course. Given that ENPP1 generates extracellular PPi, this 
observed decrease is likely also contributing towards mediating the Pi/PPi ratio to favour 
mineralisation. Runx2 is a recognised driver of osteoblast differentiation. Throughout the 
time-course, no significant difference in Runx2 mRNA expression was observed. This may 
indicate that the MC3T3-E1 sub-clone c14 cells achieved mature osteoblasts status before 
the onset of mineralisation evidenced through Alizarin red S staining and calcium assay 
analysis (Komori, 2010). To fully determine the maturity of osteoblasts, further analysis of 




phosphatase and bone matrix proteins including osteopontin, bone sialoprotein and 
osteocalcin. These markers are well recognised as determinants of mature osteoblast status 
may be assessed for protein expression in situ by immunohistochemistry  (Liu et al., 1997, 
Staines et al., 2012b, Neve et al., 2013). 
 
The decrease of Ank expression, a transmembrane protein that transports intracellular PPi to 
the extracellular milieu (Hakim et al., 1984b, Kim et al., 2010) likely contributes to ensuring a 
Pi/PPi ratio to facilitate mineral formation in the ECM. Previous studies have demonstrated 
that ank/ank mutant mice present with ectopic calcification due to a C-terminal intracellular 
domain truncation (Ho et al., 2000), demonstrating the importance of ANK in regulating 
matrix mineralisation. The return of the relative levels of Ank expression at day 21 to levels 
comparable of day 0 is indicative of the increasing the extracellular PPi levels once significant 
mineralisation of the matrix was achieved. Interestingly the levels of Pit1 expression showed 
a significant decrease at all of the time points investigated; given that Pit1 expression is often 
considered a ubiquitous supplier of Pi with important roles in the mineralisation process this 
is intriguing.  
 
The analysis of PiT1 null mice has revealed that this transporter protein is critical in 
embryonic development. Complete deletion of PiT1 leads to embryonic lethality, reportedly 
by E12.5, and hypomorphic and null alleles resulted in late embryonic lethality between 
E14.5 and E16.5 (Beck et al., 2010). Although the work by Beck et al., did not evidence any 
early skeletal formation defects, in vitro studies have demonstrated the involvement of PiT1 
in bone mineralisation, reflecting findings in vivo that PiT1 is preferentially expressed in 
chondrocytes (Palmer et al., 2001, Bourgine et al., 2011). A recent paper by Chande et al., 
reports a heterozygous mouse model with an over-expression of PiT1 which is not associated 
with embryonic lethality. This mouse model is designed as a transgenic mouse expressing a 
C-terminal influenza hemagglutinin epitope-tagged human PiT1 (hPiT1) transporter which is 
regulated by a cytomegalovirus/chicken beta-actin/rabbit beta-globin gene promoter and a 
loxP-stop-LoxP cassette. This design allows for conditional activation of transgene 
expression, whereby expression of the resultant HA-hPiT1 (determined by qPCR) was found 




tissues including cultured primary calvaria osteoblasts (Chande et al., 2019). Analysis of bone 
phenotype by µ-CT revealed no alteration in long bone (femora) mineral density and 
unaltered mineral metabolism. Conversely, investigations in the role of Pit1 in vascular 
smooth muscle cells (immortalised) showed that when intracellular Pi is increased via PiT1 
over-expression, the cells develop a mineralising phenotype as opposed to their usual 
contractile phenotype (Li et al., 2006). Additionally, knockdown of PiT1 expression via gene 
silencing results in the inhibition of Pi uptake by vascular smooth muscle cells (Li et al., 2006). 
Further investigations have revealed that mineralisation is either downregulated or 
upregulated, respectively, with under- and over-expression of PiT1 in osteoblast cultures 
(Yoshiko et al., 2007). Taken together, the in vitro data suggests that PiT1 is important in the 
regulation of bone formation by its roles in Pi regulation. Additionally, in vivo data seems to 
suggest that over-expression of PiT1 does not result in alteration of bone mineralisation.  
 
The data in this chapter demonstrates that TNAP expression was increased by day 7. The 
observed increase in Alpl, is consistent with previous findings (Hessle et al., 2002, Narisawa 
et al., 2007). In addition, the data presented in this chapter reveals that no significant 
differences in Phospho1 mRNA expression were observed with time in culture. PHOSPHO1 
has been identified as an initiator of MV-mediated mineralisation, whereby it generates Pi 
within the MV to facilitate HA deposition (Roberts et al., 2007a). As such, it is possible that 
an increase in Phospho1 mRNA expression would be expected to accompany the increased 
mineralisation observed in the MC3T3-E1 sub-clone c14 cells over time. Indeed, studies of 
MC3T3-E1 sub-clone c14 cells grown in minerlisation conditions (presence of AA  and calcium 
chloride) demonstrated a mineralisation of their ECM after 10 days in culture. In addition, 
the Phospho1 mRNA expression was significantly increased throughout the time course, 
reportedly with approximately 150-fold higher expression compared to day 0 (Houston et al., 
2016).   
 
However, it has been demonstrated that the absence of PHOSPHO1 does not prevent the 
intra-vesicular deposition of mineral (Yadav et al., 2011b). Therefore, PHOSPHO1 activity at 
the basal levels observed at day 0 in this chapter is likely sufficient to allow the initiation of 




have hypomineralised bone, with abnormal growth plates, spontaneous fracture, 
osteomalacia, scoliosis and bowed bones in early life (Yadav et al., 2011a). TNAP knockout 
mice also manifest a hypomineralisation phenotype, which is reflective of infantile 
hypophosphatasia, concluding that Alpl-/- mice are unable to initiate mineralisation in vivo 
(Wennberg et al., 2000). Furthermore, the double ablation of Phospho1 and Alpl in mice 
results in the complete lack of skeletal mineralisation and perinatal lethality (Yadav et al., 
2011a).  Together, this data indicates that TNAP and PHOSPHO1 have distinct roles, and this 
is reflected in the cell culture results reported in this thesis.  At this point, it is essential to 
take into account that the study assessed genes, but not proteins.  Indeed, this represents a 
limitation to the findings given that the changes in mRNA may not directly related to protein 
activity.  
 
Although the MC3T3-E1 sub-clone c14 cell lines provide a convenient and accessible model 
their use should be limited to appropriate and specific scientific questions whereby the 
analysis and extrapolation of their results should be completed with care. In future 
experiments, it would be worthwhile examining the protein expression to determine if this 
reflected the observed changes in mRNA expression. For this chapter, the MC3T3-E1 sub-
clone c14 cells were studied to develop a mineralisation profile of osteoblast-like cells over 
three weeks. This was important to give a baseline comparison sample to use when 
considering results from the osteoblast-specific ablated NPP1 primary osteoblasts, which are 
to be cultured under the same conditions. This involves the use of b-GP (to promote 
mineralisation) and AA (required for collagen secretion). These experiments demonstrated 
that the optimum culture conditions to induce matrix mineralisation of osteoblasts and other 
cell types (e.g. vascular smooth muscle cells) (Quarles et al., 1992, Franceschi et al., 1994, 
Steitz et al., 2001, Collet et al., 2007, Hong et al., 2010).   
 
The data presented in this chapter demonstrate that the Enpp1flox/flox;Ocn-cre primary 
osteoblasts can mineralise their matrix to a greater extent, and faster, than the Enpp1flox/flox 
control primary osteoblasts. The matrix mineralisation of the Enpp1flox/flox control isolated 
primary osteoblasts is consistent with previous studies showing calvarial osteoblasts forming 




Patel et al., 2019). As such, the ablation of NPP1 in osteoblasts results in increased 
mineralisation, reflected by qualitative and quantitative Alizarin red S staining and calcium 
deposition analysis. 
 
Typically, a positive correlation between the expression of Runx2, Alpl and Bglap is observed 
during mineralisation. Although no late time points investigated revealed significant 
differences in Bglap expression, only Runx2 expression demonstrated significantly increased 
mRNA expression in the Enpp1flox/flox;Ocn-cre isolated primary osteoblasts compared to 
Enpp1flox/flox controls. Intriguingly, Alpl was significantly decreased in the Enpp1flox/flox;Ocn-cre 
isolated primary osteoblasts, although at all other time points a trend of increased Alp 
activity in the Enpp1flox/flox;Ocn-cre isolated primary osteoblasts was observed. This suggests 
an alternative origin for high Pi levels: this is possibly achieved through significantly increased 
PHOSPHO1 expression, whereby relative mRNA levels were notably increased in the 
Enpp1flox/flox;Ocn-cre isolated primary osteoblasts, however, this was only observed at day 21.  
This is supportive of a matrix-vesical derived origin of HA mineral within the Enpp1flox/flox;Ocn-
cre primary osteoblasts (Stewart et al., 2006).  
 
No significant differences between Enpp1flox/flox;Ocn-cre and Enpp1flox/flox isolated primary 
osteoblasts for Mgp expression – a recognised inhibitor of bone mineralisation, were 
observed, indicating that the osteoblast-specific ablation of Enpp1 is enough of a driving 
force to lead to increased mineralisation even when Mgp levels remain low and unchanged  
(Murshed et al., 2004).  These findings are consistent with the literature which reports that 
Mgp expression is generally low in skeletal tissue so as not to inhibit mineralisation (and 
comparatively higher in soft tissue so at to not permit mineralisation) (Price et al., 1983, Hale 
et al., 1988, Cancela et al., 1990, Theuwissen et al., 2012).  
 
Given that one of the critical functions of NPP1 is to generate PPi from ATP, it was of interest 
to analyse the extracellular PPi concentration in the media from cultured cells. As expected, 




possibly indicating the primary mechanism through which the hypermineralisation 
phenotype of these cultures is facilitated. As demonstrated in chapter 3, the 
Enpp1flox/flox;Ocn-cre mice display a significant increase in bone formation (and bone mineral 
density) compared to Enpp1flox/flox controls. As such, it is possible to consider that the 
Enpp1flox/flox;Ocn-cre isolated primary osteoblasts have a higher metabolic demand than 
those from their control. Indeed, with increased bone formation and matrix mineralisation, 
a greater proportion of proteins (e.g. collagen and extracellular matrix proteins) and HA 
mineral must be synthesised and released which is associated with energetic cost. The 
skeleton is recognised as an endocrine organ, with roles in systemic metabolism and abilities 
to regulate energy. This concept of bone-regulated metabolism was first suggested and 
understood when Fgf23 was recognised as critical in regulating phosphate metabolism and 
thus bone mineralisation (Murshed et al., 2005). Secondly, the understanding of systemic 
functions of OCN (as detailed in chapter 1) which regulates glucose via insulin signalling 
recognised the skeleton as a mediator of energy metabolism (Karsenty et al., 2012). It is 
important to consider that bone formation (modelling and remodelling) is also associated 
with high-energetic demand, and thus may influence energy metabolism. As such, I 
investigated both the aerobic respiration and glycolytic functions of the isolated primary 
osteoblasts. The literature reports that isolated primary osteoblasts are capable of utilizing 
both aerobic glycolysis and oxidative phosphorylation during their differentiation in vitro and 
that once a cellular maturity is reached a heavier reliance on aerobic glycolysis was observed 
(Guntur et al., 2014). Furthermore, it has been demonstrated that the stimulation of aerobic 
glycolysis (via stabilisation of the Hif1a complex) in pre-osteoblasts leads to the increased 
osteoblast formation from pre-osteoblasts and bone formation in mice (Regan et al., 2014). 
It is therefore suggested that glycolysis is a notable metabolic feature of osteoblasts, and is 
critical to their phenotype. 
 
 The predominance of glycolysis when cells exhibit a high energy demand is seemingly 
counter-intuitive, given that glycolysis yields less ATP than aerobic respiration. However, it 
has been reported in several studies from the 1950’s and 1980’s that aerobic glycolysis is the 
main mechanism of glucose production in osteoblasts (Borle et al., 1960, Cohn and Forscher, 
1962). This preliminary work was conducted using slices of bone and was later confirmed in 




increased reliance on glycolysis is likely related to the large-scale production of ECM proteins 
required for bone formation. More recent in vivo analysis of primary osteoblasts has 
demonstrated that mature osteoblasts preferentially utilise aerobic glycolysis over oxidative 
phosphorylation (Guntur et al., 2014) 
  
The results presented in this chapter demonstrate a significant reduction in the glycolytic 
function indicators investigated (that is, the approximation of glycolytic function under both 
mitochondrial inhibition and full respiratory inhibition conditions, determined through the 
Seahorse Mitochondrial Stress Test). This suggests that the deletion of Enpp1 within bone is 
detrimental to the metabolic functionality of the osteoblasts, leading to impaired energy 
production compared to the controls.  
 
Further research in recent years has identified the osteoblasts as being implicated in the 
regulation of systemic glucose metabolism, evident in mouse model studies (Esen and Long, 
2014). Insulin and bone are intimately linked, whereby insulin is necessary for healthy post-
natal bone acquisition (Manolagas and Weinstein, 1999). Mice which lack the IR specifically 
in osteoblasts exhibit decreased trabecular bone volume and decreased bone formation, 
with reduced osteoblast numbers and structural strength (Fulzele et al., 2010, Clemens and 
Karsenty, 2011, Thrailkill et al., 2014). In wild-type mice, insulin serves an anabolic function, 
stimulating osteoblasts to proliferate and subsequently differentiate (Yang et al., 2010). 
Given that the osteoblast-specific IR null mice exhibit significant insulin resistance following 
chronic high-fat diet feeding, the insulin-bone relationship may be affected by the 
osteoblast-specific Enpp1 ablation.  
 
It is indeed well reported that decreased glycolysis is associated with diabetes and glucose 
metabolism dysregulation in mouse models (Guo et al., 2012). As such, the suppressed 
glycolytic function in the Enpp1flox/flox;Ocn-cre primary osteoblasts compared to Enpp1flox/flox 
controls may contribute to the worsening metabolic phenotype observed. It is important to 
note that the knowledge of metabolic profile for bone cells remains largely undetermined. 
Furthermore, the artificial environment in which in vitro experiments are conducted may 




hard to extrapolate data. These two factors demonstrate a notable limitation of this study. A 
better understanding of the bioenergetics of cells is critical to understand a holistic view of 
the metabolic regulation of bone, and the ever-increasingly complex role of bone in 
regulating energy metabolism. This knowledge may aid in the treatment of metabolic and 
bone diseases.  
 
The analysis of TNAP inhibition revealed no significant differences in mineralisation between 
genotypes at day 0 and day 21, evidenced through qualitative and quantitative Alizarin red S 
staining. This preliminary data to show that the absence of TNAP activity, coupled with the 
absence of osteoblast-specific NPP1 activity results in the absence of hypermineralisation 
phenotype likely due to a restored Pi/PPi ratio. This in vitro finding reflects the in vivo finding 
of normalised skeletal mineralisation in knockout mice null for both Alpl and Enpp1 (Hessle 
et al., 2002). The TNAP inhibitor cell culture data in this chapter would benefit from more 
detailed additional analysis to add credence to argument including mRNA, protein and total 
calcium analysis.  
 
It is important to note that alternate methods of osteoblast isolation of  mice exist. One such 
example is that of primary osteoblast isolation from the long bones. This may represent a 
suitable alternative isolation of osteoblasts, overcoming several limitations experienced I 
calvaria osteoblast isolation. For example, calvaria osteoblast isolation may result in a 
number of cell types in the final isolation including osteoclast precursor cells and fibroblasts 
(Peck et al., 1964, Burger et al., 1986). In addition, isolation from long bones would likely 
have yielded greater numbers of cells compared to the isolation of cells from individual 
calvaria of mice. This chapter would have benefitted from adopting more than one method 
of primary osteoblast isolation. Furthermore, chapter 3 demonstrates interesting sexual 
dimorphism with regard to the bone phenotype of the osteoblast-specific NPP1 ablated 
mouse. Due to the requirement to isolate primary osteoblasts from individual calvaria, it was 
not possible to separate the calvaria by sex to investigate whether sexual dimorphism was 
also observed in the mineralisation capacity of the primary osteoblast. It would have been of 




minerlisation capacity of osteoblast by assessing the temporal mineralszation of adenoviral 
Enpp1 knockdown osteoblasts isolated from long-bones of wild-type mice.  
 
Overall, the data presented in this chapter demonstrates that cultures of Enpp1flox/flox;Ocn-
cre primary osteoblasts demonstrate a hypermineralisation phenotype with concomitant 





























Chapter 5. Investigating the role of osteoblast-specific 







The global NPP1 knockout mouse (Enpp1-/-) mouse presents with a notable metabolic 
phenotype when reared on a control diet (Huesa et al., 2014). Chronic deficiency of NPP1 
resulted in changes in whole-body glucose metabolism, whereby adult global Enpp1-/- mice 
present with decreased glucose-stimulated insulin secretion (GSIS) peak across the duration 
of a GTT, indicating insulin sensitisation (Huesa et al., 2014). The Enpp1-/- mice also presented 
with unaltered serum total OCN levels (Huesa et al., 2014). However, further investigation 
revealed that the Enpp1-/- mice exhibit increased serum concentrations of the bioactive form 
of OCN (under-carboxylated (GLU13), and un-carboxylated GLU)), along with increased bone 
resorption (Huesa et al., 2014). NPP1 is recognised as a negative regulator of insulin 
signalling: these data suggest that the ablation of NPP1 results in metabolic protection via 
increased osteoclastic bone resorption (Maddux et al., 2006a, Goldfine et al., 2008, Prudente 
et al., 2009, Huesa et al., 2014). The resulting acidic environment facilitates 
undercarboxylated-OCN or uncarboxylated-OCN formation and increased insulin sensitivity 
(Nesbitt and Horton, 1997, Salo et al., 1997, Ivaska et al., 2004, Ivaska et al., 2005, Booth et 
al., 2013, Huesa et al., 2014, Wei and Karsenty, 2015b).  
 
The insulin-sensitive phenotype observed in the Enpp1-/- mice may be due to the ablation of 
NPP1 in insulin-sensitive tissues such as the liver, adipose, and the skeletal muscle, and/or 
due to increased bone turn over involving both the osteoblasts and osteoclasts. Recent 
advancements in the refinement of mouse genetics and techniques employed to investigate 
metabolism and cellular bioenergetics have greatly improved our understanding of the 
cellular mechanisms that regulate energy metabolism. The last two decades have led to 
unexpected observations in genetically modified mice, revealing novel endocrine pathways 
whereby bone cells communicate with other centres of metabolic control (e.g. OCN signalling 
to the pancreas to regulate insulin secretion and thus glucose concentration) (Ducy et al., 
1996, Lee et al., 2007, Oury et al., 2011, Guntur and Rosen, 2012, Oldknow et al., 2014, Wei 
et al., 2014, Wei and Karsenty, 2015a, Karsenty and Olson, 2016). This has resulted in 
recognition of the role that the skeleton, or more specifically of the different skeletal cell 
types, plays in overall bioenergetics (Lee et al., 2007, DiGirolamo et al., 2012, Guntur and 





Given that the skeleton completely replaces itself every 10 years (Manolagas, 2000), and that 
bone contributes  a significant proportion of total body mass, the action of osteoblasts to 
generate bone can understandably be associated with a notable energetic demand (Borisov 
and Marei, 1974, Manolagas, 2000, Vaananen et al., 2000, Karsenty et al., 2012, Zhang et al., 
2015, Suchacki et al., 2017). Bone cells require a significant proportion of the body’s overall 
fuel supply, and as such, they compete with other highly metabolic (and energy-consuming) 
tissues (Riddle and Clemens, 2017). This basic notion can explain why it is critical that bone 
cells communicate with other tissues through hormones to influence global energy 
metabolism.  Secondly,  osteoblasts  are programmed at various stages in their development 
to optimise their energy production in accordance with increased functional demand in their 
lifestyle such as when they need to synthesis a large amount of ECM collagen (Riddle and 
Clemens, 2017).  
 
The research of the last 20 years points towards increasingly complex interplays between 
bone, fat and other metabolically important organs, through shared regulatory mechanisms 
of energy metabolism (Ducy et al., 1996, Lee et al., 2007, Zhou et al., 2009, Ferron et al., 
2010a, Oury et al., 2011, DiGirolamo et al., 2012, Guntur and Rosen, 2012, Mackenzie et al., 
2012, Oldknow et al., 2014, Wang et al., 2014b, Faienza et al., 2015, Wei and Karsenty, 2015a, 
Karsenty and Olson, 2016, Zoch et al., 2016, Du et al., 2016, Suchacki et al., 2017, Roberts et 
al., 2019a, Shan et al., 2019). Basic and translational research must be conducted to 
investigate the integrated skeletal-metabolic mechanisms to better understand the role of 
specific cell types in bone health, energy metabolism, and human health and disease. Given 
the recognised role of NPP1 in insulin signalling, the notable metabolic phenotype of Enpp1-
/- mice, and the understanding of the energetic demands of osteoblasts, this chapter aimed 
to investigate the metabolic phenotype of mice lacking NPP1 specifically in the osteoblast 
utilising the novel Enpp1flox/flox;Ocn-cre mouse (Esen and Long, 2014, Guntur et al., 2014, 
Huesa et al., 2014). Therefore, the overarching aim of this chapter was to compare the 






The osteoblast-specific ablation of Enpp1 will result in increased insulin sensitivity of control-
diet fed mice reflecting the metabolically protected phenotype of the global Enpp1-/- mice.  A 
bone phenotype reflecting that of the juvenile Enpp1flox/flox;Ocn-cre mice (chapter 3) will be 
observed for 16-weeks of age control-fed Enpp1flox/flox;Ocn-cre mice.  
 
5.3. Aims 
I. To analyse the metabolic phenotype of 16-week old Enpp1flox/flox;Ocn-cre and 
Enpp1flox/flox mice. 
 
II. To analyse the bone phenotype of 16-week old Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
mice.  
 
5.4. Materials and methods  
5.4.1. Animal generation, food, weighing, and consumption 
The Enpp1flox/flox;Ocn-cre and age-matched Enpp1flox/flox control mice were generated (Section 
2.7.1) and male mice were fed a control-diet from 4-weeks of age until culling at 16-weeks 
of age (Section 2.7.2). The weight of consumed food was calculated each week. The weights 
of the mice were measured each week (Section 2.7.2).   
 
5.4.2. Gross analysis 
At 16-weeks of age, mice were culled and weight at cull was recorded. Tibiae and femora 
from male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were collected at dissection and used 
for histological analysis (Section 5.4.5). The length of these long bones were measured using 
DigiMax digital Vernier callipers (R. S. Components Ltd, Corby, Northants, UK). Mice were 






5.4.3. Glucose tolerance and insulin tolerance testing 
Male mice aged 16-weeks were weighed and fasted for 4-hours before administration of 2 
mg D-glucose per g of body weight by oral gavage (for GTT) or 0.5 mU of insulin per g of body 
weight by intraperitoneal injection (for ITT). Blood glucose and circulating insulin was 
calculated (Section 2.7.4).  
 
5.4.4. Serum OCN analysis and biochemistry  
Total OCN and uncarboxylated-OCN was measured as previously described (Ferron et al., 
2010) (Section 2.9.2). Julian Berger of Columbia University (USA) kindly completed this work. 
Glucose stimulated insulin secretion (GSIS) was detected by ELISA (ChrystalChem, Chicago, 
IL, USA) (Section 2.9.2).  
 
5.4.5. Histological analysis  
Soft tissues were collected from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice culled at 16-
weeks of age (Section 2.6.3). Tissues were prepared for microscopic analysis by fixing in 10% 
NBF (Section 2.9.1). Sections were paraffin-embedded after fixing (Section 2.9.2). Fat pads, 
liver, and pancreas sections were stained with H&E (Section 2.9.3). The pancreatic islet 
number and islet size in H&E stained sections was determined (Section 2.9.9). The number 
and area of H&E stained adipocytes in fat pad sections was assessed (Section 2.9.10). Liver 
sections were stained with Weigert’s haematoxylin and fast-green to assess architecture, and 
with picosirius red to assess fibrotic damage. Dr Timothy Kendal of the University of 
Edinburgh kindly performed the liver analysis (Section 2.9.11). 
 
5.4.6. Immunohistochemistry of pancreas 
Pancreatic tissue was collected (Section 2.6.3) and prepared for microscopic analysis by fixing 
in 10% NBF (Section 2.9.1). Pancreas sections were cut at 5 µM in thickness and insulin 
production was identified by immunohistochemistry (Section 2.9.12) to identify insulin-






5.4.7. Analysis of liver triglyceride content  
Following euthanasia of male mice at 16-weeks of age, livers were collected, frozen, and 
stored at -80° C. Tissue was prepared and total triglyceride was measured using a Triglyceride 
(TG) Assay (Sentinel Diagnostics, Milan, Italy) (Section 2.9.4).  
 
5.4.8. mRNA analysis of metabolic tissues  
mRNA was extracted from metabolic tissues (including liver, fat pads, and quadriceps 
femoris) using a Qiagen RNeasy kit according to the manufacturer’s instructions. cDNA was 
prepared (Section 2.3.2)  and was used at 5 ng/µl for RT-qPCR analysis (Section 2.3.3). Results 
were normalised to b-actin and Gapdh housekeeping gene and the relative gene expression 
level was calculated using the DDCT method (Livak and Schmittgen, 2001). 
 
5.4.9. Three-point bending of long bones 
The tibiae and femora from male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were collected. 
Three-point bending was conducted using an LXR materials testing machine (Lloyds 
Instruments, West Sussex, U.K.) (Section 2.6.1).  
 
5.4.10. µ-CT of long bones 
The tibiae and femora from 16-week old male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice 
were collected, fixed in 10% NBF for 24 hours and subsequently stored in 70% ethanol. The 
bones were scanned using a µ-CT (Skycan 1172, Bruker, Aartselaar, Belgium) to assess 
trabecular architecture and cortical geometry (Section 2.6.2).  
 
5.4.11. Catwalk analysis 
Gait analysis was recorded using a CatWalk XT gait analysis system. Mice were familiarised 
with the equipment before the recording of data. Data were collected from male 






5.5.1. Enpp1flox/flox;Ocn-cre mice demonstrate unaltered body mass and food 
consumption. 
Given that findings of the global Enpp1-/- mice revealed a notable metabolic phenotype 
following control diet feeding, I reasoned that the osteoblast-specific NPP1 knockout mouse 
may recapitulate this protected metabolic phenotype. This is grounded in two phenomena: 
firstly, that the Enpp1-/- mice demonstrate an overall alteration of development including 
reduced body mass and secondly that NPP1 is a recognised negative regulator of insulin 
signalling (Maddux et al., 1995, Maddux and Goldfine, 2000, Mackenzie et al., 2012, Huesa 
et al., 2014). The Enpp1flox/flox;Ocn-cre demonstrates no significant changes in body weight 
gain from 4-weeks of age to 16-weeks of age (Fig 5.1A) compared to  Enpp1flox/flox mice. The 
food consumption per mouse was similar in both genotypes over this duration of study (Fig. 
5.1B). 
 
5.5.2. Enpp1flox/flox;Ocn-cre mice demonstrate unaltered insulin sensitivity, reduced 
liver mass and increased muscle mass 
The Enpp1flox/flox;Ocn-cre mice exhibited unaltered glucose tolerance (Fig. 5.2A), insulin 
tolerance (Fig. 5.2B), and GSIS (Fig. 5.2C). Given that there can be a degree of variation 
between individual mice for responses to glucose and insulin, the area under the curve for 
each test was calculated. This technique is widely used to diagnose impaired glucose 
tolerance (Ayala et al., 2010). The area under the curve analysis for GTT (Fig. 5.2D), ITT (Fig 
5.2E), and GSIS (Fig 5.2F) revealed no significant differences between genotype. To ensure 
that the absence of any changes in glucose metabolism and insulin sensitivity were not a 
product of altered organ mass and function, gross analysis of organ mass was conducted at 
necroscopy. These analyses revealed no significant changes for the Enpp1flox/flox;Ocn-
cre mouse in the mass (mg/g total body mass) of brown fat, subcutaneous fat, gonadal fat, 
mesenteric fat, spleen, pancreas or kidney compared to Enpp1flox/flox counterparts (Fig. 5.3). 
Interestingly, however, Enpp1flox/flox;Ocn-cre mice demonstrated significantly reduced liver 
mass (49.10 mg/g total body mass vs. 58.57 mg/g total body mass; P<0.05) (Fig. 5.3). Given 
the critical importance of the liver in metabolic function, this warranted further investigation 




muscles were significantly increased in mass in the Enpp1flox/flox;Ocn-cre mice compared to 
Enpp1flox/flox controls (Left: 8.45 mg/g total body mass vs. 7.46 mg/g total body mass; P<0.05: 
Right: 8.48 mg/g total body mass vs. 7.38 mg/g total body mass; P<0.01) (Fig. 5.3). The gain 
of muscle quadriceps femoris muscle mass is indicative of increased loading via exercise, and 
as such it was pertinent to further investigate the altered muscle mass by analysing the gait 







Figure 5.1. Weight gain and food consumption of mice is not altered between 
genotype. 
(A) Analysis of Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice.  There was no significant difference 
in weight gain between genotype. To ensure this was not a result of disparity in feeding, (B) 
weekly food consumption was calculated revealing no difference between genotype 







Figure 5.2. Assessment of glucose tolerance and insulin sensitivity is not altered between genotype.  
Metabolic analysis of 16-week old male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice. (A) GTT and (D) area under the curve, (B) ITT and (E) area under the 
curve and (C) GSIS and (F) area under the curve showed similar blood glucose levels of Enpp1flox/flox;Ocn-cre compared to Enpp1flox/flox mice. Data are 




























Figure 5.3. Organ mass at 16-weeks of age reveals differences in mass 
between genotype for liver, left and right quadriceps femoris muscle.  
The Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were culled at 16-weeks of age and 
then dissected. The tissues were removed and weighed: brown fat, subcutaneous 
fat, gonadal fat, mesenteric fat, spleen, pancreas, kidney, liver, left quadriceps, and 
right quadriceps. Dissection analysis revealed that the liver mass (mg/g body total 
body weight) of Enpp1flox/flox;Ocn-cre mice was significantly reduced, whereas left 
and right quadriceps femoris were significantly greater in mass compared to the 
Enpp1flox/flox control mice. Data are presented as the mean ± S.E.M (n≥4). 






5.5.3 Enpp1flox/flox;Ocn-cre mice exhibit altered gait 
Results from CatWalk gait analysis did not show any changes in stride length of the 
Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox controls (Fig. 5.4). However, 
Enpp1flox/flox;Ocn-cre mice did present with a number of altered gait parameters.  
Enpp1flox/flox;Ocn-cre mice exhibit significantly increased initial dual stance (0.06 s vs. 0.027 s; 
P<0.05) (Fig. 5.5A),  increased front paw base of support (1.53cm vs. 1.32 cm; P<0.05) (Fig. 
5.5B), increased support girdle (1.85% vs. 1.12%; P<0.05) (Fig. 5.5C), decreased right front 
left front coupling (47.35% vs 50.89%; P<0.05) (Fig. 5.5D), increased right hind left front 
coupling (79.08% vs. 50.89%; P<0.05) (Fig. 5.5E) and left hind foot maximum intensity (48.54 
% vs. 42.38 %; P<0.05) (Fig. 5.5F) compared to Enpp1flox/flox control mice. 
 
5.5.4. Analysis of Enpp1flox/flox;Ocn-cre mice liver histology and triglyceride content.  
Given the alterations to the mass of the liver for the Enpp1flox/flox;Ocn-cre (Fig. 5.3), it was 
important to assess the general histology of the liver to investigate if any tissue damage had 
occurred. A detailed histological appraisal by Dr Timothy Kendall indicated no pathological 
alterations were observed in the Enpp1flox/flox;Ocn-cre mice or Enpp1flox/flox controls. The 
Enpp1flox/flox;Ocn-cre mice and Enpp1flox/flox controls revealed no fibrosis and tissue damage 
through inflammation. Given the metabolic protection of the global Enpp1-/- mouse, I next 
wanted to investigate whether the decreased liver size of the Enpp1flox/flox;Ocn-cre mouse 
was due to a decrease in liver triglyceride deposition. However, analysis of this revealed no 
significant difference between the genotypes (Fig. 5.6). Therefore, the liver mass difference 
between genotypes is likely not attributable to any triglyceride storage changes nor tissue 





























 Figure 5.4. The stride length of mice is not altered between genotype. 
The gait of male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were assessed  at 14-weeks of 
age. Stride length of the (A) right front, (B) right back, (C) left hind and (D) left front legs. 




















Figure 5.5. Gait analysis reveals an unstable gait in the osteoblast-specific NPP1 ablated mouse model. 
The gait of male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were assessed at 14-weeks of age. Parameters showing significant 
differences included (A) initial dual stance, (B) front paw base of support, (C) support girdle, (D) right front let front coupling, (E) right 
hind left front coupling and (F) Left hind max intensity at (%) mean. Data are presented as the mean ± S.E.M (n≥6). Significance 



























Figure 5.6. Liver triglyceride quantification reveals no differences 
between genotype. 
Quantitative analysis of liver triglyceride demonstrates no difference between 
genotype in triglyceride content. Images are representative. Data are 




5.5.5. Enpp1flox/flox;Ocn-cre mice exhibit increased uncarboxylated-OCN and 
unaltered pancreata.  
Analysis demonstrated an unaltered serum concentration of total OCN (Fig. 5.7A). When 
considering only uncarboxylated-OCN, the Enpp1flox/flox;Ocn-cre mice present with a 
significantly increased serum concentration compared to Enpp1flox/flox controls (Fig. 5.7B) 
(22.87 ng/ml vs. 11.74 ng/ml; P<0.05). Given that undercarboxylated-OCN or 
uncarboxylated-OCN exerts a systemic effect on the pancreas, whereby it promotes insulin 
secretion, the insulin-secreting islets of the pancreas were next analysed. The 
Enpp1flox/flox;Ocn-cre mice demonstrate no significant difference in the size (Fig. 5.7C) or 
number (Fig 5.7D) of insulin-secreting pancreatic islets. This indicates that osteoblast-specific 
NPP1 ablation does not result in the alteration of pancreatic beta-cell function, despite the 
significant changes to the uncarboxylated-OCN secretion.  
 
5.5.6. Analysis of adipocytes from the white and brown fat depots 
The analysis of organ mass following culling at 16-weeks of age revealed no significant 
difference in the mass of the white fat depots (mg/g total body weight) (Fig. 5.8). To 
determine whether the deletion of osteoblast-specific NPP1 resulted in an alteration of the 
adipocyte’s ability to store lipid, the average number and average area of adipocytes for each 
of the white adipocyte depots were analysed. This revealed no significant difference between 
genotype for adipocyte number (Fig. 5.8A) or adipocyte area (Fig. 5.8B) in any of the three 
white fat depots.  To determine whether there was variation in the adipocyte size, a size-
frequency distribution of adipocytes for the subcutaneous fat pad (Fig 5.8C), the gonadal fat 
pad (Fig. 5.8D) and the mesenteric fat pad (Fig 5.8E) was conducted. This revealed a minor 
increase in the number of larger adipocytes in the subcutaneous and the gonadal fat pad of 
the Enpp1flox/flox;Ocn-cre mice compared to the Enpp1flox/flox controls. Overall, the size 
distribution of adipocytes did not largely vary in the depots investigated.  This suggests that 
there is no alteration in the hyperplasia or hypertrophy of the white adipocytes in the 
Enpp1flox/flox;Ocn-cre mice.  The number of adipocyte nuclei per field for brown fat showed 
no differences between genotype (Fig. 5.9). This indicates no change in brown fat 







Figure 5.7. Osteoblast-specific NPP1 ablated mice have increased 
undercarboxylated OCN and unaltered pancreatic islet morphology.  
Analysis of (A) total serum OCN and (B) undercarboyxlated-OCN, and the (C) area and (D) 
number of insulin-secreting pancreatic islets determined through immunohistochemistry 
and ImageJ quantitation. Data are presented as the mean ± S.E.M (n≥6). Significance 







Figure 5.8. Analysis of the white fat depots adipocyte number, area, and size-frequency distribution is largely unchanged between 
genotypes. 
The average (A) number and (B) area of adipocytes for the subcutaneous (SC), gonadal (G) and mesenteric (Mes) fat pad were analysed. The size-
frequency distribution of adipocytes was analysed for the (C) SC, (D) G and (E) Mes fat pads. Data are presented as the mean ± S.E.M (n≥6). Significance 






Figure 5.9. Quantitative assessment of brown adipose tissue nuclei 
reveals no difference between genotypes. 
Analysis of H&E stained nuclei from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
mice revealed no difference in nuclei/field. Data are presented as the mean 





5.5.7. Analysis of metabolic genes in metabolic tissues  
The expression of genes associated with metabolism was evaluated in key metabolic tissues 
including quadriceps femoris muscle, brown fat, liver and white adipocytes (gonadal 
adipocytes). For the quadriceps femoris muscle, the glucose transporter (GLUT) receptors 
were analysed. This included Solute Carrier Family 2 Member 1 (Slc2a1), Solute Carrier Family 
2 Member 2 (Scl2a2), Solute Carrier Family 2 Member 4 (Scl2a4), Solute Carrier Family 2 
Member 10 (Slc2a10) and Solute Carrier Family 2 Member 12 (Scl2a12). These genes are 
reported in the literature to play key roles in metabolism (Mueckler and Thorens, 2013, Deng 
and Yan, 2016, Navale and Paranjape, 2016). No significant difference in the expression of 
any of the GLUT receptors of the investigated was noted (Slc2a1, Slc2a2, Slc2a4, Slc2a10, 
Slc2a12) for Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox controls (Fig. 5.10A-E). 
Similarly, no difference in the mRNA expression of GLUT receptors (Slc2a1, Sl2a2, Slc2a1, and 





























Figure 5.10. Analysis of the GLUT receptors of quadriceps femoris muscle reveals no differences between genotypes. 
The quadriceps femoris mRNA expression of selected GLUT receptors including (A) Slc2a1, (B) Slc2a2, (C) Slc2a4, (D) Slc2a10 and (E) 
Slc2a12 was analysed. mRNA values generated were normalised to the geometric mean of Gapdh and b-actin house-keeping genes. Data 










Figure 5.11. Analysis of the GLUT receptors of gonadal fat pad reveals no 
difference between genotypes. 
The gonadal fat pad mRNA expression of selected GLUT receptors including (A) 
Slc2a1, (B) Slc2a2, (C) Slc2a10, (D) Slc2a12 was analysed. mRNA values generated 
were normalised to the geometric mean of Gapdh and b-actin house-keeping genes. 







The liver was next analysed. Again, reflecting other metabolic tissues, no difference between 
genotype for the mRNA expression of the liver-expressed GLUT receptor (Slc2a2) was 
observed (Fig. 5.12A). No difference in the mRNA expression of liver peroxisome proliferator-
activated receptor alpha (PPARa) was observed (Fig 5.12B). The liver phosphoenolpyruvate 
carboxykinase (Pck1) mRNA expression was significantly increased in Enpp1flox/flox;Ocn-cre 
mice compared to Enpp1flox/flox control mice (Fold change of 1.81 vs. 1.00; P<0.05) (Fig. 5.12C). 
 
The analysis of brown adipose tissue mRNA expression revealed largely unaltered expression 
of metabolic genes including; Slc2a1, Slc2a4, uncoupling protein-1 (Ucp1), uncoupling 
protein 2 (UCP2), diacylglycerol O-acyltransferase 2 (Dgat2), and lipoprotein lipase (Lpl) (Fig. 
5.13. The mRNA expression of diacylglycerol O-acyltransferase 1 (Dgat1) was significantly 
reduced in the Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox controls (Fold change of 
0.45 vs. 1.00; P<0.05) (Fig 5.13E). This enzyme is involved in the synthesis of triglycerides (Yen 
et al., 2008, Liu et al., 2012). However, Dgat2 mRNA expression remained unchanged 
between genotypes (Fig. 5.13F), and this enzyme is involved in the synthesis of triglycerides 













































. Figure 5.12. Analysis of liver metabolic genes demonstrates increased Pck1 in osteoblast-
specific NPP1 ablated mice. 
The liver mRNA expression of selected metabolic genes including (A) Slc2a2, (B) Ppara, (C) 
Pck1, (D) Slc2a12 was analysed. mRNA values generated were normalised to the geometric 
mean of Gapdh and b-actin house-keeping genes. Data are presented as the mean ± S.E.M 









Figure 5.13. Analysis of selected brown adipose tissue metabolic genes reveals largely no difference in expression between genotypes.  
The brown fat mRNA expression of selected metabolic genes including (A) Slc2a1, (B) Slc2a4, (C) Ucp1, (D) Ucp2, (E) Dgat1 (F) Dgat2 and (G) Lpl was 
analysed. mRNA values generated were normalised to the geometric mean of Gapdh and b-actin house-keeping genes. Data are presented as the 




5.5.8. Analysis of long bone micro-architecture, length and mechanical strength. 
To investigate whether osteoblast-specific ablation of Enpp1 caused alterations to bone 
architecture at 16-weeks of age, a µ-CT analysis of the diaphyseal bone of tibiae and femora 
from male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice was conducted. For the tibia, no 
genotype differences were observed for the analysed trabecular parameters (Fig. 5.14) or 
cortical parameters (Fig. 5.15). For the femora, no significant differences between genotype 
were observed for trabecular (Fig. 5.16) or cortical (Fig. 5.17) diaphyseal bone. These results 
reflect the absence of difference in skeletal phenotype of 22-week old male Enpp1flox/flox;Ocn-
cre mice (chapter 4). The length of long bones was also assessed to determine whether a 
disparity in growth was evident at 16-weeks of age for the Enpp1flox/flox;Ocn-cre mice. No 
significant difference between genotype was observed regarding tibia or femora length nor 
mechanical properties (Table 5.1). This too reflects observations of the skeletal phenotype 






















Figure 5.14. µ-CT analysis of tibiae trabecular bone from 16-week male mice demonstrates no difference between 
genotypes. 
The following parameters were measured; (A) percent bone volume (BV/TV), (B) trabecular number, (C) trabecular thickness, (D) 
trabecular pattern factor, (E) trabecular separation and (F) Structural model index. Data are presented as the mean ± S.E.M 






























Figure 5.15. µ-CT analysis of tibiae trabecular bone from 16-week male  
mice demonstrates no difference between genotypes.  
The following parameters were measured; (A) bone volume, (B) cortical thickness 
and (C) cortical porosity. Data are presented as the mean ± S.E.M (n³3). No 























Figure 5.16. µ-CT analysis of femora trabecular bone from 16-week male mice reveals no differences between 
genotypes. 
The following parameters were measured; (A) percent bone volume (BV/TV), (B) trabecular number, (C) trabecular thickness, (D) 
trabecular pattern factor, (E) trabecular separation and (F) Structural model index. Data are presented as the mean ± S.E.M (n³3). 









Figure 5.17. : µ-CT analysis of femora trabecular bone from 16-week male mice 
reveals no difference between genotypes. 
The following parameters were measured; (A) bone volume, (B) cortical thickness and 




























































































Table 5.1. Length and mechanical properties of long bones from 16-week old male mice reveals no functional differences between 
genotypes. 
Gross analysis of long bones revealed no difference in length (n=6). Assessment of mechanical strength via 3-point bending analysis revealed no 





NPP1 has previously been demonstrated as a critical regulator of bone mineralisation via 
generation of PPi (Rutsch et al., 2003, Li et al., 2014b, Huesa et al., 2015b). Moreover, I have 
demonstrated for the first time that the osteoblast-specific ablation of NPP1 results in 
increased bone mass and mineral density (chapter 3). Additionally, increased matrix 
mineralisation was evident in the cultured of osteoblasts isolated from Enpp1flox/flox;Ocn-cre 
mice (chapter 4). In the current chapter, the metabolic phenotype of 16-week old male 
Enpp1flox/flox;Ocn-cre and Enpp1flox/flox control mice was assessed.  
 
The use of genetically modified animals, integrated physiology and clinical observations has 
greatly improved our understanding of bone and energy metabolism. Previous studies 
revealed a notable metabolic phenotype, including increased insulin sensitivity, of the global 
Enpp1-/- mouse (Huesa et al., 2014). The literature has not previously assessed the osteoblast-
specific contributions of NPP1 to the metabolic phenotype observed in the global Enpp1-/- 
mouse despite many reports acknowledging the role that osteoblasts (and bone in general) 
play within whole organism metabolism (DiGirolamo et al., 2012, Lee et al., 2017, Motyl et 
al., 2017). 
 
Chapter 3 of this thesis revealed that the Enpp1flox/flox;Ocn-cre mice demonstrate increased 
long bone mass and mineralisation. The formation of bone has indeed been associated with 
metabolic cost (Motyl et al., 2017), and as such, I aimed to investigate whether the 
osteoblast-specific ablation of NPP1 would result in a concomitant skeletal and metabolic 
phenotype.  
 
The data presented in this chapter reveals that there is not a notable metabolic phenotype 
in the control-diet fed 16-week old male Enpp1flox/flox;Ocn-cre mice. The data in this chapter 
does not confirm my original hypothesis that Enpp1flox/flox;Ocn-cre mice would recapitulate 
the metabolic phenotype observed in the Enpp1-/- mice. The Enpp1flox/flox;Ocn-cre mice 
present with no alterations to their body weight, food consumption, glucose tolerance, 
insulin tolerance or GSIS. Furthermore, necroscopy results largely do not reflect changes in 




in the Enpp1flox/flox;Ocn-cre, this did not translate to altered function evident through 
histological analysis and quantitative investigation of liver triglyceride content. The increased 
muscle mass of the quadriceps femoris is a likely product of the altered gait observed in the 
Enpp1flox/flox;Ocn-cre mice indicative of increased instability in movement. Given that the 6-
week old Enpp1flox/flox;Ocn-cre present with notable alterations to their long bones length and 
microarchitecture, the gait alterations may be a consequence of the altered juvenile bone 
development and resultant skeletal phenotype.  
 
Interestingly, when the 16-week old control-diet fed male Enpp1flox/flox;Ocn-cre mouse long 
bones were assessed, no bone phenotype was revealed. Given that the 22-week old male 
Enpp1flox/flox;Ocn-cre mice also do not present with notable bone phenotype (chapter 3), this 
new evidence adds credence to the conclusion that osteoblast-specific NPP1 ablation results 
in altered juvenile mouse bone formation but not adult bones. Given that this bone 
phenotype is not maintained throughout the lifespan of the mouse, it is possible that an 
alternate source of PPi is compensating for the locally reduced PPi product of the osteoblast-
specific ablation. This could come from the liver, which produces the majority of plasma PPi 
(Jansen et al., 2014, Kauffenstein et al., 2018). The analysis of a liver-specific NPP1 ablated 
mouse model would be important for determining whether liver-derived PPi is critical in the 
regulation of mineralisation and bone development.  
 
The Enpp1flox/flox;Ocn-cre mice did present with increased uncarboxylated-OCN yet this was 
not capable of providing metabolic protection for the Enpp1flox/flox;Ocn-cre mice, which did 
not demonstrate insulin sensitivity. This is perplexing, given that OCN is recognised to 
increase insulin sensitivity and secretion (Lee et al., 2007, Karsenty et al., 2012). Adipose 
tissue, including white adipose tissue and thermogenic active brown adipose tissue, are 
complex and play important roles in energy homeostasis regulation (Fonseca-Alaniz et al., 
2007). They act as reservoirs for storing lipids as a source of energy and are capable of 
secreting paracrine factors to act on metabolic tissues (Ahima and Flier, 2000, Kershaw and 
Flier, 2004). If the fat stores are not able to store energy, fat deposition in other tissues that 
regulate glucose may occur; this is a risk factor for insulin resistance and T2DM (Rutkowski 




of fat within the adipocytes. By determining this, it is possible to eliminate lipotoxicity as a 
contributor to why the increased uncarboxylated-OCN did not result in increased insulin 
sensitivity in the Enpp1flox/flox;Ocn-cre mice  
 
The analysis of organ mass at cull revealed no significant difference in the mass of the white 
fat depots (mg/g total body weight). However, this does not reflect the morphology or health 
of the individual adipocyte. Adipocytes are highly dynamic and can be structurally modified 
(Drolet et al., 2008, Spalding et al., 2008, Jo et al., 2009). For example, when in a caloric 
excess, adipocytes can undergo tissue remodelling and increase in number (hyperplasia) and 
size (hypertrophy) (Cawthorn et al., 2014, Hardouin et al., 2016). Healthy adipocytes should 
be relatively uniform and should be able to adapt in-keeping with the energy storage 
requirements which come hand in hand with energy excess (Faust et al., 1978). Energy excess 
can occur through two basic mechanisms: increased caloric intake (food excess) or decreased 
caloric output (e.g. decreased locomotion) (Hill and Commerford, 1996, Sandoval et al., 2008, 
Hill et al., 2012). Adipocytes may be deranged in a variety of metabolic-related disorders 
including T2DM, dietary-induced obesity, or conditions whereby the adipocyte is directly 
affected such that lipid storage ability is limited (e.g. lipodystrophy) (Goralski et al., 2007, 
Garg, 2011). Histological analysis revealed adipocyte morphology and size distribution, 
comparable between genotypes, suggesting no alteration to the adipocyte capability to store 
fat.  
 
The brown adipose tissue thermogenic function may differ between genotypes: this may 
offer one explanation for why the global Enpp1-/- mice demonstrate metabolic protection. 
Brown adipose tissue is capable of thermogenesis, and this releases a large amount of energy 
as heat (Smith and Hock, 1963, Cypess et al., 2009, Lee et al., 2010). This process is a 
contributor to the regulation of whole-body energy metabolism, although the extent of this 
is debated within the literature (Muzik et al., 2013, Carpentier et al., 2018, Fernández-
Verdejo et al., 2019). For example, brown adipose tissue may account for up to 60% of ‘non-
shivering’ thermogenesis in small mammals (Heldmaier and Buchberger, 1985, Foster et al., 
2007). To combat obesity, a caloric deficit must be obtained by either restricting food intake 




although the medical community has progressed to include surgical intervention (e.g. gastric 
bypass surgery) which alters satiety and/or fat malabsorption (Plourde et al., 2014, Grenier-
Larouche et al., 2017, Narayanaswami and Dwoskin, 2017, Lean et al., 2018). These 
interventions result in profound anti-diabetic and anti-obesity effects (Khera et al., 2016).  
 
It may also be possible to alter energy homeostasis to promote exercise and non-exercise 
related thermogenesis, thus combating obesity and T2DM. The scientific and medical 
community has a renewed interest in determining the roles of BAT as a potential target in 
the treatment of metabolic conditions including obesity and T2DM by promoting energy 
expenditure in this metabolic tissue (Cypess and Kahn, 2010, Nedergaard and Cannon, 2010, 
Tseng et al., 2010, Bonet et al., 2013, Trayhurn, 2018). This involves delineating the role of 
different genes and factors in brown tissue behaviour. This is of particular interest given that 
studies demonstrate that cold exposure (5-8 hours), which activates brown adipose tissue, 
lead to increased basal and insulin-stimulated whole-body glucose disposal (Chondronikola 
et al., 2014). As such, the activation of brown adipose tissue may be a pertinent therapeutic 
target for T2DM management. The data presented in this chapter revealed no difference in 
brown adipose tissue morphology or nuclei number was observed between genotypes. 
Therefore, NPP1 appears not to be a critical regulator of brown adipose tissue activity 
regarding control-fed dietary conditions. Additionally, no alterations to the pancreas were 
evident between genotypes. To assess the function of metabolic tissues, mRNA expression 
was analysed. This did not reveal any notable upregulation of metabolic genes, supporting a 
largely unaltered metabolic phenotype amongst the Enpp1flox/flox;Ocn-cre mice.  
 
Interestingly, the mRNA expression of the brown fat Diacylglycerol O-Acyltransferase 1 
(Dgat1) was significantly reduced in the Enpp1flox/flox;Ocn-cre mice. This enzyme is involved in 
the synthesis of triglycerides (Chitraju et al., 2017). However, Dgat2 mRNA expression 
remained unchanged between genotypes, and this enzyme is involved in the synthesis of 
triglycerides (Cases et al., 1998).  A recent study has revealed that following regular chow 
feeding, Dgat1 and Dgat2 can compensate for each other and that either enzyme is fully 




2017). As such, the alterations of Dgat1 mRNA expression with the absence of Dgat2 changes 
are largely insignificant concerning metabolic health and function.  
 
No difference in the mRNA expression of liver peroxisome proliferator-activated receptor 
alpha (PPARa) were observed. This transcription factor is a major regulator of lipid 
metabolism in the liver and is responsible for the regulation of mitochondria and fatty acid 
oxidation (Kersten et al., 1999). However, the liver phosphoenolpyruvate carboxykinase 
(Pck1) mRNA expression was significantly increased in Enpp1flox/flox;Ocn-cre mice compared 
to Enpp1flox/flox controls. This gene is one of the main control points for the regulation of 
gluconeogenesis (Millward et al., 2010). It has been shown that the deletion of Pck1 in mice 
results in increased plasma free fatty acid levels and is a contributing factor to insulin 
resistance (Millward et al., 2010) (Hanson and Garber, 1972). As such, the deletion of Enpp1 
within the osteoblast serves to increase liver Pck1 expression and promote fatty acid 
oxidation and metabolic protection. This may indicate a bone-liver metabolic axis involving 
NPP1.  
 
A possible limitation of this study was that observations were only made in male mice. 
However, by studying only male mice, I have eliminated the influence of oestrogen signalling 
regarding metabolic phenotype. Indeed, an increasing body of evidence, including human 
and murine based studies, has linked altered oestrogen signalling with metabolic 
dysregulation, including the metabolic syndrome (Heine et al., 2000, Munoz et al., 2002, 
Bryzgalova et al., 2006, Eshtiaghi et al., 2010, Matic et al., 2013). 
 
In conclusion, the results presented in this chapter highlight that the osteoblast-specific 
ablation of NPP1 in mice does not recapitulate the phenotype of the global Enpp1-/- mice. 
Importantly, I have demonstrated that the osteoblast-specific ablation of NPP1 results in 
increased uncarboxylated-OCN, but that this is not able to facilitate improved insulin 
sensitivity. Given that NPP1 is recognised as a pathogenic factor for insulin resistance, it is 
important to assess the Enpp1flox/flox;Ocn-cre following metabolic stress in the form of chronic 




and as such phenotyping of high-fat diet fed Enpp1flox/flox;Ocn-cre male mice was next 





































Chapter 6. Investigating the role of osteoblast-specific 
ablation of NPP1 on the metabolic phenotype of 





Obesity is recognised as the single most important risk factor for the development of T2DM 
(Tuomilehto et al., 2001a, Belkina and Denis, 2010). T2DM itself is characterised by a 
resistance to insulin-stimulated glucose uptake, resulting in decompensation of systemic 
glucose metabolism (Cefalu, 2001, Reaven, 2004, Dongiovanni et al., 2010, Sinaiko and 
Caprio, 2012). The scientific community has made notable progress in understanding glucose 
metabolism: however, the mechanisms and regulation of glucose metabolism in health and 
disease remain incompletely understood. In a chronic overfeeding situation the peripheral 
IR-associated signalling will be altered, and reduced sensitivity to insulin-mediated glucose 
regulation will occur (Nagy and Einwallner, 2018). High-fat diet fed mice are frequently used 
as a model for diet-induced insulin resistance (Winzell and Ahrén, 2004). The subsequent 
utilisation of an oral GTT can shed light on the peripheral disposal of orally adminstered 
glucose and insulin secretion (Nagy and Einwallner, 2018). Additionally, the ITT will glean 
insights into the regulation of whole-body insulin action. When these GTT and ITT data are 
considered together, they can characterise the metabolic phenotype (Ayala et al., 2010, 
Alquier and Poitout, 2018, Nagy and Einwallner, 2018). By assessing specific knockout mouse 
models, this can identify genes important in glucose homeostasis. This work aids in the 
understanding of metabolic pathogenesis and identifying possible therapeutic interventions.   
 
Insight has already been gained regarding the role of NPP1 in diabetes (Dong et al., 2005, 
Maddux et al., 2006a, Bacci et al., 2007, Bhatti et al., 2010, Di Paola et al., 2011, Pan et al., 
2011, Huesa et al., 2014). It is recognised that NPP1 binds to the a-subunit of the IR, impairing 
the insulin stimulation of the IR and thus abrogating its downstream signalling (Goldfine et 
al., 2008). There are multiple clinical and basic research observations that link ENPP1 in 
humans (and mice) to insulin resistance and T2DM (Grupe et al., 1995, Maddux et al., 1995, 
Frittitta et al., 1998, Maddux and Goldfine, 2000, Abate et al., 2003, Dong et al., 2005, Bacci 
et al., 2007, Di Paola et al., 2011, Frittitta et al., 2001, Huesa et al., 2014, Pan et al., 2011). 
For example, ENPP1 expression was assessed and was increased in the muscle cells from 
insulin-resistant human patients (Maddux et al., 2006b, Goldfine et al., 2008). The insulin 
from these cells was also found to be incapable of promoting the IR autophosphorylation 
which occurs as a result of insulin binding to the a-subunit of the IR (Maddux et al., 1995). 




cells (MCF7 cells) were isolated and induced to overexpress ENPP1. As a result, decreased 
insulin responsiveness was observed in these cells (Grupe et al., 1995).  
 
Animal studies have also been enlightening regarding the role of ENPP1 and insulin 
resistance. Indeed, overexpression of ENPP1 in a variety of primary cell types including 
muscle, liver and adipose tissue induces insulin resistance and glucose intolerance in rodent 
models (Maddux et al., 1995, Dong et al., 2005, Maddux et al., 2006a, Pan et al., 2011, Pan 
et al., 2012). Recent investigations into the metabolic phenotype resulting from the 
knockdown of NPP1 have demonstrated that the global ablation of NPP1 results in improved 
insulin sensitivity in mice (Huesa et al., 2014). However, the cell-specific contributions 
towards the metabolic phenotype observed in the global Enpp1-/- mouse have not been 
delineated.  
 
Given that the worldwide incidence of T2DM is set to reach over 640 million adults in 2040 
(Ogurtsova et al., 2017), its burden is undeniable for the health of developed and developing 
countries. T2DM itself is a common, yet multifactorial syndrome, the incidence of which is 
rapidly increasing due to the contribution of a variety of factors, namely obesity 
(Weigensberg and Goran, 2009, Ershow, 2009, Al-Goblan et al., 2014, Wu et al., 2014). As 
such, it is of great importance to comprehend the genetic components which underlie the 
predisposition to diabetes and insulin resistance including considering the roles that such 
genes play in obesogenic settings. The high-fat diet model is crucial to understand this.  
 
For the treatment of T2DM, the scientific community could aim to normalise the basic defects 
that occur in diabetes, including insulin resistance. T2DM is caused by inadequate β-cell 
compensation in response to insulin resistance which results in a relative insulin deficiency, 
culminating in hyperglycemia (Butler et al., 2003, Del Guerra et al., 2005, Florez, 2008, 
McCarthy, 2010, Ashcroft and Rorsman, 2012, Cerf, 2013). T2DM is closely associated with 
obesity, as one its main pathological causes of insulin resistance. As such, the majority of 
animal models are obese, and their primary importance is in understanding obesity-induced 
insulin resistance and its effects (King and Bowe, 2016b). Animal models have long been used 




monogenic mouse models which aid in understanding insulin resistance development in an 
obesity phenotype. One frequently used monogenic mouse model of altered leptin signalling 
is the Lepob/ob mouse, which has no functional leptin, resulting in hyperphagia. These mice, 
as an effect of this, develop obesity, hyperinsulinemia and hyperglycemia (Lindstrom, 2007, 
Wang et al., 2014a). Obesity can also be induced by feeding a rodent a high-fat diet, whereby 
weight gain, associated insulin resistance, and aberrant glucose metabolism can be observed 
following chronic feeding (of 8 weeks or more) (Surwit et al., 1998, Winzell and Ahrén, 2004). 
The method of chronic high-fat diet feeding was utilised for the studies described in this 
chapter.  
 
Attention must be given to specific genes, including ENPP1, to understand the contribution 
to the pathogenesis of T2DM and to better diagnose, treat and eventually prevent incidence. 
This underpins the importance of this chapter, which investigates and profiles the metabolic 
phenotype of the osteoblast-specific NPP1 ablated mouse model under obesogenic 
conditions (via chronic high-fat diet feeding). This recapitulates the energy imbalance 
observed in a significant proportion of our human population and is critical to our 
understanding of cell-specific contributions of certain genes to global energy metabolism. 
 
The previous analysis of global Enpp1-/- mice revealed that, following a high-fat diet 
challenge, the global Enpp1-/- mice exhibit a pronounced resistance to obesity (Huesa et al., 
2014). My initial studies of the Enpp1flox/flox;Ocn-cre mice revealed no difference in weight 
gain compared to Enpp1flox/flox mice on a control-diet (Chapter 5). A metabolic phenotype may 
only present when the mouse is experiencing a chronic high caloric intake (i.e. under 
obesogenic conditions). As such, the Enpp1flox/flox;Ocn-cre mice were fed a 60% fat diet from 






Following chronic high-fat diet feeding, a protected metabolic phenotype, with resistance to 
obesity will be evident in the osteoblast-specific NPP1 ablated mouse. These mice will 




I. Analyse the metabolic phenotype of the high-fat diet challenged Enpp1flox/flox;Ocn-cre 
and Enpp1flox/flox mice. 
 
II. Analyse the bone phenotype of high-fat diet Enpp1flox/flox;Ocn-cre and Enpp1flox/flox 
mice.  
 
6.4. Materials and methods  
6.4.1. Animal generation, food, weighing and consumption. 
The Enpp1flox/flox;Ocn-cre and age-matched Enpp1flox/flox control mice where generated 
(Section 2.7.1). Male mice were fed a high-fat diet from 4-weeks of age until cull at 16-weeks 
of age (Section 2.7.2). Male high-fat diet fed mice were fed a high-fat diet from 4-weeks of 
age until cull at 16-weeks of age (Section 2.7.2). The weight of consumed food was calculated 
each week. The weights of the mice were analysed each week (Section 2.7.2).   
 
6.4.2. Gross analysis 
At 16-weeks of age, mice were culled and weight at cull was recorded. Tibiae and femora 
from male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice aged 16-weeks were taken at dissection 
and soft tissue removed. The length of these long bones were measured using DigiMax digital 
Vernier callipers (R. S. Components Ltd, Corby, Northants, UK). Mice were dissected and soft 






6.4.3. Glucose tolerance and insulin tolerance testing 
Male mice aged 16-weeks were weighed and fasted for 4-hours prior to administration of 2 
mg D-glucose per g of body weight was administered by oral gavage (for GTT) or 0.5 mU of 
insulin per g of body weight was administered by intraperitoneal injection (for ITT). Blood 
glucose and circulating insulin was calculated (Section 2.7.4).  
 
6.4.4. Serum OCN analysis and biochemistry  
Total OCN and uncarboxylated-OCN was measured as previously described (Ferron et al., 
2010) (Section 2.9.2). Julian Berger of Columbia University (USA) kindly completed this work. 
Glucose stimulated insulin secretion (GSIS) was detected by ELISA (ChrystalChem, Chicago, 
IL, USA) (Section 2.9.2).  
 
6.4.5. Histological analysis  
Soft tissues were collected from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice culled at 16-
weeks of age (Section 2.6.3). Tissues were prepared for microscopy analysis by fixing in 10% 
NBF (Section 2.9.1). Sections were paraffin-embedded after fixing (Section 2.9.2). Fat pads, 
liver and pancreas sections were stained with H&E (Section 2.9.3). Islet number and size was 
determined in H&E stained sections of pancreas (Section 2.9.9). The number and area of 
adipocytes in fat pads was determined (Section 2.9.10). Liver sections were stained with 
Weigert’s haematoxylin and fast-green to assess architecture, and with picosirius red to 
assess fibrotic damage (Section 2.9.11). 
 
6.4.6. Immunohistochemistry of pancreas 
Pancreas tissue was collected (Section 2.6.3) and prepared for microscopy analysis by fixing 
in 10% NBF (Section 2.9.1). Pancreas sections were taken at 5 µM and were stained for insulin 





6.4.7. Analysis of liver triglyceride content  
Following euthanasia of livers were collected, frozen, and stored at -80° C. Tissue was 
prepared and total triglyceride was measured using a Triglyceride (TG) Assay (Sentinel 
Diagnostics, Milan, Italy).  
 
6.4.8. mRNA analysis of metabolic tissues  
mRNa samples were extracted from metabolic tissues (including liver, fat pads and 
quadriceps femoris) using a Qiagen RNeasy kit according to the manufacturer’s instructions. 
cDNA was prepared (Section 2.3.2) and was used at 5 ng/µg for RT-qPCR analysis (Section 
2.3.3). Results were normalised to b-actin and Gapdh housekeeping gene and the relative 
gene expression level was calculated using the DDCT method (Livak and Schmittgen, 2001). 
 
6.4.9. Three-point bending of long bones 
The tibiae and femora from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were collected. Three-
point bending also conducted on tibiae and femora using a LXR materials testing machine 
(Lloyds Instruments, West Sussex, U.K.) (Section 2.6.1).  
 
6.4.10. µ-CT of long bones 
The tibiae and femora from Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were collected, fixed 
in 10% NBF for 24 hours and subsequently stored in 70% ethanol. The bones were scanned 
using a micro-computed tomography (µ-CT) system (Skycan 1172, Bruker, Aartselaar, 
Belgium) to assess trabecular architecture and cortical geometry (Section 2.6.2).  
 
 
6.4.11. Catwalk analysis 
Gait analysis was recorded using a CatWalk XT gait analysis system. Mice were familiarised 
with the equipment prior to the recording of data. Data was collected from male 






6.5.1. Enpp1flox/flox;Ocn-cre do not demonstrate resistance to obesity following chronic 
high-fat diet challenge 
The Enpp1flox/flox;Ocn-cre mice demonstrate no significant changes in body weight gain from 
4-weeks of age to 16-weeks of age (Fig 6.1A) compared to  Enpp1flox/flox mice. Furthermore, 
no difference between genotype in food consumption per mouse was observed (Fig. 5.1B). 
 
6.5.2. Enpp1flox/flox;Ocn-cre demonstrate glucose intolerance, insulin resistance and 
increased brown fat and liver mass  
The Enpp1flox/flox;Ocn-cre mice on a high-fat diet exhibited a decreased ability to regulate their 
glucose following the administration of an oral glucose bolus (GTT) (Fig. 6.2A), which was 
reflected in the area under the curve analysis (4849.25 arbitrary units (AU) vs. 3913.88 AU; 
P<0.05) (Fig. 6.2D). In addition, the Enpp1flox/flox;Ocn-cre mice demonstrated reduced ability 
to respond to insulin and decrease their glucose compared to Enpp1flox/flox control mice, 
indicative of insulin resistance, notably at time points of 30 minutes (0.73 % of basal glucose 
vs. 0.52 % of basal glucose; P<0.05) and 120 minutes (0.90 % of basal vs. 0.58 % of basal; 
P<0.01) (Fig. 6.2B). However, this did not translate to statistical significance when area under 
the curve was analysed (Fig. 6.2E). The GSIS was also comparable in both genotypes (Fig. 
6.2C, 6.2F). To ensure that the absence of any changes in glucose metabolism and insulin 
sensitivity were not the product of altered organ mass and function, gross analysis of organ 
mass was conducted at necroscopy. These analyses revealed no significant changes for the 
Enpp1flox/flox;Ocn-cre mouse in the mass (mg/g total body mass) of white fat (subcutaneous, 
gonadal or mesenteric), spleen, pancreas, kidney or quadriceps femoris muscle compared to 
Enpp1flox/flox control mice (Fig. 6.3). The liver was further analysed to determine whether such 
pathological non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis 
(NASH) changes had occurred (Section 6.5.3).  
 
The weight of brown fat of Enpp1flox/flox;Ocn-cre was increased following high-fat diet feeding 
(8.78 mg/g vs. 7.18mg/g; P<0.05) compared to Enpp1flox/flox control mice (Fig. 6.3). The brown 
fat of the high-fat diet fed Enpp1flox/flox;Ocn-cre mice was significantly increased compared to 




P<0.05). The thermogenic capacity of this fat depot was analysed to investigate whether this 
could contribute to the metabolic phenotype observed (Section 6.5.4). 
 
Figure 6.1. Weight gain and food consumption of high-fat diet fed mice reveals no 
difference between genotypes. 
(A) Mass of high-fat diet Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice weighed each week 
revealed no significant difference between genotype in weight gain. To ensure this was not 
a result of disparity in feeding, (B) weekly food consumption was calculated revealing no 
significant difference between genotype throughout the time course. Data are presented as 























Figure 6.2. Assessment of glucose tolerance and insulin sensitivity of high-fat diet fed mice reveals insulin resistance and glucose 
intolerance in the osteoblast-specific NPP1 ablated mice.  
Metabolic analysis of 16-week old control fed male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice. (A) GTT and (D) area under curve, (B) ITT and (E) 
area under the curve and (C) GSIS and (F) area under the curve shows no difference in reduction of blood glucose levels of Enpp1flox/flox;Ocn-cre 




Figure 6.3. High-fat diet fed osteoblast-specific ablated NPP1 mice have greater 
brown fat pad and liver mass. 
The Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice were culled at 16-weeks of age and then 
dissected. The outlined tissues were removed and weighed: brown fat, subcutaneous fat, 
gonadal fat, mesenteric fat, spleen, pancreas, kidney, liver, left quadriceps and right 
quadriceps. Dissection analysis revealed that the liver mass (mg/g body total body weight) 
of Enpp1flox/flox;Ocn-cre mice was significantly reduced, whereas left and right quadriceps 
femoris were significantly heavier than the Enpp1flox/flox counterpart mice. Data are 





6.5.3. Analysis of Enpp1flox/flox;Ocn-cre liver histology and triglyceride content.  
The control-diet fed Enpp1flox/flox;Ocn-cre mice exhibit livers of decreased mass, but with no 
abnormal liver pathology or adiposity alterations between genotypes (chapter 5, Section 
5.5.4). Given that the high-fat fed Enpp1flox/flox;Ocn-cre mice have livers of significantly 
increased mass compared to Enpp1flox/flox control mice (59.81 mg/g total body weight vs. 
45.70 mg/g total body weight; P<0.01) (Fig. 6.3), I next assessed the liver histology and 
triglyceride content in collaboration with Dr Timothy Kendall. The high-fat fed Enpp1flox/flox 
mice demonstrated extensive small droplet macro-vesicular steatosis (5/6 of mice 
investigated) with no inflammation or fibrosis. 
 
Of the 6 Enpp1flox/flox;Ocn-cre mice assessed, five presented with no detectable steatosis nor 
inflammation or steatosis. However, the remaining mouse presented with small droplet 
steatosis comparable to the Enpp1flox/flox mice (Huesa et al., 2014). Assessment of the liver 
triglyceride content was conducted and demonstrated that the Enpp1flox/flox;Ocn-cre mice 
have significantly increased triglyceride content (9.65 mg/g vs. 5.21 mg/g; P<0.05) (Fig. 6.4) 
compared to Enpp1flox/flox control mice. Therefore, the Enpp1flox/flox;Ocn-cre mice have raised 
fatty acid content of the liver which may account for the increased mass (compared to 
Enpp1flox/flox controls)  yet this does not present as steatosis. 
 
6.5.4. Enpp1flox/flox;Ocn-cre mice exhibit unaltered OCN and pancreata  
The osteoblast-specific NPP1 ablation of control-diet fed mice results in altered OCN 
carboxylation status, as observed in the Enpp1-/- mice (Fig. 5.5B). This was not observed 
following high-fat diet feeding, whereby no difference in total (Fig. 6.5A) or uncarboxylated-
OCN (Fig. 6.5B) was observed between the two genotypes. Given that undercarboxylated 
and/or uncarboxylated-OCN exerts a notable effect on the pancreas, whereby it promotes 
insulin secretion, the insulin-secreting islets of the pancreas were next analysed. The 
Enpp1flox/flox;Ocn-cre mice demonstrate no significant difference in the size (Fig. 6.5C) or 
number (Fig 6.5D) of insulin-secreting pancreatic islets compared to Enpp1flox/flox control 
mice. This indicates that osteoblast-specific NPP1 ablation does not result in the alteration 















Figure 6.4. High-fat diet fed osteoblast-specific NPP1 ablated mice have grater 
liver triglyceride content.  
Quantitative analysis of liver triglyceride demonstrates no difference between genotype in 

















Figure 6.5. Analysis of serum OCN and insulin-secreting pancreatic islets of high-fat 
diet fed mice demonstrates no difference between genotype. 
Analysis of high-fat diet fed Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice (A) total serum OCN and 
(B) undercarboyxlated-OCN and the (C) area, and (D) number of insulin-secreting pancreatic 
islets determined through immunohistochemistry and ImageJ quantitation Data are presented 




6.5.5. Analysis of adipocytes from the white and brown fat depots 
The analysis of organ mass at cull revealed that high-fat diet fed Enpp1flox/flox;Ocn-cre mice 
have significantly increased brown fat mass (Fig. 6.3), yet unaltered white adipose tissue 
mass (mg/g total body weight) (Fig. 6.3) compared to Enpp1flox/flox control mice. To assess 
whether these data were associated with altered morphology and health of adipose tissue, 
further histology to assess adipocyte number and size-frequency distribution and qPCR to 
analyse mRNA expression was conducted. No significant difference in subcutaneous or 
mesenteric fat depot adipocyte area (Fig. 6.6A) or adipocyte number (Fig. 6.6B) was observed 
between genotype. However, Enpp1flox/flox;Ocn-cre mice demonstrate significantly greater 
average area of gonadal fat pad adipocytes  (6215.91 µm2 vs. 3051.27 µm2; P<0.01) (Fig. 
6.6A), and a significantly reduced number of adipocytes/micrograph (85.18 
adipocytes/micrographs vs. 283.19 adipocytes/micrographs; P<0.01) (Fig. 6.6B) compared to 
Enpp1flox/flox controls.  
 
Analysis of the adipocyte size distribution from each of the white adipocyte depots revealed 
no significant difference in the size distribution for the gonadal (Fig. 6.6D) and mesenteric fat 
pads (Fig. 6.6E). The Enpp1flox/flox;Ocn-cre mice demonstrated an overall slight increase in 
larger sized subcutaneous adipocytes (4.18 % of total adipocytes vs. 2.02% of total adipocytes 
at size of 6500 µm2; P<0.01) (Fig. 6.6C) compared to Enpp1flox/flox control mice. This suggests 
that overall there is little alteration in the hyperplasia or hypertrophy of the white adipocytes 
in the Enpp1flox/flox;Ocn-cre mice. 
 
The number of brown fat adipocyte nuclei per field were similar between genotype (Fig. 6.7). 
This may indicate no change in brown fat adipogenesis, hyperplasia or hypertrophy as a result 
of osteoblast-specific NPP1 knockout, although the overall mass of brown adipose tissue 






Figure 6.6. Analysis of the white fat depot adipocyte number, area and size-frequency distribution of high-fat diet fed mice 
demonstrates difference between genotype in the gonadal adipose depot.  
The average (A) number and (B) area of adipocytes for the subcutaneous (SC), gonadal (G) and mesenteric (Mes) fat pad were analysed. The size-
frequency distribution of adipocytes was analysed for the (C) SC, (D) G and (E) Mes fat pads. Data are presented as the mean ± S.E.M (n≥6). 

































Figure 6.7. Quantitative assessment of brown adipose tissue nuclei of 
high-fat diet fed mic reveals no difference between genotype. 
Analysis of H&E stained nuclei from high-fat diet fed Enpp1flox/flox;Ocn-cre and 
Enpp1flox/flox mice reveals no difference in nuclei/field. Data are presented as 





6.5.6. Analysis of metabolic genes in metabolic tissues from high-fat diet fed mice.  
The Enpp1flox/flox;Ocn-cre mice had a significantly lower level of Slc2a2 mRNA expression 
compared to the Enpp1flox/flox control mice (0.44 fold change vs. 1; P<0.05) (Fig 6.8B). No 
significant difference in any of the other GLUT receptors investigated were observed for 
Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox  controls (Fig. 6.8A, Fig. 6.8C-E). Similarly, 
no significant difference between genotype for the GLUT receptors investigated in gonadal 
adipose tissue was observed (Fig. 6.9A-D).  
 
Furthermore, the mRNA expression of metabolic genes for liver and brown adipose tissue 
were analysed. Given that there were mass changes between genotypes for both these 
organs following high-fat diet changes, it was important to assess whether gene function was 
also altered. No significant difference in mRNA expression for the genes assessed were 
observed for the liver (Fig. 6.10A-C) or brown adipose tissue (Fig. 6.11A-G). 
 
6.5.6. Analysis of long bone micro-architecture, length and mechanical strength. 
To investigate whether osteoblast-specific ablation of Enpp1 caused alterations to bone 
architecture in high-fat diet fed mice at 16-weeks of age, µ-CT analysis of the diaphyseal bone 
of tibiae and femora from male Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice was conducted. 
For the tibiae, no genotype differences were observed for the analysed trabecular 
parameters (Fig. 6.12). The cortical tibial assessed parameters revealed a significant increase 
in the cortical porosity of Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox controls (2.78 
mm3 vs. 2.03 mm3; P<0.05) (Fig. 6.13C). For the femora, no significant differences between 













Figure 6.8. The mRNA expression of GLUT receptors of quadriceps femoris muscle of 
high-fat diet fed mice is largely unchanged between genotypes. 
The quadriceps femoris mRNA expression of selected GLUT receptors including (A) Slc2a1, (B) 
Slc2a2, (C) Slc2a4, (D) Slc2a10, and (E) Slc2a12 was analysed. mRNA values generated were 
normalised to the geometric mean of Gapdh and b-actin house-keeping genes. Data are 







Figure 6.9. The mRNA expression of GLUT receptors of gonadal fat pad of 
high-fat diet fed mice in unaltered between genotypes. 
The gonadal fat pad mRNA expression of selected GLUT receptors including (A) Slc2a1, 
(B) Slc2a2, (C) Slc2a10, and (D) Slc2a12 was analysed. mRNA values generated were 
normalised to the geometric mean of Gapdh and b-actin house-keeping genes. Data are 





























Figure 6.10. The mRNA expression of liver tissue-associated metabolic genes 
of high-fat diet fed mice is unchanged between genotypes. 
The brown fat mRNA expression of selected metabolic genes including (A) Slc2a1, (B) 
Slc2a4, (C) Ucp1, (D) Ucp2, (E) Dgat1 (F) Dgat2, and (G) Lpl was analysed. mRNA 
values generated were normalised to the geometric mean of Gapdh and b-actin 





















Figure 6.11. The mRNA expression of brown adipose tissue-associated metabolic genes of high-fat diet fed mice is unchanged 
between genotypes.  
The brown fat mRNA expression of selected metabolic genes including (A) Slc2a1, (B) Slc2a4, (C) Ucp1, (D) Ucp2, (E) Dgat1 (F) Dgat2, and (G) 
Lpl was analysed. mRNA values generated were normalised to the geometric mean of Gapdh and b-actin house-keeping genes. Data are 






Figure 6.12. µ-CT analysis of tibiae trabecular bone of high-fat diet fed mice reveals no difference between genotypes. 
The following parameters were measured; (A) bone volume (BV/TV), (B) trabecular number, (C) trabecular thickness, (D) trabecular pattern factor, (E) 




Figure 6.13. µ-CT analysis of tibiae cortical bone of high-fat diet fed mice shows 
increased cortical porosity of osteoblast-specific NPP1 ablated mice. 
The following parameters were measured; (A) bone volume, (B) cortical thickness and 
(C) cortical porosity. Data are presented as the mean ± S.E.M (n³3). Significance is 














Figure 6.14. µ-CT analysis of femora trabecular bone of high-fat diet fed mice 
demonstrates no differences between genotypes. 
The following parameters were measured; (A) percent bone volume (BV/TV), (B) trabecular 
number, (C) trabecular thickness, (D) trabecular pattern factor, (E) trabecular separation and (F) 














Figure 6.15. µ-CT analysis of femora cortical bone of high-fat diet fed mice reveals 
no differences between genotypes. 
The following parameters were measured; (A) bone volume, (B) cortical thickness, (C) cortical 





6.5.6. Analysis of long bone marrow adipose tissue by osmium staining 
The analysis of differing bone marrow adipose depots in the tibiae revealed no significant 
difference in adipocyte quantification between genotype (Fig 6. 16), nor did it reveal a diet-
effect, whereby there was not a notable expansion of adipocyte tissue following chronic high-
fat diet feeding. The total femoral marrow adipose tissue reflected these findings, with no 






Figure 6.16. Osmium staining of tibiae marrow adipose tissue of high-fat diet fed mice shows no difference between genotypes. 
The marrow adipose tissue of control diet fed (CD) and high-fat diet fed (HFD) Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice quantified by osmium tetroxide 
staining and µ-CT analysis. This included the different anatomical regions, including tibia-fibula junction (T/F/J) to proximal end, proximal growth plate 
(GP) to T/F/J, proximal epiphysis (Prox Epi) and the bone marrow from the total length of the tibiae. Data are presented as the mean ± S.E.M (n³3). No 








Figure 6.17. Osmium staining of total femoral marrow adipose tissue of high-fat diet fed mice shows no difference between 
genotypes.. 
The marrow adipose tissue of control diet fed (CD) and high-fat diet fed (HFD) Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice quantified by osmium 





Previous work to this thesis has well established the metabolic phenotype changes that occur 
following high-fat diet feeding in mice (Winzell and Ahrén, 2004, King and Bowe, 2016a, Nagy 
and Einwallner, 2018). This has been instrumental in aiding the understanding of metabolic 
syndrome pathophysiology, including the disease states of obesity and T2DM (Lindstrom, 
2007, Wang et al., 2014a, King and Bowe, 2016b). The use of a high-fat diet feeding model 
can allow for the probing of a genes function within the obesogenic landscape. I have utilised 
this model to understand the role of osteoblast-specific NPP1, to determine whether this 
confers metabolic protection as evidenced in the global Enpp1-/- knockout mice.  
 
Chapter 3 of this thesis revealed that the Enpp1flox/flox;Ocn-cre mice demonstrate increased 
long bone mass and mineralisation. The formation of bone has been associated with 
metabolic cost, and as such, I aimed to investigate whether the osteoblast-specific ablation 
of NPP1 would result in a concomitant skeletal and metabolic phenotype, perhaps only being 
evident under situations of chronic caloric excess. For this chapter, male mice were used to 
assess the effect of high-fat diet between genotypes in order to avoid the confounding 
effects estrogen may have on dietary induced phenotypes (Acharya et al., 2019a, Yepuru et 
al., 2010, Litwak et al., 2014, Acharya et al., 2019b, Ting et al., 2017, Omotola et al., 2019).  
 
The data presented in this chapter reveals that the osteoblast-specific ablation of NPP1 in 
mice confers a lack of metabolic protection. These findings are not consistent with my 
original hypothesis that the ablation of NPP1 in osteoblasts would result in increased insulin 
sensitivity and provide overall protection against the detrimental effects of chronic 
obesogenic feeding. The observed increase of the Enpp1flox/flox;Ocn-cre mice liver mass at 
necroscopy can be explained by the increased liver triglyceride content, a typical change 
following high-fat diet feeding (Eisinger et al., 2014).  
 
Lipidomic analysis has revealed that approximately 60% of the lipids altered in mice fed a 
high-fat diet were also altered in the serum (Eisinger et al., 2014). Further studies would be 




Enpp1flox/flox;Ocn-cre mice to determine if this reflected literature reported alterations of 
lipids in high-fat diet fed rodent models of obesity. For example, Seferovic et al., report 
notable changes in liver lipids involved in the sphingolipid pathway, which has been 
implicated by others in high-fat diet models, after only 1-week of high-fat diet challenge of 
mice (Clements and Reynertson, 1977, Yang et al., 2009, Seferovic et al., 2018). Furthermore, 
ultra-performance liquid chromatography–quadrupole time-of-flight mass-spectrometry 
analysis of high-fat diet fed C57BL/6J mice revealed a significantly altered triglyceride level 
compared to controls (Nam et al., 2015). Notably, this included a difference in the acyl chain 
length and degree of unsaturation (Nam et al., 2015). Continued investigation of the 
Enpp1flox/flox;Ocn-cre lipid profile and triglyceride content may identify novel pathways of 
bone-specific NPP1 and liver lipid synthesis and storage.  
 
The absence of fibrosis and steatosis in the Enpp1flox/flox;Ocn-cre mice reported by Dr Timothy 
Kendall of the University of Edinburgh perhaps hints that safer storage of triglyceride in the 
liver is occurring. Typically, following high-fat diet feeding, mice will develop a fatty liver 
NAFLD which may progress to NASH (Kohli and Feldstein, 2011, Takahashi et al., 2012, 
Clapper et al., 2013, Savari et al., 2019, Velázquez et al., 2019). The caloric excess of mice in 
chronic high-fat feeding conditions leads to excess energy. This excess energy leads to an 
increase of non-esterified fatty acids and pro-inflammatory cytokine release (White and 
Marette, 2014, Després and Lemieux, 2006). This increases fat deposition in the liver 
(Despres, 2006, Tilg and Hotamisligil, 2006, Clapper et al., 2013) and is reflective of the major 
risk factors for the development of metabolic syndrome in humans (Hariri and Thibault, 
2010, James et al., 2012).  
 
An alternative explanation for increased liver mass and triglyceride content with no 
inflammation and fibrosis could be that the hepatocytes exhibit a higher than usual turnover 
of fatty acids, with increased transient storage in the form of triglycerides in lipid droplets. A 
study by Salmon and Hems revealed that genetically obese ob/ob mice exhibit significantly 
increased hepatic triglyceride and phospholipid synthesis compared with lean mice (Salmon 
and Hems, 1973). The use of a methionine-choline deficient (MCD) diet will rapidly and 




4 weeks of feeding (Weltman et al., 1996, Sahai et al., 2004, Machado et al., 2015). After this 
point, progressive inflammatory damage and fibrosis will occur (Sahai et al., 2004, Weltman 
et al., 1996, Rinella et al., 2008, Stephenson et al., 2018). This highlights an important 
variation in dietary regimes and outcomes, demonstrating various alterations to the liver 
phenotype dependent on the composition of the diet. To investigate whether osteoblast-
specific NPP1 ablation is truly protective against NAFLD and NASH in the liver, feeding with 
an MCD diet followed by comprehensive liver phenotyping including lipidomic profiling, 
proteomic profiling and histological assessment would be informative.  
 
Alternatively, excess lipids may be stored in a different location. For example, the 
Enpp1flox/flox;Ocn-cre mice demonstrate significantly increased gonadal fat pad mass 
compared to Enpp1flox/flox controls: this may represent an adipose tissue depot site that is 
more able to expand. Brown fat is an organ which is specialised for energy expenditure. This 
adipose depot is characterised by several small lipid droplets (multilocular), the presence of 
many mitochondria, and the unique expression of uncoupling protein 1 (UCP1) (Ravussin and 
Kozak, 2009, Cannon and Nedergaard, 2010, Nedergaard and Cannon, 2010, Nedergaard et 
al., 2010, Richard et al., 2010, Richard and Picard, 2011). This protein acts to uncouple 
oxidative phosphorylation from ATP production, thereby released energy as heat 
(thermogenesis) (Nicholls and Locke, 1984, Cannon and Nedergaard, 1985, Matthias et al., 
2000). Despite the increased brown fat mass, the thermogenic function as evidenced 
through qPCR analysis was unaltered. The fat pad mass of the Enpp1flox/flox;Ocn-cre mice 
reflected those of the Enpp1flox/flox mice, demonstrating a comparable ability to expand and 
store excess triglyceride in lipid droplets, whereby adipocytes undergo hypertrophy. This 
indicates that osteoblast-derived NPP1 does not lead to changes in the metabolic action of 
brown fat in thermoneutral conditions. However, a more in-depth thermogenic analysis 
beyond mRNA level (e.g. western blot analysis) is needed to confirm brown fat metabolic 
activity.  
 
Reflecting the results observed in the control-diet fed mice, the high-fat diet fed mice do not 
present with a notable bone phenotype. The high-fat diet and its effect on bone has been 




level following 12-weeks of chronic high-fat diet feeding (Wohl et al., 1998, Doucette et al., 
2015). Predominantly, an expansion of the bone marrow adipose tissue (BMAT) (184% 
following 12-weeks of high-fat diet feeding), with a deleterious effect on the skeleton is 
observed (Doucette et al., 2015). Such deleterious effects include reduced trabecular bone 
mass (29%) and reduced cortical thickness (5%) (Tencerova et al., 2018) Indeed, this study 
also demonstrates that it is the expansion of BMAT in response to high-fat diet feeding that 
exerts the deleterious skeletal changes.  
 
The accumulation of BMAT is reportedly associated with obesity, insulin resistance and 
T2DM in mice and humans (Lecka-Czernik, 2010, Bredella et al., 2011, Bredella et al., 2013, 
Doucette et al., 2015, Gawronska-Kozak et al., 2014). To assess the expansion of BMAT 
following chronic high-fat diet feeding, osmium staining followed by μ-CT analysis was 
performed as described previously (Scheller et al., 2014, Styner et al., 2014, Styner et al., 
2015). This was conducted for the tibiae at various anatomical regions since BMAT expansion 
occurs heterogeneously throughout the long bones, whereby different regions respond in 
variable ways to stimuli (Meunier et al., 1971, Minaire et al., 1974, Wronski et al., 1981, Cup 
et al., 2000, Nuttall and Gimble, 2000, Devlin et al., 2010, Akune et al., 2004, Cawthorn et al., 
2014).  The sites investigated included the tibia-fibula Junction (T/F/J) to the proximal end of 
the bone, proximal growth plate (GP) to T/F/J, and proximal epiphysis (Prox Epi), and the 
bone marrow adipose tissue throughout the total length of the bone. The more proximal 
regions contain a fat known as regulated marrow adipose tissue (rMAT) which contains 
adipocytes interspersed with haematopoiesis and which forms shortly after post-natal 
development (Pichardo et al., 2007, Scheller and Rosen, 2014). Secondly, there is constitutive 
marrow adipose tissue (cMAT) which is more distal and contains larger white-adipose tissue-
like adipocytes (Scheller et al., 2015). The expansion of BMAT following chronic high-fat diet 
feeding of the Enpp1flox/flox;Ocn-cre mice was assessed by osmium staining, revealing little 
difference between the control-diet and high-fat diet fed mice. The absence of BMAT 






Previous work has revealed that BMAT increases in high-fat diet fed C57BL/6J mice. These 
studies routinely report that there is a significant increase in BMAT, yet the trabecular and 
cortical bone mass remains unchanged (Doucette et al., 2015), or decreased (Cao et al., 2010, 
Patsch et al., 2011). Experimental and clinical evidence both point towards the reduction of 
osteoblastogenesis at the expense of adipogenesis, for example, humans with osteoporosis 
(and decreased bone mass) present with increased marrow adipose tissue (Prockop, 1997, 
Rosen and Bouxsein, 2006, Rodriguez et al., 2008, Nishio et al., 2012, Ambrosi et al., 2017). 
This is due to the shared lineage origin of bone marrow mesenchymal stem cells (MSC) for 
both osteoblast and adipocytes (Kim et al., 2004, Muruganandan et al., 2009, Krings et al., 
2012, Ortuño et al., 2013, Muruganandan and Sinal, 2014, Ambrosi et al., 2017). These MSCs 
are self-renewing and pluripotent. When MSCs differentiate into adipocytes, this can affect 
bone remodelling by the suppression of intracellular osteogenic signals (such as Runx2, 
osterix, and β-catenin), while simultaneously promoting the secretion of adipogenic 
signalling molecules such as leptin, adiponectin, chemerin, omentin-1, resistin, and visfatin 
(Ambrosi et al., 2017, Krings et al., 2012, Muruganandan et al., 2009, Muruganandan and 
Sinal, 2014, Ortuño et al., 2013, Kim et al., 2004). The increased bone mass of the juvenile 
Enpp1flox/flox;Ocn-cre mice compared to Enpp1flox/flox control mice was likely facilitated at the 
expense of the bone BMAT development and expansion (Muruganandan et al., 2009, 
Muruganandan and Sinal, 2014). To confirm this, assessment of BMAT adipogenesis 
signalling molecules could be performed by mass-spectrometry and microarray analysis of 
gene expression (Lee et al., 2004, Welsh et al., 2004, Liu et al., 2011). Further investigation 
of the osteogenic signalling by assessing osteogenic-associated pathways and protein 
expression could indicate whether there is increased osteoblastogenesis at the expense of 
adipogenesis as hypothesised. 
 
Despite the control-diet fed Enpp1flox/flox;Ocn-cre mice presenting with increased 
uncarboxylated-OCN, this was not observed in the chronic high-fat diet fed mice. This 
suggests a loss of OCN-associated metabolic protection of the Enpp1flox/flox;Ocn-cre mice 
following chronic high-fat diet challenge. The normalisation of undercarboxylated and/or un-
carboxylated-OCN following high-fat diet feeding has been reported in several mouse 
studies, including those with targeted gene deletion in osteoblasts (Kashiwagi et al., 2011). 




alongside significantly increased serum triglyceride (Gu et al., 2017).  It has been reported 
that two osteoblast transcription factors (Fork-head box O and activating transcription factor 
3) both suppress OCN activity by favouring the expression of embryonic stem cell 
phosphatase (ESP) (Kode et al., 2012). Insulin binds to its receptor in osteoblasts and is 
responsible for disengaging it from its role as a substrate for ESP (Lee et al., 2007). As such, 
the IR is subsequently activated, which activates a molecular pathway inducing bone 
resorption, which provides the acidic bone ECM that favours OCN decarboxylation (Kode et 
al., 2012). By upregulating ESP through osteoblast-specific transcription factors, a decrease 
of undercarboxylated and uncarboxylated-OCN occurs (Lee et al., 2007, Ferron et al., 2010a, 
Kode et al., 2012). It would be of great interest to investigate whether this mechanism was 
occurring, and thus explain the loss of difference between genotype of uncarboxylated OCN, 
in the osteoblast-specific NPP1 ablated high-fat diet fed mice.   
 
In conclusion, the results presented in this chapter highlight that the chronic high-fat diet 
feeding of osteoblast-specific NPP1 ablated male 16-week old mice is unexpectedly 
metabolically detrimental. These data also indicated that the Enpp1flox/flox;Ocn-cre mice are 
incapable of expanding their BMAT and that this may aid in conferring protection of the 
bone. Further work would be required to assess this. Further work is also required to 
determine the mechanistic explanations of why ablation of NPP1 at one of its principal sites 
of action does not result in the metabolic protection observed in the Enpp1-/- mice.  
 
Given that Enpp1flox/flox;Ocn-cre mice only have NPP1 ablated from the osteoblast, NPP1 from 
alternate tissue or cell-type may be responsible for driving the insulin-resistant phenotype in 
this mouse. The literature reports that NPP1 is expressed ubiquitously, with relatively higher 
expression levels in certain tissue types including in bone, liver, testis and kidney (Harahap 
and Goding, 1988, Yano et al., 1985, Funakoshi et al., 1992, Huang et al., 1994). As such, I 
suggest that the careful assessment of cell-specific ablation of NPP1 from these tissue types 
be investigated to determine which tissue-knockout can recapitulate the metabolic 
































7.1. General discussion 
The establishment of bone as an endocrine organ, utilisation of mouse models, clinical 
observations and integrative physiological approaches has led to unanticipated advances 
within the bone biology field. The contemporary understanding of the roles of the skeleton 
extends well beyond the traditional views of bone as a structural scaffold, mineral 
homeostasis regulator and haematopoietic niche. Indeed, the skeleton is now recognised to 
contribute to systemic glucose metabolism, insulin secretion and response by insulin-target 
tissues, brain development, male fertility and others (Clemens and Karsenty, 2011, Oury et 
al., 2011, Wei et al., 2014, Delezie and Handschin, 2018, Shan et al., 2019). These data 
emerging over the last 20 years have firmly established a bone-endocrine function, and have 
borne witness to an increase in the number of laboratories working within this field.  
 
The continued study of bone has identified the critical importance of matrix mineralisation 
regulators (Gurley et al., 2006a, Sweet and Green, 1981, Hakim et al., 1984a, Hessle et al., 
2002, Johnson et al., 2003, Harmey et al., 2004, Roberts et al., 2007a, Festing et al., 2009, 
Collins and Boehm, 2011, Mackenzie et al., 2012, Huesa et al., 2015a, Houston et al., 2016, 
Tong et al., 2018, Bonnet et al., 2019, Dillon et al., 2019, Roberts et al., 2019b). In recent 
years, several studies have advocated a non-skeletal role for these regulators in a range of 
human diseases, including metabolic, cardiovascular and neurodegenerative disease 
(Maddux et al., 2006a, Malkin et al., 2006, Goldfine et al., 2008, Kiechl et al., 2013, Diaz-
Hernandez et al., 2015, Dayeh et al., 2016, Sayols-Baixeras et al., 2016). This is an emerging 
area of interest and the functional roles and mechanisms of action of these various endocrine 
factors, phosphatases and phosphodiesterase enzymes in different pathologies are of great 
interest. Mechanistic insight into the pathways where mineralisation promotors and 
inhibitors act may identify druggable targets for commonly experienced morbidities, notably 
those related to metabolism and metabolic syndrome. 
 
The formation of bone and its resorption are events which occur throughout life and are 
associated with high energetic cost. This has led to the hypothesis that energy metabolism 
and bone formation regulate one another in a feedback loop. Following work by Professor 




Hopkins University, Baltimore) which led to the discovery of undercarboxylated 
(metabolically active) OCN, a hormone secreted specifically by the osteoblast to promote 
insulin sensitivity (amongst other systemic functions), further evidence has emerged for the 
metabolic role of bone (Clemens and Karsenty, 2011). Many laboratories are engaged in 
determining the precise mechanisms, aetiology, genetics and molecular components that 
are involved in the physiology and pathophysiology of bone-endocrine function.  
 
T2DM represents a notable global health crisis, with a projected incidence of 643 million by 
2040 (https://diabetesatlas.org/), 90% of which will be T2DM (Bruno et al., 2005, Holman et 
al., 2015). The literature reports that the main drivers of T2DM are the rise in obesity, 
sedentary lifestyle, consumption of energy-dense foods and an ageing population (Chan et 
al., 2009, Hu, 2011, Polonsky, 2012, Roglic, 2016). However, an individual’s genetic 
architecture also may determine their response to these environmental challenges. This can 
be characterised as modifiable (e.g. environmental) and non-modifiable risk factors (e.g. 
genetics); the combination of these factors may lead an individual to suffer from the 
metabolic syndrome, including hypertension, dyslipidaemia, insulin resistance, obesity and 
more (Fig. 7.1). A more comprehensive understanding of the role of mineralisation regulators 
and their contribution to energy metabolism may be helpful for the identification and 
development of new preventative, therapeutic and genetic strategies to combat 
components of the metabolic syndrome, notably, T2DM. This is timely, given that T2DM 
represents an ever-increasing burden of disease in both developed and low-income 
countries. For example, the reported increase in health loss from T2DM since 1990 in India 
is the highest amongst all major non-communicable diseases (Tandon et al., 2018) whilst 
alarmingly almost 10% of the American population (30.2 million individuals) have diabetes, 










Figure 7.1. Risk factors and disease experienced in the metabolic syndrome. 
Schematic figure demonstrating non-modifiable and modifiable risk factors that may contribute to an individuals incidence of 






Obesity and insulin resistance are preventable and reversible diseases and simple 
interventions (e.g. daily exercise) and alterations to lifestyle (e.g. dietary  choices) can 
decrease mass and improve insulin sensitivity (Ross et al., 2000, Assali et al., 2001, Janssen 
et al., 2002, Toledo et al., 2008). The use of lifestyle intervention strategies has been 
demonstrated as effective in controlled and randomised trials across the globe, including the 
Chinese Da Qing study, the Finish Diabetes Prevention Programme, the Indian Diabetes 
Prevention program and the U.S Diabetes Prevention Programme (Pan et al., 1997, 
Tuomilehto et al., 2001b, Knowler et al., 2002, Ramachandran et al., 2006). However, the 
deployment of lifestyle-based intervention strategies throughout entire populations (e.g. 52 
million people North America) is a massive, and arguably an unachievable task (Florez, 2016).   
 
Alternative strategies have been implored including the use of metformin 
(dimethylbiguanide).  The oral administration of this first-line pharmacological treatment for 
T2DM results in lowered blood glucose concentrations (Bailey and Turner, 1996, Kirpichnikov 
et al., 2002). The Diabetes Control and Complications Trial (1993) has demonstrated that 
there is a casual relation between T2DM and microvascular disease. Patients with T2DM 
often have several risk factors for the development of atheroma, hypertension, 
dyslipidaemia and vascular disease (Stout, 1990, DeFronzo and Ferrannini, 1991, Reaven, 
1988). A study of insulin-treated patients with T2DM in Japan revealed that improved 
glycaemic control was associated with decreased progression of microvascular disease 
(Ohkubo et al., 1995). Such observations have been reflected in further human-based 
studies, reflecting the vasculoprotective effects of metformin including the UK Prospective 
Diabetes Study (1998) and others (Bailey, 2008). Various animal models have highlighted that 
metformin acts to prevent vascular endothelial dysfunction by increasing nitric oxide 
bioavailability (Mather et al., 2001, Vitale et al., 2005, Sena et al., 2011, Forouzandeh et al., 
2014). 
 
The mechanisms of action for metformin and metabolism remain largely unknown, with 
reports suggesting that a range of organs are targeted including the liver and the gut (Wang 
et al., 2002, Tiikkainen et al., 2004, Natali and Ferrannini, 2006, Shu et al., 2007, Zema, 2012, 




metformin-induced hepatotoxicity and side-effects including dizziness, muscle pain, 
tiredness, respiratory difficulties, irregular heartbeat, diarrhoea, nausea and vomiting  
(Baradaran, 2012, Miralles-Linares et al., 2012, Gheshlaghi, 2012, Scheen and Paquot, 2013, 
Nasri et al., 2014). A population-based study showed that approximately 25% of patients 
taking prescribed metformin had contraindications to its use (Emslie-Smith et al., 2001). 
Alternate strategies to tackle T2DM are required and this necessitates continued 
investigative efforts into the genetic components of the disease.  
 
This thesis has specifically focused on determining the effect of osteoblast-specific ablation 
of NPP1 on both skeletal and metabolic phenotypes. NPP1 is an indispensable mineralisation 
regulator through its action whereby extracellular PPi is generated by ATP hydrolysis. 
Previous work has demonstrated that the global ablation of NPP1 in mice results in a 
hypermineralisation of the joints, spinal ankylosis, and ectopic mineralisation (e.g. the tunica 
media of the aorta) (Mackenzie et al., 2012). Previous work also demonstrated that the 
global ablation of NPP1 is metabolically protective, whereby Enpp1-/- mice challenged with 
high-fat diet were protected against obesity and insulin resistance (Huesa et al., 2014). The 
cell-specific contributions of NPP1 to these phenotypes remain undetermined. Here, I show 
that the osteoblast-specific ablation of Enpp1 engenders an increase in bone mass and bone 
mineralisation (chapter 3). I demonstrated that this bone phenotype is reflected at the in 
vitro level, whereby primary osteoblasts isolated from the osteoblast-specific Enpp1-ablated 
mouse mineralise their matrix more quickly and to a greater extent compared to their 
controls (chapter 4). Furthermore, the work presented in this thesis demonstrates that 
osteoblast-specific Enpp1 ablation does not result in the alteration of systemic PPi and is not 
able to recapitulate the pathological ectopic mineralisation observed in the global Enpp1-/-.  
 
This thesis has also investigated the effect of osteoblast-specific Enpp1 ablation on metabolic 
phenotype. Here, I show that osteoblast-specific Enpp1 ablation of control-diet fed mice 
facilitates an increase in uncarboxylated-OCN reflecting observations of the global Enpp1-/- 
mouse. However, following chronic high-fat diet feeding, osteoblast-specific Enpp1 ablation 
does not result in metabolic protection as observed in the global Enpp1-/- mouse. Indeed, the 




metabolic phenotype including insulin resistance and obesity. These data demonstrate that 
the ablation of NPP1 at one of its key sites of action is metabolically detrimental. The 
metabolic phenotyping conducted would have benefitted from an additional analysis using 
a euglycemic clamp to further assess insulin sensitivity. This technique is considered the gold-
standard method to assess insulin action on glucose utilisation in animals and humans alike 
(Shen et al., 1970, DeFronzo and Beckles, 1979). 
 
The bone phenotype of the osteoblast-specific Enpp1 ablated mouse model represents a 
novel finding. As discussed in chapter 3, there are several mouse models which have been 
used to investigate Enpp1 ablation, including transgenic, naturally occurring mutants and 
knock-out models. However, these models do not report any increase in bone mineral 
density, as determined by µ-CT or otherwise (e.g. ashing, back-scattered scanning electron 
microscopy or detailed histological assessment). The novel finding demonstrated in this 
thesis highlights that osteoblast-derived NPP1 is critical in the maintenance of physiological 
bone mineralisation. However, it appears that osteoblast-derived NPP1 is not critical for the 
regulation of systemic (e.g. ectopic) mineralisation. As hypothesised in this thesis, I propose 
that osteoblast-specific NPP1 ablation results in the local reduction of PPi concentration 
which affects the bone mineralisation but leaves systemic PPi and the viscera unaffected by 
pathological mineralisation. This could indicate that circulatory PPi generated from liver-
derived NPP1 may be exerting crucial systemic protective effects against ectopic 
mineralisation.  
 
The metabolic phenotype of the global Enpp1-/- may be governed by liver-specific NPP1. This 
is supported by reports in the literature from both clinical observations and basic research 
that highlights the liver as a key NPP1 target (Fig. 7.2). A full serum biochemical analysis of 
the control-fed female Enpp1flox/flox;Ocn-cre mouse revealed depressed serum albumin, total 
protein, globulin and cholesterol concentrations compared to controls (Fig. 7.3). A study by 
Desmarchelier et al. revealed that mice on a high-fat diet (termed ‘western diet’) for 12 
weeks demonstrated significantly increased plasma cholesterol levels (Desmarchelier et al., 
2012). Furthermore, it is well recognised that the accumulation of hepatic free cholesterol 




The reduction of serum cholesterol in female Enpp1flox/flox;Ocn-cre mice may indicate the 
existence of a protective mechanism against non-alcoholic fatty liver disease. To further, 
investigate this, gas- and liquid chromatography/mass spectrometry-based profiling of 
lipidomic and metabolic changes in the liver and plasma of our Enpp1flox/flox;Ocn-cre mice 
could be conducted as described in previous studies (Tu et al., 2017). Such studies take 
advantage of non-targeted metabolomics and lipidomic profiling to comprehensively assess 
mechanisms involved in disease development (Xu et al., 2019). This would facilitate an 
unbiased probing of potential liver-specific lipid and metabolic pathway changes in the 
Enpp1flox/flox;Ocn-cre mice related to published libraries for non-alcoholic fatty liver disease 
in mice (Dumas et al., 2006, Puri et al., 2007, Thomas et al., 2012, Lai et al., 2015). 
Furthermore, given that the male counterparts revealed no significant differences in serum 
biochemistry between genotype, it would be pertinent to investigate sex differences in liver 
function and metabolic phenotype of cell-specific NPP1 knockout mice in future studies (Fig. 
7.3). A suggested future study, therefore, could take advantage of analysing an 
Enpp1flox/flox;Albumin-cre mouse model, including basic metabolic profiling and bone 








Figure 7.2. Schematic representing the proposed role and downstream effects of ENPP1 expression in 
the liver. 
Decreased ENPP1 expression is associated with improved metabolic phenotype, whereby increased ENPP1 
expression is associated with worsening metabolic phenotype. Results summarised include both clinical and basic 








Figure 7.3. Serum analyte analysis from female mice. 
Serum analysis from (A) female and (B) make Enpp1flox/flox;Ocn-cre and Enpp1flox/flox mice was 
performed by Colin Wood. Cholesterol, globulin, total protein and albumin were analysed. Data 
are presented as average values presented with their standard errors of the mean (SEM) (n=6). 






The development of insulin resistance, viewed as a pre-requisite for T2DM, occurs when insulin is 
produced at a higher level than normal for a prolonged time (Cefalu, 2001, Reaven, 2004). This 
causes a reduction in the sensitivity of tissues to insulin and can occur years in advance of glucose 
intolerance and pancreatic β-cell dysfunction (Cerf, 2013). Following the discovery of 
undercarboxylated- and uncarboxylated-OCN, which stimulates insulin secretion, pancreatic β-
cell proliferation and promotes insulin sensitivity in peripheral organs in mice, attention has been 
focused on determining whether these mechanisms exist in humans also.  
 
It has been shown that polymorphisms in human BGLAP (OCN) are associated with T2DM and 
obesity (Xu et al., 2010, Korostishevsky et al., 2012). Murine studies have also shown that it is the 
under-carboxylated form of OCN that influences glucose metabolism (Ferron et al., 2010a, 
DiGirolamo et al., 2012, Huesa et al., 2014, Faienza et al., 2015, Chapurlat and Confavreux, 2016). 
However, the majority of clinical studies use total levels of OCN as the clinical readout (Lee et al., 
2007, Reinehr and Roth, 2010, Sarkar and Choudhury, 2013, Chin et al., 2014, Wang et al., 2014b).  
As such, the current understanding of OCN in the human context is limited due to the lack of 
information about undercarboxylated- and uncarboxylated-OCN concentrations.  
 
As determined in chapter 5 and 6, the control-fed Enpp1flox/flox;Ocn-cre mice present with 
significantly increased serum concentrations of uncarboxylated-OCN, which reflects findings of 
the global Enpp1-/- mouse (Huesa et al., 2014). As such, an OCN-dependent mechanism of Enpp1 
regulating energy metabolism may exist. This is notable since the Enpp1-/- mice maintain this 
favourably altered bioactive OCN level following chronic high-fat diet feeding (Huesa et al., 2014). 
However, the high-fat diet fed Enpp1flox/flox;Ocn-cre mice do not afford the metabolic protection 
and have unaltered OCN levels, bioactive or otherwise (chapter 6).   
 
In conclusion, this thesis identifies for the first time that osteoblast-specific NPP1 ablation 
engenders increased bone mass and bone mineral density. This indicates the critical role of 
osteoblast-derived NPP1 in regulating bone mineralisation. This thesis also reports that 
osteoblast-specific NPP1 ablation is, unexpectedly, metabolically detrimental and drives obesity 
and insulin resistance following high-fat diet feeding. The work presented in this thesis suggests 





generating and maintaining physiological systemic levels of PPi? As such, is the liver-generated 
NPP1 responsible for regulating ectopic mineralisation? Could osteoblast-specific NPP1 be 
targeted with inhibitors to improve bone conditions whereby bone mass and bone mineralisation 
decrease (e.g. osteoporosis)? Why does the osteoblast-specific ablated mouse lack metabolic 
protection, yet the global Enpp1-/- maintains this following high-fat diet feeding? What other cell-
specific contributions of NPP1 are there regarding metabolic phenotypes? Our understanding of 
the complex relationship of matrix mineralisation regulators, such as NPP1, and their role in 
energy metabolism will undoubtedly increase in the years to come.  It is of great importance that 
the scientific community continue to delineate the mechanisms that underpin these systemic 
endocrine roles to enable better diagnosis, management and treatment of patients with 





7.2. Direction for future research 
One area that has not been considered in this thesis is the role of osteoblast-specific NPP1 ablation 
on tooth development. The tooth consists of the crown, neck and root. Within these distinct 
regions are corresponding specialised tissues, including enamel (the mineralised portion), dentin, 
the pulp (soft tissue containing blood and nerve supply) and cementum (bone-like tissue covering 
tooth root) (Li et al., 2017a). 
 
 It has been shown that OCN is expressed in the later stages of odontoblast cytodifferentiation 
during tooth development (Zweifler et al., 2015). OCN has also been detected in odontoblasts and 
their processes within the ECM at the maturation stage of enamel formation (Bronckers et al., 
1994, Papagerakis et al., 2002). The teeth consist of a dentin matrix, which is quite similar 
(although not identical) to the bone ECM and can be mineralised (Satoyoshi et al., 2001, Petridis 
et al., 2018). The odontoblasts have been demonstrated to synthesise and deposit OCN into the 
mineralising dentin (Bronckers et al., 1985, Bronckers et al., 1998). As such, the mouse model here 
is well suited to study the osteoblast-specific contributions of NPP1 regarding tooth 
mineralisation. It has been demonstrated that NPP1 and PPi are critical in physiological tooth 
development (Beertsen et al., 1999, Rutherford et al., 2006, Foster et al., 2012). However, to date, 
the osteoblast-specific contributions of NPP1 in tooth mineralisation have not been investigated.  
 
Cementum is important for anchoring the insertion of periodontal ligament fibres to the tooth 
root (Diekwisch, 2001). Cementum is a mineralised tissue layer, which covers the tooth root 
(Bosshardt, 2005, Foster et al., 2007). This comprises of two layers including acellular and cellular 
cementum (Foster et al., 2012). The cellular cementum is thicker, and bone-like, occupying the 
apical portion of the root (Foster et al., 2012) and has roles in the post-eruption adjustment of 
tooth occlusion (Diekwisch, 2001, Bosshardt, 2005, Foster et al., 2007). The present understanding 
of the developmental regulation of the acellular cementum is poorly comprehended, which 
restricts efforts for regeneration.  Work by Foster et al has identified that the Alpl-/- mice exhibit 
excess PPi and concomitantly inhibited cementum formation (Foster et al., 2012). This results in 
root detachment, a phenomenon consistent with premature tooth loss in the human condition of 
hypophosphatasia (Bloch-Zupan, 2016). This group also analysed the global Enpp1-/- mouse, 
demonstrating decreased PPi and increased cementum apposition and thickness compared to 





remains restricted. It would be of great interest to assess the dental phenotype of the osteoblast-
specific Enpp1 mice to aid in the identification of clinical targets for tooth loss. This could be 
initially conducted by completing a µ-CT analysis. 
 
NPP1 is detectable in cementoblasts following acellular cementum formation, and at low levels 
around cellular cementum, and likely plays a crucial role in generating PPi to regulate bio-
mineralisation of the mandible (Zweifler et al., 2015).  It has been shown that Enpp1-/- 
demonstrate a rapidly forming cementum, reflecting tooth development in a low PPi environment 
(Nociti et al., 2002, Zweifler et al., 2015). However, the cell-specific roles of NPP1 in tooth 
mineralisation remain undetermined. Identifying this may aid in explaining differences in NPP1’s 
precise function in cementogenesis. A deeper understanding of the role of NPP1 in this context 
will aid in providing insights into tooth root developments and identification of therapeutic 
interventions to promote cementum regeneration and functionality of teeth. This is particularly 
timely and relevant, giving the increasing body of evidence recognising that the acellular 
cementum is potently influenced by PPi (and Pi) concentrations. 
 
Although this project was able to provide a comprehensive analysis of the bone phenotype for the 
Enpp1flox/flox;Ocn-cre mouse, there are various aspects which could be built upon to strengthen the 
data. Suggestions for additional research that could overcome these issues are suggested below.  
 
The use of µ-CT has provided a useful resource to study the architecture of bone and assess the 
bone mineral density. However, as discussed in chapter 3, the analysis in this thesis focused on 
specific regions of the bone, at the distal portion of the femur and the proximal portion of the 
tibia. Although this allowed me to confirm a significant difference in bone mineral density 
between groups, this may not be reflective of bone mineral density alterations throughout the 
bone. Efforts were made to corroborate this data, by completing a histological assessment of 
juvenile bones using a Bioquant OSTEO software and determining osteoid width. However, these 
methods to visualise and asses the micro-architecture of bone are not well suited to studying 






One suitable further technique to support the findings of increased bone mineral density would 
be the use of Raman spectroscopy, which has been used by several basic studies to evaluate bone 
quality and bone mineral density (Tarnowski et al., 2002, Chappard et al., 2011, Morris and 
Mandair, 2011, Fu et al., 2012). This technique involves the inelastic scattering of monochromatic 
laser light, providing vibrational information of chemical bonds and symmetry of molecules. This 
can be utilised to determine the components of bone and bone mineral. This data may have 
supported a hypermineralisation phenotype.  
 
One underappreciated area in this thesis is the role of sexual dimorphism with regard to bone, 
and it’s potential wider effects on systems biology in mice. In recent years, there is increasing 
evidence emerging to demonstrate complex and multiple levels of sexual divergence in bone. One 
example of this is that the regulation of the bone vascular network  is sexually dimorphic. Here, 
Goring et al assessed the phenotype of mice conditional disruption of VEGF in osteocalcin-
expressing cells (osteoblasts). This study demonstrate that VEGF, which is critical for bone growth 
and repair, and it’s signaling exerts a divergent effect on bone properties from between sexes at 
multiple levels (morphological, cellular and whole bone level). This sophisticated phenotyping 
included detailed imaging methodology such as synchrotron computed tomography and scanning 
electron microscopy to reveal significant increases in unmineralized osteoid, enlarged blood 
vessel canals and increase osteocyte lacunae size in cortical bone of osteoblast-specific VEGF 
conditional male knockout mice, but not in female mice. Sexual differences in the skeleton are 
evident in puberty, adulthood and old age, whereby significant quantities of literature 
demonstrate the importance of sex steroids as key regulators of bone health and mechanical 
function. It is critical that future studies assess the contribution of sex steroids regarding bone 
phenotype in order to reveal underlying sex-specific genetic regulators of bone mineralisation. 
This thesis would likely have benefited from more in-depth assessment of sexual dimorphism 
regarding the bone phenotype. Given that male mice were selected for metabolic studies, the 
possibility to assess sexual dimorphism within different feeding conditions is not possible within 
this study, although also would be warranted. This may have offered greater insight into whether 
sex-specific changes of bone led to alterations in hormonal signaling (e.g. secreted osteocalcin 
levels) and cellular signaling (e.g. NPP1 activity), and whether this linked to functional outputs 
such as resistance to obesity and/or insulin resistance. This work is warranted in future mouse 






Seahorse metabolic analysis of primary osteoblasts isolated from the osteoblast-specific NPP1 
ablated mouse revealed a reduced glycolytic function and capacity compared to controls. These 
data indicate that the osteoblast-specific NPP1 ablated mouse osteoblasts have compromised 
mitochondrial function. Recently, a transgenic mitochondrially localised 3XHA epitope tag (MITO-
Tag) mouse has been developed (Bayraktar et al., 2019), which allows for rapid, cell-type-specific 
immune-isolation of mitochondria from tissues of interest. This would allow for the isolation of 
mitochondrial specifically from osteoblasts, and analysis of the mitochondrial behaviour and 
metabolite usage. This would permit a comprehensive study of mitochondrial physiology, and 
would greatly aid the understanding of the metabolic changes in osteoblasts. Such findings may 
help identify whether these changes are associated with alterations in metabolic demand due to 
increased mineralisation activity, which is observed in the osteoblast-specific NPP1 ablated 
mouse.  
Furthermore, it would have been insightful to test potential explanatory mechanisms which exist 
in vivo buy using more easily available and rapid tools in vitro. For example, to robustly examine 
the cell signaling mechanisms resultant of osteoblast-specific NPP1 ablation, it would have been 
useful to utalise knock-down experiments. More quickly and easily available wild-type animals 
may have been used to isolate both primary osteoblasts from calvaria and primary osteoblasts 
from long bones (e.g. from the femur). Using specific silencing RNA’s (shRNA), a specific 
knockdown of NPP1 activity in the cell type may be achieved. This could provide a large number 
of cells such that appropriate technical and biological replicate samples may be utilised, and such 
that genetic, protein, lipid and metabolite changes may be investigated. This would involve use of 
more sophisticated, and large dataset, methodology such as proteomics, metabolomics, 
lipidomics and microarray analysis. This could identify significantly altered downstream effects of 
NPP1 knockout, and would identify any potential confounding differences between osteoblasts 
isolated from the calvaria versus osteoblasts isolated from the long bones. Such work would 
undeniably have been insightful, but was unfortunately unattainable due to financial constraints 
at the time of study.  
 
Given the changes observed in the concentrations of uncarboxylated-OCN in the Enpp1flox/flox;Ocn-
cre mice, it would be of great interest to generate an Enpp1 and Ocn double knockout mouse. As 
the global Enpp1-/- mice present with significantly increased undercarboxylated-OCN and 
uncarboxylated OCN, insulin sensitivity and resistance to obesity following high-fat diet feeding, 





determine whether insulin sensitivity and metabolic protection is an OCN-dependent or OCN--
independent mechanism. It would be interesting to extend this analysis, and generate an 
Enpp1flox/flox;Ocn-cre mouse on an Ocn knockout background, to determine whether the 
differences in metabolic protection between the global and conditional NPP1 knockouts are truly 
due to the action of OCN.   
 
One further metabolic analysis area of interest identified in this project involves the brown 
adipose tissue. The high-fat diet fed Enpp1flox/flox;Ocn-cre mice presented with significantly 
increased brown adipose tissue mass compared to Enpp1flox/flox controls. This could suggest an 
increase in the number of brown fat mitochondria, and as such, the brown fat may contribute to 
metabolic change due to changes in non-shivering thermogenesis.  The activation of brown fat, or 
so-called ‘beiging’ of white fat, is a hot topic of study and a potential mechanism for regulating 
obesity and insulin resistance.  Despite the notable increase in BAT of 22% in the Enpp1flox/flox;Ocn-
cre mice, I did not observe differences in the expression of BAT enriched genes (e.g. Ucp1 and 
Ucp2), suggesting that canonical thermogenesis through Ucp1 is not a mechanism involved in the 
metabolic phenotype determined in this thesis. It would be interesting to conduct these 
experiments at conditions outside of the thermoneutrality window. Indeed, the experiments 
described within this thesis were conducted at standard ambient temperatures of 23°C. This is 
reported as a mild cold stress for mice. To test the BAT thermogenesis of these mice, they could 
be challenged with cold temperature to stimulate the Ucp1, by placing in a cold exposure (8°C for 
98 hours, then to 4°C for up to 5 weeks). Subsequently, glucose tolerance and insulin tolerance 
testing, followed by necroscopy to assess body weight, fat and muscle mass could be conducted 
to assess metabolic phenotype. The analysis of BAT mitochondrial activity could also be assessed 
by targeted qPCR and western blot analysis for genes involved in BAT fat oxidation (e.g. Ucp3, 
Cpt1b). Furthermore, in vitro metabolic profiling of primary isolated brown adipocytes could be 
conducted using seahorse technology.  
 
T2DM is a complicated disease with multiple aetiologies and progressively develops over several 
years. The identification and assessment of therapeutic agents or targeted interventions to delay 
progression from pre-diabetic to diabetic state, therefore, take many years and tremendous 
financial resource and effort to identify. It is critical to better understand the pathogenesis of 





and susceptibilities to be studied, relatively quickly and with reduced expense compared to large 
animal counterparts (King, 2012, King and Bowe, 2016b). However, for a more translational study 
of animal to human, an appropriate animal model should mirror the pathophysiology and natural 
history of T2DM. Alternately, the animal model would be suitable if it develops complications of 
T2DM with an aetiology reflecting that of humans. One example of a suited animal model for 
T2DM is the feline model (Henson and O'Brien, 2006). Cats, particularly domestic cats, share the 
same environment as humans and are subject to physical inactivity and obesity (Henson and 
O'Brien, 2006). Cats have litters, which can facilitate the study of genetic linkage. Similarly, the 
natural lifespan of a cat, being less than primates and more than mice, allows a study of the onset, 
progression, treatment and prevention over a more achievable timeframe compared to monkeys 
or humans (Gurda et al., 2017). Additionally, feline diabetes mellitus typically occurs in middle 
age, associated with declining insulin secretion and loss of pancreatic β-cell mass, reflecting 
human disease (O'Brien et al., 1986, Henson and O'Brien, 2006). Furthermore, feline diabetes can 
be induced by partial (50%) pancreatectomy followed by the addition of dexamethasone and 
growth hormone (Hoenig et al., 2000, Henson and O'Brien, 2006). CRISPR-Cas9 is a third-
generation engineered nuclease which is capable of causing double-strand DNA breaks, eliciting 
the non-homologous end-joining and homologous recombination repair systems (Sander and 
Joung, 2014). The utilisation of the CRISPR/Cas9 system to generate cell-specific NPP1 knockout 
in cats may allow for a greater comprehension of the relationship of NPP1 and T2DM within a 
pathophysiological context more similar to humans than other animal models (e.g. mice).  
 
At present, it is recognised that there is no ideal animal model consistent with clinical presentation 
and pathology of human T2DM (Rees and Alcolado, 2005), although improvements to animal 
models are occurring. There is an unmet need to establish genetically modified miniature pig 
diabetes models to comprehensively study pathogenesis and prevention of T2DM and its 
downstream consequences. It is recognised that the miniature pig is a highly suitable candidate 
for investigating metabolic-related human disease (King, 2012). Notable features of the pig that 
make it a suitable research model include similar anatomy, physiology and biochemical 
metabolism to humans (Meurens et al., 2012, Roura et al., 2016). More specifically, pigs are 
omnivores, demonstrating similar dietary needs, nutritional balance and digestion compared to 
humans (Guilloteau et al., 2010). Indeed, pigs represent the animal model closest to humans 
(excluding non-primates)  (Meurens et al., 2012). The development of an osteoblast-specific NPP1 





demonstrating the translational aspects of the work presented in this thesis. The utilisation of the 
pig model in this way would aid in bridging the gap between animal and human studies in the field 
of bone and metabolism.  
 
The experiments suggested in this section would aid in demonstrating the complex and cell-
specific contributions of NPP1 in the regulation of skeletal formation and energy metabolism. 
Uncovering the mechanisms through which NPP1 elicits its action in energy metabolism is likely 
to aid in the identification and development of novel therapeutic and intervention strategies 
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Primer Sequence (5' to 3') From Source 
Ank Forward GCC CAT TGT CAA CCT CTT CGT Sigma  (Kim et al., 2012) 
  Reverse GAA TGG CCA CTG CCT CTG TAG     
Atgl Forward GGC CAT GAT GGT GCC CTA T PrimerBank Dr Karla Suchacki  
  Reverse CAC TCC AAC AAG CGG ATG AT     
β-actin Forward AGT TCG CCA TGG ATG ACG AT Sigma Dr Dongxing Zhu 
  Reverse TGC CGG AGC CGT TGT C     
Dgat1 Forward GTG CAC AAG TGG TGC ATC AG Eurofins Dr Carmen Huesa 
  Reverse CAG TGG GAT CTG AGC CAT CA     
Dgat2 Forward ACT CTG CAG GTT GGC ACC AT Eurofins Dr Carmen Huesa 
  Reverse GGG TGT CGGC TCA GGA GGA T     
Enpp1 Forward GCT AAT CAT CAG GAG GTC AAG Sigma  Dr Dongxing Zhu 
  Reverse CTG GTA GAA TC CGT CA     
Fgf23 Forward GGA TCT CCA CGG CAA CAT TT Eurofins Dr Dongxing Zhu 
  Reverse GTA GTG ATG CTT CTG CGA CAA     
Glut2 Forward TGT GCT GCT GGA TAA ATT CGC CTG  Eurofins Dr Carmen Huesa 
  Reverse AAC CAT GAA CCA AGG GAT TGG ACC     
Leptin Forward ATTTCACACACGCAGTCGGTAT PrimerBank Dr Karla Suchacki  
  Reverse GGTGGAGCCCAGGAATGAAG     
Lpl Forward TCT GTA CGG CAC AGT GG PrimerBank Dr Karla Suchacki  
  Reverse CCT CTC GAT GAC GAA GC     
Mgp Forward GTG GCA ACC CTG TGC TAC Eurofins Dr Dongxing Zhu 
  Reverse CAG GCT TGT TGC GTT CC     
Ocn Forward sequence not available PrimerDesign Primerdesign 
  Reverse sequence not available     
Opn Forward GGA TGC TGT GTC CTC TGA AGA Eurofins Dr Dongxing Zhu 
  Reverse ATC GTC ATC ATC ATC GTC ATC AT     
Pck1 Forward CAT ATG CTG ATC CTG GGC ATA AC PrimerBank Dr Karla Suchacki  
  Reverse CAA ACT TCA ATC CAG GCA ATG TC     
Phospho1 Forward GAC AAT GAG CGG GGT GTT TTC Sigma Dr Dongxing Zhu 
  Reverse GGG GAT GGT CTC GTA GAC AG     
Pparα Forward CCC TGA ACA TCG AGT GTC GA PrimerBank Dr Karla Suchacki  
  Reverse AAT AGT TCG CCG AAA GAA GCC     
Pparg Forward CTG CCT ATG ACT TCA CAA  Eurofins Dr Carmen Huesa 
  Reverse CTC TTG TGA ATG GAA TGT CTT CA     
Ppargca1 Forward CCCTGCCATTGTTAAGACC PrimerBank Dr Karla Suchacki  
  Reverse TGCTGCTGTTCCTGTTTTC     





  Reverse CGTACACGCAAATAATAGGGGTT     
Runx2 Forward ACC ATA ACA GTC TTC ACA A Sigma Dr Dongxing Zhu 
  Reverse CAG GCG ATC AGA GAA CAA A      
Slc2a1 Forward TCA ACA CGG CTT CAC TG PrimerBank (Flessner et al., 2012) 
  Reverse CAC GAT GCT CAG ATA GGA CAT C     
Slc2a2 Forward TGT GTC GCT GGA TAA ATT CGC CTG PrimerBank (Flessner et al., 2012) 
  Reverse AAC CAT GAA CCA AGG GAT GGA CC     
Slc2a4 Forward CCA GTA TGT TGC GGA ATG  CTA T PrimerDesign Dr Karla Suchacki  
  Reverse TTA GGA AGG TGA AGA TGA AGA AG     
Slc2a10 Forward ACC AAA GGA CAG TCT TTA GCT G PrimerBank (Flessner et al., 2012) 
  Reverse ATC TTC CAA CGA GAC GGA TG     
Slc2a12 Forward GGG TGT CAA CCT TCT CAT CTC PrimerBank (Flessner et al., 2012) 
  Reverse CCA AAG AGC ATC CCT TAG TCT C     
Tnap Forward GGG ACG AAT CTC AGG GTA CA Sigma Dr Dongxing Zhu 
  Reverse AGT AAC TGG GGT CTC TCT CTT T     
Ucp1 Forward AGG CTT CCA GTA CCA TTA GGT PrimerBank Dr Karla Suchacki  
  Reverse CTG AGT GAG GCA AAG CTG ATT T     
Ucp2 Forward AAT CTC GGG AGG CAC CTT TC PrimerBank Dr Karla Suchacki  
  Reverse GAG AAT GGG ACT GGG CAG AG     
18s Forward GTA ACC CGT TGA ACC CCA Eurofins Dr Dongxing Zhu 






Appendix II. Buffers and solutions. 
Cell Culture buffers 
Primary osteoblast and cell line calcification media medium 
aMEM with 10% FBS, 0.05mg/mol gentamicin. 
 
Primary osteoblast and cell line calcification media medium 
aMEM with 10% FBS, 0.05mg/mol gentamicin, 5Mm b-GP, 50mg/ml ascorbic acid. 
 
Primary osteoblast TNAP inhibition study cell medium  
aMEM with 10% FBS, 0.05 mg/mol gentamicin and 30 µM TNAP inhibitor. 
 
Freezing mix for cell lines 
60% DMEM/F-12; 20% FBS; 20% DMSO 
 
 Gel Electrophoresis 
Tris-Acteric Acid-EDTA (TAE) 
40 mM Tris, 1 mM EDTA, 0.1 % Acetic Acid  
Tris-Boric Acid-EDTA (TBE) 
(90 mM Tris, 2 mM EDTA, 90 mM boric acid  
 
Western Blotting 
MOPS running buffer 
50 mM MOPS pH 7.7, 50 mM Tris, 0.1% SDS, 1mM EDTA  
1X Transfer buffer 





10X Transfer buffer 
29.3 mg/ml glycine, 58 mg/ml Tris Base (trismethylamine), 18.8 μl/ml 20% SDS in dH2O  
Tris-Bufferd Saline with Tween 20 (TBST) 
10mM Tris HCl pH8.0, 150mM NaCl, 0.1% Tween-20  
Blocking Solution 
5% (w/v) BSA Faction V in TBST 
Fixatives and histological Stains 
10% Neutral Buffered Formalin (NBF) 
100 ml strong formalin, 900 ml tap water, 4.0 g sodium dihydrogen phosphate, monohydrate 
(NaH2PO4.H2O) and 6.5 g Disodium hydrogen phosphate, anhydrous (Na2HPO4)  
4% Paraformaldehyde (PFA) 
800 ml 1x PBS 60°C, 40 g paraformaldehyde powder, 1M NaOH added dropwise until the 
solution cleared, adjust volume to 1L with 1x PBS  
Oil-Red-O stock stain 
0.5 g Oil-Red-O (CI 26125, Merc Millipore) dissolve in 100 ml isopropanol with gentle heat  
 
Oil-Red-O working solution 
Dilute 30 ml stock stain in 20 ml of dH20, stand and filter  
 
General buffer recipes  
PBS 
140 mM NaCl, 2.5 mM KCl, 10 mM NaH2PO4, 1.8 mM KH2PO4 
 
Hanks Buffered Saline Solution (HBSS) 
1.26 mM CaCl2, 0.493 mM MgCl2, 0.407 mM MgSO4, 5.33 mM KCl, 0.441 mM KH2PO4, 4.17 mM 





Appendix III. Schematics of Animal Use. 







Schematic of mouse use for bone and metabolic phenotyping.  
 
